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ABSTRACT

THE GENETIC AND MOLECULAR CHARACTERIZATION OF THE
POLYCYSTIC KIDNEY DISEASE-CAUSING MOUSE GENE BICC1
by Sarah J. Price
Polycystic kidney disease (PKD) is one of the most common hereditary diseases
and is characterized by progressive cyst formation, substantial renal
enlargement, and frequently, progression to end-stage renal disease. One way
to learn more about the etiology of this disease is to study mouse models that
imitate the human situation. The juvenile congenital polycystic kidney disease
(jcpk) gene on mouse Chromosome 10 has been found to cause a severe, early
onset form of PKD when inherited in an autosomal recessive manner (Flaherty et
al., 1995). Previous genetic studies mapped the jcpk locus to a 1 cM region on
mouse Chromosome 10 between the markers D10Mit115 and D10Mit173 (Bryda
et al., 1996). To positionally clone this gene, high resolution genetic and
radiation hybrid maps were generated along with a detailed physical map of the
critical region thought to contain the jcpk gene. Fine mapping studies allowed
extensive reduction of this region to a section of mouse Chromosome 10
contained within three Bacterial Artificial Chromosomes (BACs). Nucleotide
sequence analysis was performed to determine the presence of transcribed
genes within this section of the chromosome. The only predicted gene was the
mouse homologue of the Drosophila gene Bicaudal-C (Bicc1). Bicc1 was
evaluated as a disease-susceptibility gene by examining the sequence of the
Bicc1jcpk allele for mutations using a combination of RT-PCR and sequence
analysis. A single base-pair change (G to A) was detected in the consensus
splice acceptor site of exon 3. This frameshift mutation produces a premature
stop codon predicted to result in a truncated protein. The function of the Bicc1
protein is unknown; however, several functional domains have been identified:
three K Homology (KH) RNA binding domains and one sterile alpha motif (SAM).
Ribonucleotide homopolymer analysis determined that Bicc1 binds RNA in vitro.
In preliminary analyses of PKD-affected Bicc1jcpk/jcpk mice, left/right patterning
defects including dextrocardia and lung isomerism were identified in one animal.
The present work has enabled the identification of a gene, Bicc1, previously
unknown to be involved in PKD pathogenesis and begins to explore the role of
this gene and its corresponding protein in the kidney.

DEDICATION
I would like to dedicate this dissertation to my parents.
Without their understanding, patience and love, the completion of this work would
not have been possible.

iii

ACKNOWLEDGMENTS
I would like to thank the members of my committee for their guidance and
support. Their firm direction has been most appreciated. I would also like to
thank the members of the Department of Microbiology, Immunology, and
Molecular Genetics for their encouragement and assistance. I would like to
personally thank Bryan Brubaker, Bryan O’Dell, William Ian Towler, and Jad
Walters for their dedication and good humor. I would also like to acknowledge
my friends and family for their undying patience.
Finally, I would like to thank my mentor and friend, Dr. Elizabeth C. Bryda. From
the beginning she had confidence in my abilities to not only complete a degree,
but to complete it with excellence.

iv

TABLE OF CONTENTS
ABSTRACT ......................................................................................................................ii
DEDICATION...................................................................................................................iii
ACKNOWLEDGMENTS ..................................................................................................iv
TABLE OF CONTENTS ...................................................................................................v
LIST OF TABLES ............................................................................................................vi
LIST OF FIGURES .........................................................................................................vii
CHAPTER I.......................................................................................................................1
INTRODUCTION................................................................................................................1
Purpose of the Research......................................................................................................... 1
Significance of the Research................................................................................................... 2
Organization of the Dissertation .............................................................................................. 2

CHAPTER II......................................................................................................................4
REVIEW OF THE LITERATURE ...........................................................................................4
Polycystic Kidney Disease ...................................................................................................... 4
Murine Models for Human Disease ....................................................................................... 14
Ciliocentric Theory of PKD Pathogenesis ............................................................................. 22
Vertebrate Left-Right Asymmetry .......................................................................................... 27
Summary ...............................................................................................................................29

CHAPTER III...................................................................................................................30
MATERIALS AND METHODS ............................................................................................30
Genetic and Physical Mapping.............................................................................................. 30
Gene Identification ................................................................................................................ 43
RNA Analysis......................................................................................................................... 48
Protein Analysis..................................................................................................................... 54
RNA Binding Study................................................................................................................ 59
Asymmetry Study .................................................................................................................. 62

CHAPTER IV ..................................................................................................................63
RESULTS ......................................................................................................................63
Genetic and Physical Mapping.............................................................................................. 63
Gene Identification ................................................................................................................ 72
RNA Analysis......................................................................................................................... 84
Protein Analysis................................................................................................................... 118
RNA Binding Study.............................................................................................................. 126
Asymmetry Study ................................................................................................................ 129

CHAPTER V .................................................................................................................132
DISCUSSION................................................................................................................132
Summary and Conclusions ................................................................................................. 132
Future Directions ................................................................................................................. 149

APPENDIX A ................................................................................................................152
APPENDIX B ................................................................................................................155
APPENDIX C ................................................................................................................160
APPENDIX D ................................................................................................................162
APPENDIX E ................................................................................................................165
APPENDIX F.................................................................................................................173
APPENDIX G ................................................................................................................174
BIBLIOGRAPHY...........................................................................................................179
CURRICULUM VITAE ..................................................................................................205

v

LIST OF TABLES
Table 4.1 Exon to exon comparison of the mouse and human Bicaudal-C genes....................... 83
Table 4.2 Description of cell lines examined for Bicc1 expression............................................... 86
Table 4.3 Real-time PCR analysis of PKD genes in jcpk/jcpk mice. ............................................ 94
Table 4.4 Conservation of KH domains across species ............................................................. 123

vi

LIST OF FIGURES
Figure 2.1 Cyst formation in PKD. ................................................................................................... 5
Figure 2.2 Pathological findings observed in cyst formation........................................................... 6
Figure 2.3 Illustration of primary cilia. ........................................................................................... 22
Figure 2.4 Primary cilia extend into the renal tubule lumen.......................................................... 23
Figure 4.1 Genetic map of the 1-cM region containing the jcpk gene. ......................................... 64
Figure 4.2 Physical map of the jcpk region on mouse Chromosome 10. .................................... 65
Figure 4.3 Minimum BAC tiling pattern covering the jcpk critical region...................................... 66
Figure 4.4 EcoR I restriction digestion of BACs within the physical map. ................................... 67
Figure 4.5 Hind III restriction digestion of selected BACs............................................................ 68
Figure 4.6 Radiation hybrid (RH) map of mouse Chromosome 10. ............................................ 71
Figure 4.7 RT-PCR analysis of exons 2-4 of the Bicc1 gene. ..................................................... 74
Figure 4.8 Mutation analysis of the Bicc1 gene. .......................................................................... 75
Figure 4.9 Sequence analysis of the Bicc1 transcript in jcpk/jcpk kidney tissue. ........................ 76
Figure 4.10 Genomic sequence analysis of Bicc1 around exon 3................................................. 76
Figure 4.11 Sequence analysis of the Bicc1 transcript.................................................................. 78
Figure 4.12 PCR analysis to determine alternative transcripts for Bicc1....................................... 79
Figure 4.13 Two protein isoforms are predicted for the Bicc1 gene. ............................................. 80
Figure 4.14 Predicted proteins encoded by the bpk and jcpk alleles. ........................................... 82
Figure 4.15 Tissue expression of Bicc1. ........................................................................................ 84
Figure 4.16 Expression analysis of Bicc1 in mouse cell lines........................................................ 86
Figure 4.17 Embryonic expression of Bicc1................................................................................... 88
Figure 4.18 RT-PCR analysis of embryonic mRNA....................................................................... 89
Figure 4.19 Northern blot analysis of Bicc1 in normal and affected kidney................................... 89
Figure 4.20 Real-time PCR analysis of Bicc1 in jcpk/jcpk kidney.................................................. 91
Figure 4.21 Real-time PCR analysis of Bicc1 in bpk/bpk kidney. .................................................. 92
Figure 4.22 Real-time PCR analysis of pkd1 mRNA expression................................................... 95
Figure 4.23 Real-time PCR analysis of pkd2 mRNA expression................................................... 96
Figure 4.24 Real-time PCR analysis of orpk mRNA expression. .................................................. 97
Figure 4.25 Real-time PCR analysis of Invs mRNA expression. ................................................... 98
Figure 4.26 Real-time PCR analysis of jck mRNA expression. ..................................................... 99
Figure 4.27 Real-time PCR analysis of kat mRNA expression.................................................... 100
Figure 4.28 Real-time PCR analysis of cpk mRNA expression. .................................................. 101
Figure 4.29 Microarray analysis of normal versus polycystic kidneys. ........................................ 102
Figure 4.30 Pax2 gene expression analysis by real-time analysis. ............................................. 104

vii

Figure 4.31 RT- PCR analysis of Egfr (ErbB1) gene expression................................................. 109
Figure 4.32 Real-time PCR analysis of Egfr mRNA expression. ................................................. 110
Figure 4.33 RT-PCR analysis of Tgf-α gene expression. ............................................................ 111
Figure 4.34 Real-time PCR analysis of Tgf-α mRNA expression................................................ 112
Figure 4.36 Real-time PCR analysis of Egf mRNA expression. .................................................. 113
Figure 4.37 Breeding scheme between jcpk and waved-2 mice. ................................................ 114
Figure 4.38 Real-time PCR analysis of ErbB2............................................................................. 117
Figure 4.39 Western blot analysis of the Bicc1 protein................................................................ 119
Figure 4.40 Mouse Bicc1 has two types of functional domains. .................................................. 119
Figure 4.41 Sequence comparison of Bicaudal-C from 10 different species............................... 121
Figure 4.42 Multiple species sequence alignment of the SAM domain of Bicaudal-C. ............... 122
Figure 4.43 Percent sequence homology of the Bicc1 SAM domain in 7 species. ..................... 122
Figure 4.44 Percent sequence homology of all three KH domains. ............................................ 124
Figure 4.45 Consensus sequence comparison in multiple species............................................. 125
Figure 4.46 Schematic diagram summarizing recombinant RNA binding constructs.................. 127
Figure 4.47 RNA binding assay using immobilized poly(U) homoribopolymer............................ 128
Figure 4.48 Summary of RNA binding analysis. .......................................................................... 129
Figure 4.49 Comparison of the presence of L/R patterning defects in littermates. ..................... 131

viii

CHAPTER I
INTRODUCTION

Polycystic kidney disease (PKD) represents a set of hereditary and
acquired nephropathies characterized by progressive cyst formation, substantial
renal enlargement, and frequently, progression to end-stage renal disease. In
the mouse, several distinct recessive mutations produce PKD phenotypes that
mimic the human disease (89). Genetic analysis of epithelial cyst formation in
animal models has facilitated the molecular characterization of novel genes
required for normal epithelial function and has contributed to the understanding
of the cellular pathology observed in cystic disease.

Recent evidence has

suggested that the abnormal kidney development and cyst formation observed in
PKD may be due to structural or functional alterations in the primary apical cilium
of renal epithelial cells. Cilia, which extend from the surfaces of many cell types
and are found in many species, contribute to fluid movement, chemoreception,
and patterning of the left-right body axis (27, 191, 199).
The juvenile congenital polycystic kidney (jcpk) mutation is an autosomal
recessive mouse model of PKD first identified during chlorambucil mutagenesis
studies (67). The initial signs of PKD are visible as early as three days after birth
and are characterized by large cysts in all areas of the nephron, enlargement of
the gallbladder and abnormalities of the biliary and pancreatic ducts.

Purpose of the Research
The objective of the following body of research is to characterize the jcpk
mouse model for polycystic kidney disease (PKD) through both genetic and
molecular analyses. The jcpk locus was previously localized to a 1 cM region
located on mouse Chromosome 10 (28). Two other mouse models, bpk and
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67Gso, have been shown to be allelic to jcpk through complementation analysis
(90, 206).

The purpose of the following research is 1) to identify the PKD

disease-causing gene shared by the jcpk, bpk and 67Gso mouse models; 2) to
use current molecular analyses to evaluate the mRNA and protein expression of
jcpk; and 3) to begin to establish a role for the jcpk gene in the context of current
theories of PKD pathogenesis.

Significance of the Research
The rationale for the research is that once we have discerned the
mechanisms involved in cystogenesis, we will be better able to design treatments
for the more than 12.5 million individuals world-wide who suffer from PKD (35).
Currently, the only established treatments for PKD are renal dialysis and
transplantation. Slowing or eliminating cyst formation may drastically improve
the quality of life for these sufferers. This research is significant in that, unlike
other models for PKD, the jcpk mouse model has a phenotype that encompasses
characteristics observed in many subtypes of PKD as well as other cystic
disorders. Therefore, the information gathered is invaluable to the understanding
of cystic pathogenesis regardless of the genetic cause.

Elucidating the

interaction of the multitude of proteins known to be involved in PKD pathogenesis
will bring scientists closer to effective treatments for PKD and eventually a cure.
This dissertation contributes to the current understanding of PKD
pathogenesis in that it identifies a new gene involved in PKD and begins to
address the possible functional role of the corresponding protein in the kidney.

Organization of the Dissertation
The dissertation is divided into five chapters.

Chapter I defines the

purpose of the dissertation and provides a context for understanding the
following research.

Chapter II provides a precise overview of the relevant

literature describing polycystic kidney disease as well as the current theories of
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cyst formation and progression.

Chapter III is a detailed account of the

methodology and experimental design. Chapter IV provides the results of the
research.

Chapter V summarizes the previous chapters, discusses the

conclusions that can be drawn from the dissertation research, and communicates
the significance of the work in the context of current PKD research.
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CHAPTER II
REVIEW OF THE LITERATURE

Polycystic Kidney Disease
Cystic diseases of the kidney are a clinically important and genetically
diverse group of disorders that share in common altered tubular morphology. Of
these cystic disorders, polycystic kidney disease (PKD) is a principal cause of
end-stage renal failure in individuals who require chronic dialysis and
transplantation (209).

PKD affects over 600,000 Americans and 12.5 million

individuals world-wide (35).

PKD represents one of the most remarkably

dynamic alterations in pathobiology, since affected renal tubules can increase in
diameter from 3 µm to over 5 cm (37). Human PKD can pursue an aggressive
course where renal failure can occur perinatally, or an indolent course with few
symptoms developing during the course of the patient’s life. Historical references
to PKD can be found as early as the 15th century, and since that time there have
been a multitude of publications that have contributed to our current
understanding of the genetic and molecular mechanisms leading to PKD
pathogenesis (258).

Pathogenesis of cyst formation
Renal cysts are abnormal, fluid-filled sacs that arise as dilatations of any
portion of the nephron and collecting ducts. Cysts are lined by a single layer of
continuous epithelium that has a primitive morphologic appearance characterized
by the loss of the apical brush border in proximal tubular cells, cell shape
alterations and an increase in the nuclear/cytoplasmic ratio (148).

Independent

of the cause, only a small fraction of the total nephron population undergoes
cystic change in affected individuals. Cysts may occur in the medulla, in the
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cortex, or in both regions of the kidney and may or may not be associated with
other systemic abnormalities. Cysts seem to originate as diverticula within the
walls of renal tubules (Figure 2.1). These focal areas of tubule wall enlarge
progressively, until eventually, the expanding cysts lose attachment with their
tubule of origin (148).
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CYST
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Gale et al, 2001

Figure 2.1 Cyst formation in PKD. Cysts arise as diverticula of any part of the nephron and
collecting ducts. These out-pocketings eventually lose attachment with their tubule of origin.

Other pathological findings consistently observed in PKD include
alterations in extracellular matrix composition, transepithelial fluid secretion,
changes in epithelial cell polarity, an increase in cellular apoptosis, and improper
epithelial differentiation and proliferation (Figure 2.2) (34).

PKD can also be

characterized as a systemic disorder affecting the liver, spleen, pancreas, biliary
tract, heart, or brain. The extent of extra-renal involvement is dependent on the
type of genetic mutation present and tissue expression of the resulting peptide
products.
5
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Figure 2.2 Pathological findings observed in cyst formation. A number of cellular
abnormalities accompany cystogenesis and include extracellular matrix alterations, primitive
cellular morphology, increased cell proliferation, fluid accumulation and cellular apoptosis.

A variety of polypeptide growth factors have been implicated in the altered
cellular proliferation which accompanies renal tubular cyst formation and
enlargement. Attention has particularly focused on the epidermal growth factor
(EGF)/transforming growth factor α (TGF-α)/epidermal growth factor receptor
(EGFR) axis in mediating tubular cyst formation.

Studies in a number of

laboratories have determined that 1) EGF and TGF-α are cystogenic in a variety
of in vitro systems (13); 2) cystic renal tissue has increased expression of TGF-α
and EGFR (10, 126, 136); and 3) renal cyst fluid contains bioactive and
immunoreactive EGF peptides in mitogenic concentrations (159, 245).
The broad tissue distribution of the EGFR signal-transduction pathway
contributes to the regulation of numerous cellular processes in the development
of both the embryonic and adult kidney. EGFRs are located exclusively to the
basolateral membranes of normal renal tubule epithelia. However, EGFR has
been shown to become mislocalized to the apical surface on the epithelial cells
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lining cystic structures (10). This mislocalization of the EGFR is known to occur
in both humans and mice and is a common end point associated with several
different forms of polycystic kidney disease which are initiated by mutations in
different genes (184, 212, 275). Just recently, it has been observed in a number
of PKD patients that certain alleles of the EGFR transcript may determine the
clinical progression of cystic disease (142). How these different alleles of EGFR
confer susceptibility or protection has yet to be determined. Establishing clinical
treatments for PKD will be greatly facilitated by an understanding of how
individual gene products participate in the disease pathway.

Genetics of PKD
Polycystic kidney disease was once considered to be a rare congenital
malformation with a fate predetermined at birth. Recognition of the hereditary
nature of PKD nearly a century ago has led to the understanding that cyst
formation can result from a mutation in a single susceptibility gene. However, to
alter the normal state of renal epithelia, it is likely that the consequence of this
genetic alteration is the abnormal expression of other genes, initiating a cascade
of gene expression events that ultimately results in cells that function atypically to
initiate cystogenesis.
PKD can be inherited as an autosomal dominant (ADPKD) or an
autosomal recessive trait (ARPKD) (118). ADPKD is a common disease that
occurs in both children and adults, whereas ARPKD is relatively rare and occurs
primarily in neonates and children (73, 288). ADPKD is caused by mutations in
at least two genes on different chromosomes, whereas a single gene is
responsible for ARPKD (200, 283).
Disease progression is quite variable among human PKD families with
either ADPKD or ARPKD. Possible genetic mechanisms that may contribute to
variable expressivity include: 1) mutations in different disease-susceptibility
genes; 2) different alleles of the same disease gene; 3) random somatic events
that disrupt the expression of the wild-type allele; or 4) modifying influences such
as gene-gene or gene-environment interactions (118).

7

Limited genotype-

phenotype analyses of human families with the same disease locus have
revealed minimal correlation between mutant alleles and clinical phenotypes (16,
216).

These data are consistent with observations from other single-gene

disorders in human families where, despite the inheritance of the same mutant
allele, phenotypic expression varies greatly. It has been proposed that in single
gene disorders such as PKD, the primary mutant gene product is embedded in a
highly complex system that includes other independent genetic variations and
modulating environmental factors (56). Therefore, the complexity of PKD makes
it difficult to quickly develop effective therapeutic interventions.

Autosomal Dominant PKD (ADPKD)
ADPKD is one of the most common genetic diseases in humans affecting
all ethnic groups worldwide with an incidence of 1 in 500 to 1 in 1,000 individuals
(148). ADPKD is genetically heterogeneous and can arise from mutations in two
genes, PKD1 and PKD2. Mutations of PKD1 located on human chromosome
16p13.3 are responsible for 85% of cases, whereas mutations of PKD2 on
chromosome 4q21-23 are responsible for close to 15% (200).

Mutations of

PKD1 and PKD2 produce similar renal and extra-renal manifestations. However,
compared with PKD1 patients, PKD2 patients present later in life, have longer
renal survival, and have fewer complications (98). Some patients with typical
features of autosomal dominant polycystic kidney disease have no mutations in
PKD1 or PKD2, suggesting that there may be a rare third form of the disease,
although the proposed gene - PKD3 - has not been identified (274).
The PKD1 gene consists of 46 exons distributed over 52 kb of genomic
DNA (112). The gene encodes a 14.1 kb mRNA transcript that is translated into
a protein composed of 4302 amino acids. Interestingly, the region of the gene
encoding exon 1 to exon 33 is duplicated at six other sites on chromosome 16p.
The duplicated genes are expressed as mRNA transcripts and may represent
pseudogenes (21). The existence of these duplications has hindered mutational
analysis because it can be difficult to distinguish mutations of PKD1 from
sequence variations within the pseudogenes. Different types of mutations within
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PKD1 include splice site mutations, in-frame and out-of-frame deletions as well
as insertions, nonsense mutations, and missense mutations (198, 252).

No

correlations between specific mutations and specific clinical manifestations have
been identified, but mutations in the 5’ end of the gene appear to be associated
with an earlier onset disease than mutations at the 3’ end (65).
The second ADPKD gene, PKD2, was identified in 1996 by a positional
cloning approach (155). The PKD2 gene is located on chromosome 4q21-23
and encodes a 5.3-kb mRNA transcript that is translated into a 968 amino acid
protein. PKD2 is approximately 25% homologous to a region of the PKD1 gene
(155).

Mutations have been identified throughout the transcript and mostly

consist of truncating mutations (frame-shift, splicing, and nonsense mutations)
that would be predicted to inactivate the gene product. Only 5% of mutations
identified are missense mutations (266).
Despite the fact that almost all of the genetically caused cases of ADPKD
are due to mutations in either PKD1 or PKD2, a third gene, PKD3, has been
implicated as the cause of hereditary PKD in a select number of families. A total
of five families have been recognized that have an inheritable autosomal
dominant form of PKD that has no linkage to either PKD1 or PKD2 (7, 50, 51,
150, 177). This form of ADPKD represents a much milder form than PKD1 and
PKD2 where cysts are present in the liver or kidney or both (150). It has been
suggested that this form is so mild that many families carrying mutations in PKD3
remain undetected (7).

Polycystins
The proteins encoded by the PKD1 and PKD2 genes define a new protein
family, the polycystins, which play important roles in a variety of biological
processes including fertilization, ion translocation, and mechanosensation (18,
96, 172). Understanding the structure and function of these proteins has led to a
better understanding of PKD pathogenesis.
Polycystin-1, the product of the PKD1 gene, is an integral membrane
protein that contains several different protein motifs that are involved in protein-
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protein or protein-carbohydrate interactions.

Polycystin-1 is expressed in a

variety of tissues including kidney, heart, bone, and muscle.

In the kidney,

polycystin-1 has been identified in the plasma membrane of tubular epithelial
cells within the nephron and collecting ducts (116). Polycystin-1 is also present
in cell junctional complexes, including adherens junctions and desmosomes
(225).
Polycystin-1 is thought to have several functions within the cell.

The

carboxyl-terminus has been shown to activate the Wnt signaling pathway by
stabilizing β-catenin and activating T-cell factor (TCF) transcription factors during
embryonic kidney development (214).

Polycystin-1 has also been shown to

have a direct role in the regulation of the cell cycle by inducing cell cycle arrest at
the G0/G1 transition.

Progression through the cell cycle is arrested by

polycystin-1 through activation of the JAK-STAT signaling pathway. Activation of
this pathway inhibits Cdk2 by up-regulating its inhibitor, p21CIP1/WAF1.

Mouse

embryos lacking polycystin-1 have defective Stat1 phosphorylation and Waf1
induction (18). Polycystin-1 is also a component of the primary apical cilium on
tubular epithelial cells and is thought to mediate flow response (172).
The PKD2 gene encodes a protein, polycystin-2, that, like polycystin-1, is
predicted to be an integral membrane protein.

Polycystin-2 shares many

structural features with transient receptor potential (TRP) channels as well as
voltage-activated calcium and sodium channels (155).

The carboxyl-terminal

domain contains a motif known as an EF hand that can bind calcium (130).
Polycystin-2 is widely expressed in many tissues, particularly the kidney, heart,
ovary, testis, vascular smooth muscle and the small intestine (145).

In the

kidney, polycystin-2 is expressed in all areas of the nephron except the thin limbs
of the loops of Henle and glomeruli. Within the cell, polycystin-2 was found to be
located in the premedial Golgi compartments (224).
Several studies have shown that the polycystin-2 channel conducts
divalent cations including calcium and that this activity can be stimulated by
calcium on the cytosolic side (83, 96, 264). Another study further determined
that polycystin-2 can amplify calcium release from intracellular stores in response
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to hormone stimulation that transiently increases cytosolic calcium (130).

A

naturally occurring human PKD mutation altering the membrane spanning region
results in complete loss of channel function without apparent loss of expression
of the polycystin-2 protein (130). Taken together, these studies indicate that
polycystin-2 acts to increase cytosolic calcium, and that the loss of this ability
contributes to polycystic kidney disease pathogenesis.
Further in vivo and in vitro analyses have shown that polycystin-2 directly
interacts with polycystin-1 (129, 172, 175).

The carboxyl-terminal domain of

polycystin-1 contains a coiled-coil motif that binds to the carboxyl-terminal
domain of polycystin-2. A deletion in either one of these domains destroys the
interaction (261). Furthermore, co-expression and co-assembly with polycystin-1
have been shown to displace polycystin-2 from the Golgi compartments and
allow relocalization to the cell surface in CHO cells (96). The in vivo functional
significance of this interaction is supported by the observation that polycystin-1
and polycystin-2 act non-redundantly in the same genetic pathway in C. elegans
(14).

The interaction between polycystin-1 and polycystin-2 in a common

pathway would explain why mutations in either PKD1 or PKD2 produce disease
with similar clinical phenotypes.

Autosomal Recessive PKD (ARPKD)
ARPKD is one of the most important childhood nephropathies. It is far less
common than ADPKD with an overall frequency that is estimated to be 1 in
20,000 live births (182). The disease is characterized by a combination of renal
cystic disease, biliary dysgenesis, and portal tract fibrosis (48). ARPKD typically
begins in utero presenting with fusiform dilatation of the renal collecting ducts
that radiate from the medulla to the cortex (122). During fetal development, cysts
also appear transiently in the proximal tubules (171). The renal cystic disease is
invariably associated with biliary dysgenesis, which is a ductal plate malformation
characterized by abnormal intrahepatic bile ducts and portal fibrosis (254).
Fibrosis of the pancreas has also been observed in some patients (289).
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Like ADPKD, the clinical presentation of ARPKD is highly variable and can
present as a perinatal, neonatal, infantile, or juvenile on-set disease (19). The
variability in the age of onset is thought to be due to allelic heterogeneity of the
same gene combined with the effects of modifier genes and environmental
factors rather than mutations within different genes (122). Intrafamilial variability
is far less common than variability between families (52).

Other clinical

manifestations of ARPKD in children and adults include pulmonary hypoplasia,
systemic

hypertension,

growth

retardation,

urinary

tract

infection

and

hyponatremia (69).
All cases of ARPKD are due to a mutation of the Polycystic Kidney and
Hepatic Disease-1 (PKHD1) gene on chromosome 6p21.1-p21. The PKHD1
gene is very large and consists of 86 exons extending over 469 kb of human
genomic DNA (269).

The gene undergoes a complex pattern of alternative

splicing to generate mRNA transcripts ranging in size from 8.5 kb to 13 kb.
Consistent with the phenotype of ARPKD, PKHD1 is expressed in the kidney,
liver and pancreas (269). Different mutations of PKHD1 have been identified in
patients and include frameshift, nonsense, and out-of-frame splicing alterations
that are consistent with a loss of function (269). In addition, an abundance of
missense variants have been identified, the effects of which remain unclear
(269). Further studies are necessary to determine if there is any relationship
between the nature of the mutation and the clinical course of the disease.

Fibrocystin
The protein product of PKHD1 has been named fibrocystin (or polyductin)
and is composed of 4074 amino acids.

Fibrocystin is a membrane protein

consisting of an amino-terminal signal sequence, a large extracellular domain, a
single transmembrane segment, and a short carboxyl-terminal tail with three
potential phosphorylation sites (269). A splice variant that encodes a truncated
protein lacking the transmembrane segment has also been identified and may
encode a secreted form of the protein (283). Based on its predicted protein
structure, fibrocystin may either be a cell surface receptor or a secreted protein.
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Western blot analysis detected fibrocystin in the human kidney and liver.

In

tissues from ARPKD patients, fibrocystin is not expressed verifying that loss of
function mutations are responsible for ARPKD (270).
Immunohistochemical analysis of developing kidneys indicates expression
of fibrocystin in the branching ureteric bud and collecting ducts. This expression
has been found to persist throughout adulthood (270). Extrarenal expression has
been

noted

in

the

biliary

duct,

pancreas

and

developing

testis.

Immunofluorescence analysis of fibrocystin in Madin-Darby canine kidney
(MDCK) cells has shown that it is localized to the primary cilia (270).

Treatment Prospects for PKD
Advances in molecular biology and genetics in the last three decades
have made possible a greater understanding of the mechanisms responsible for
the development of PKD and have laid the foundation for the development of
effective therapies (162). To date, specific treatment strategies for PKD are still
under investigation; but for now, patients are treated as symptoms arise. The
only therapies currently available for PKD affected patients are renal dialysis and
kidney transplantation. The molecular interactions of PKD-susceptibility genes
and their putative genetic modifiers are likely to define critical pathways
fundamental to cystogenesis and PKD progression.

The characterization of

these complex pathways will provide new insights into disease pathogenesis,
identifying new genetic markers for prognosis, and establishing a platform from
which to develop targeted therapies to halt disease progression. One way to
investigate these complex pathways is to study animal models that mimic the
human disease.
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Murine Models for Human Disease
The contribution that animal models have made to the understanding of
the etiology and pathogenesis of human kidney diseases has been invaluable.
Numerous mouse models have been described with mutant phenotypes that
closely resemble human PKD with respect to cyst morphology and localization,
as well as disease progression. These models are the result of gene-specific
targeting in murine orthologues of human PKD genes, spontaneous mutations,
chemical mutagenesis, or transgenic technologies. Several models resemble
human ADPKD as to cyst localization, slow disease progression and extra-renal
abnormalities (86, 89, 168, 227). Other models mimic the pathological features of
ARPKD with rapidly progressing disease and fusiform dilatation of the renal
tubules (168).

PKD Models Arising From Gene-Specific Mutagenesis
The identification of the human ADPKD genes, PKD1 and PKD2, has
prompted the identification and targeted mutagenesis of their mouse orthologues,
Pkd1 and Pkd2. Both null and hypomorphic alleles (Pkd1del34; Pkd1L; Pkd1del1721βgeo

; Pkd1m1Bei) have been generated for the Pkd1 gene (18, 25, 102, 125, 139,

140, 163, 197, 281). Pkd2 mutant alleles have also been generated and include
Pkd2WS25 and Pkd2-/Lacz (197, 281).
Mice heterozygous for the Pkd1 mutant alleles develop renal, biliary, and
pancreatic cysts between 4 and 19 months of age. In homozygous mutants,
disease progression is rapid with embryonic lethality occurring in most cases.
Homozygotes develop renal and pancreatic cysts by embryonic day 15.5 (E15.5).
This is coincident with the initial expression of Pkd1 and Pkd2 in normal maturing
tubular epithelium (25).
Both transgenes for Pkd2 represent null mutations (197, 280).

In

particular, Pkd2-/Lacz homozygous embryos die between E12.5 and birth and are
characterized by cardiac defects and renal failure (197).
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These data

demonstrate that the loss of either PKD1 or PKD2 is sufficient to cause renal
cysts (89).

PKD Models Arising From Spontaneous Mutations
The cpk (congenital polycystic kidneys) mouse model was the first mouse
model for PKD to be described and as such it is the most extensively
characterized (72, 205). Inherited as an autosomal recessive trait, the mutation
spontaneously arose in the C57BL/6J mouse strain at The Jackson Laboratory,
Bar Harbor, Maine. Homozygous affected mutants appear normal at birth but
soon develop aggressive renal cystic disease in a pattern resembling human
ARPKD (46). Cysts have been observed as early as embryonic day 16 (E16)
and are localized to the proximal tubules (12, 75). By post-natal day 5, cysts
begin to develop in the collecting ducts and by post-natal day 21, cystic disease
is primarily localized to the cortical and outer medullary collecting ducts (12).
Death occurs by 3-4 weeks of age from uremia and renal failure (144).
In the cpk mouse model, disease expression and severity have been
shown to be modulated by genetic background (92, 277). Biliary dysgenesis, an
abnormality often associated with human ARPKD, is not penetrant in the
C57BL/J6-cpk/cpk mouse (72).

When the cpk allele is expressed on other

genetic backgrounds (CAST/Ei, DBA/2J, BALB/c, or CD1), cpk mutants have
renal collecting duct cysts as well as both biliary and pancreatic duct
abnormalities (76, 78, 92, 213).

C57BL/J6-cpk heterozygous mice do not

develop cystic disease; however, aged F1 generation heterozygotes on DBA/2J
or BALB/c genetic backgrounds have been shown to develop biliary cysts (89).
The cpk gene, Cys1, maps to mouse Chromosome 12 and was identified
using a positional cloning approach (108, 235). The mutation within the cpk
allele was determined to be a deletion within the first exon.

This mutation

causes a frameshift which results in a premature stop in translation.

The

resulting truncated protein is thought to be nonfunctional (108). Cystin, the 145
amino acid protein encoded by Cys1, is expressed in the primary apical cilia of
renal epithelial cells (108, 284).
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The inv (inversion of embryonic turning) mutation arose in the OVE210
transgenic line due to a random insertional event of the tyrosinase minigene
causing a deletion of exons 3-11 in the Invs gene (158).

Inherited in an

autosomal recessive manner, homozygous mutants are characterized by a
complete reversal of embryonic left-right body axis determination (situs inversus),
renal cysts, pancreatic islet cell dysplasia, and abnormal liver and biliary
development (158). Cardiac malformations of the right ventricular outflow tract
and ventricular septum have also been observed in affected homozygotes (151).
Death due to renal insufficiency usually occurs within the first week of life (154).
The Invs gene maps to mouse Chromosome 4 (158).

The syntenic

interval on human chromosome 9q21-22 contains NPHP2, a gene locus
associated with infantile nephronophthisis (NPHP) type 2 (94). NPHP is a cystic
kidney disease phenotypically similar to PKD and the most frequent genetic
cause of end-stage renal failure in children and adults (103).

Recently, the

NPHP2 gene has been found to be orthologous to the Invs gene in the mouse
(187). The Invs gene has been hypothesized to be a genetic modifier for multiple
renal cystic mouse models, such as the pcy, cpk and jck mouse models (89, 133,
278).
Inversin, the protein encoded by Invs, is a novel protein containing ankyrin
repeats and calmodulin-binding motifs (158). At least three isoforms of inversin
exist, each localizing to different subcellular compartments, including the
nucleus, cell-cell contacts complexed with N-cadherin and the catenins, the
centrosomes, and in primary apical cilia of renal epithelia (158, 178).
The bpk (BALB/c polycystic kidneys) mutation arose as a spontaneous
mutation in an inbred colony of BALB/c mice (188). The bpk mutation is fully
penetrant and transmitted in an autosomal recessive manner (173). Affected
homozygotes die within four weeks after birth from renal insufficiency caused by
massively enlarged kidneys.

Initially, cysts form in the proximal tubules;

however, by post-natal day 21, there is a shift in the location of the cystic lesions
to the collecting ducts (173).

Homozygotes also exhibit liver abnormalities

consisting of proliferative intrahepatic biliary tract ectasia and non-obstructive

16

dilation of the common bile duct (173). The bpk locus was mapped to mouse
Chromosome 10 and through complementation testing was found to be allelic to
jcpk (40, 90, 206).
The jck (juvenile cystic kidney) mutation occurred in a transgenic line of
mice carrying the MMTV/c-myc transgene (8). Additional analyses demonstrated
that the jck locus and the transgene segregated independently.

Thus, the

mutational event that occurred to produce the jck allele was unrelated to the
transgene (8). Homozygous affected mice have palpably enlarged kidneys from
4 to 7 weeks of age and survive 5 to 6 months. However, histological analysis
has shown that focal renal cysts are present as early as three days after birth.
Progressive cystic changes were found with increasing age, shifting from cortical
involvement to outer medullary involvement. Unlike other models for PKD, no
extra-renal abnormalities have been detected (8).
The severity of the renal cystic disease in jck animals has been shown to
be modulated by genetic background and modifier loci have been identified on
mouse Chromosome 1 and mouse Chromosome 10 (114, 133). The jck locus
has been mapped to mouse Chromosome 11 using an intercross between
C57BL/6J-jck and DBA/2J mice (115). The gene has been cloned and the jck
mutant allele has been found to carry a missense mutation in the Nek8 gene
which encodes NIMA (never in mitosis A)-related kinase 8 (138).
The kat (kidney, anemia, testes) mutation arose spontaneously in the
inbred RBF/Dn mouse strain and a second mutant allele, kat2J, occurred
independently in the C57BL/6J strain (119). The kat2J allele is associated with
rapidly progressing renal cystic disease, whereas PKD associated with the kat
allele progresses more slowly. Both kat and kat2J homozygotes express a fully
penetrant, pleiotropic phenotype that includes PKD, facial dysmorphism,
dwarfing, male sterility, anemia, and cystic choroid plexus (119, 262, 267). Renal
cystic disease is first evident at approximately two months of age, with cysts
expressed primarily in the Bowman’s capsule and proximal tubules. Disease
severity is strongly influenced by genetic background (263).
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The kat locus has been found to map to mouse Chromosome 8. The kat
allele involves a 1.3 kb deletion, whereas the kat2J allele results from a single
base-pair insertion (119). The two alleles represent distinct mutations in the
Nek1 gene which encodes the NIMA (never in mitosis A)-related kinase 1. Both
mutations fall within the kinase domain of the protein and are predicted to result
in proteins that lack the entire C-terminal tail (262).
The pcy (polycystic kidney disease) mutation spontaneously occurred in
the KK mouse strain and was found to be transmitted in an autosomal recessive
manner (248). Due to poor reproduction of the KK-pcy mouse strain, a congenic
pcy strain was developed in DBA/2J mice where the mutation was also
transmitted as a fully penetrant, autosomal recessive trait (247). Cystic lesions
observed in newborn pups are localized to the distal tubules. Cysts gradually
extend to all areas of the nephron and death occurs between 30 and 36 weeks of
age (165). Cystic disease severity has been shown to be modulated by genetic
background and two modifier loci regions have been identified (166, 278). Extrarenal abnormalities are uncommon; however, a few mutants do develop cerebral
vascular aneurysm in the later stages of the disease (248). Thus, considering
the slow progression of renal cystic disease and the presence of vascular
aneurysm, the pcy mouse model has long been considered a model for human
ADPKD.
The pcy locus maps to mouse Chromosome 9 which is syntenic to human
chromosome 3q21-22 (167). This region on human chromosome 3 contains the
genetic locus NPHP3, a late onset form of nephronophthisis/medullary cystic
disease (180).

PKD Models Arising From Chemical Induction or Insertional
Mutagenesis
The orpk (Oak Ridge polycystic kidney) mutation was developed as part of
a large-scale insertional mutagenesis program and is designated TgN(lmorpk)737Rpw, abbreviated as TgN737Rpw (160). The transgenic line was generated
on the FVB/N inbred genetic background by pronuclear microinjection of a
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construct containing the bacterial chloramphenicol acetyltransferase gene under
the control of a mutated version of the polyoma early region promoter (22). In
the FVB/N inbred genetic background, homozygous mutant animals have scruffy
fur, pre-axial polydactyly of all limbs, polycystic kidney disease, abnormalities of
the intrahepatic biliary tract, pancreatic ductal hypoplasia, and are severely
growth-retarded (160, 286). Skeletal anomalies have also been observed and
include craniofacial abnormalities, cleft palate, and extra teeth (290).
Most orpk/orpk mice on the FVB/N genetic background die within the first
week of life, although a few animals live for several months. In contrast, on the
C3H inbred background, affected mice display a less severe phenotype (239).
These animals live longer, have polydactyly that is more variable, have renal
cysts that progress at a slower rate, and have less aggressive liver disease. This
difference in phenotypic expression dependent on genetic background suggests
the presence of important modifier genes. This variable phenotypic severity is
also seen in human ARPKD, in which the severity of the phenotype and the
nature of the liver disease are quite variable (17, 239).
The mutant locus in the TgN737Rpw transgenic line has been mapped to
mouse Chromosome 14 (247).

This novel gene encodes polaris, a protein

containing multiple copies of a 34-amino acid tetratricopeptide repeat (TPR)
(160). The TPR motif was first described in lower eukaryotes and found to exist
in proteins involved in cell cycle control, protein import, and transcription (82,
234). Protein localization studies have shown that polaris is expressed in basal
bodies and the primary cilia of renal epithelium (251). The human gene has
been cloned and maps to human chromosome 13 (160).
Northern blot analysis has indicated that the primary transcript of 3.2 kb is
normally expressed in a number of tissues including kidney and liver but was
absent in all tissues in orpk/orpk homozygotes. Two other larger transcripts of
lower abundance have also been found.

Expression of the predominant

transcript as a transgene (Tg737Bap) in orpk mutants rescues the renal cystic
phenotype (285).
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Genetic analysis has also determined that Tg737orpk is a hypomorphic
allele (160, 251, 286). An SV40 conditionally immortalized cortical collecting duct
cell line has been derived from Tg737orpk homozygous mice. These cells do not
develop normal primary renal cilia, but can be corrected by the introduction and
re-expression of the wild type Tg737 gene (284).
A second targeted mutation, Tg737∆2-3βGal, represents a null allele (161).
Homozygous Tg737∆2-3βGal embryos die in early to mid-gestation, with left-right
axis specification defects, failure of neural tube closure, and limb patterning
defects (161).
The 67Gso (t(2;10)67Gso) mutation arose during the course of large-scale
mutagenesis studies (40). Animals homozygous for the 67Gso mutation express
a severe form of early onset PKD characterized by renal and hepatic cysts at
birth. Affected newborns are smaller and much weaker than their littermates,
and develop a protruding abdomen by one day after birth. Survival is limited to
three to four days after birth.

Affected pups develop a yellow-orange

pigmentation before death, indicating liver failure. Histological examination of the
kidneys indicated many narrow, elongated cysts that extended from the cortex
radially toward the medullary pyramid (40).
The phenotype expressed by 67Gso homozygotes is associated with
inheritance of a t(2;10)(H1;C1) reciprocal translocation.

Complementation

studies with 67Gso heterozygotes and jcpk heterozygotes, another autosomal
recessive PKD mouse mutation (see below), produced animals with disease
indicating that 67Gso was allelic to jcpk (40, 206).

Further, FISH analysis has

indicated that the putative 67Gso breakpoint on mouse Chromosome 10 is within
the region containing the jcpk gene (41).
The jcpk (juvenile congenital polycystic kidney) mutation was first
identified during chlorambucil (CHL) mutagenesis studies (66). The disease in
homozygous jcpk/jcpk mice is characterized by severe cystic disease in all areas
of the nephron, from the glomerulus to the collecting ducts (66). Signs of the
disease are visible as early as 3 days after birth, with death generally occurring
by ten days of age.

A number of extra-renal abnormalities have also been
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observed, including enlargement of the gallbladder and abnormalities of both the
biliary and the pancreatic ducts. Heterozygotes appear phenotypically normal;
however, 30% of these mice exhibit cystic disease localized to the glomeruli by
the age of 10 months. Bile duct abnormalities and hepatic cysts were also noted
in some heterozygous animals (66).
The jcpk locus has been previously localized by precise genetic mapping
in an intercross with Mus musculus castaneus, to a region of approximately 1 cM
flanked by the polymorphic genetic markers D10Mit115 and D10Mit173 on
mouse Chromosome 10 (28). Another autosomal recessive PKD mouse mutant,
bpk, has also been localized to this same genetic region (90). Affected bpk
homozygotes have disease that is different in terms of age of onset and
phenotype compared to jcpk homozygotes. However, complementation testing
between heterozygotes (+/jcpk X +/bpk) resulted in offspring with cystic kidney
disease, indicating that jcpk and bpk are allelic.

The differences in disease

between jcpk versus bpk mice are likely due to the effect of the particular
mutation carried by each and to differences in genetic background (C57BL/6J for
jcpk versus BALB/c for bpk). As previously mentioned, similar complementation
studies between jcpk and 67Gso indicated that these two mutations are also
allelic. Based on these data, it was predicted that all three mouse models were
due to different mutations in the same gene. The genetic region containing the
jcpk/bpk/67Gso locus overlaps with the genetic interval containing a putative
PKD modifying locus, Pkdm2, which influences the disease phenotype of another
independent PKD mouse mutant, jck (115). The disease-causing gene shared
by the jcpk, bpk, and 67Gso mouse models, Bicc1, its identification,
characterization and potential role in PKD pathogenesis are the focus of this
dissertation.
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Ciliocentric Theory of PKD Pathogenesis
Despite the growing number of genetic mutations attributed to the
formation of cysts in the kidney, the pathogenic mechanisms behind PKD still
remain elusive. Recent studies in human and animal models have suggested
that primary cilia of renal tubular epithelial cells may function to maintain normal
tubular architecture, and that ciliary abnormalities may be a cause of cyst
formation in polycystic kidney disease.
Primary cilia have an axonemal structure consisting of a circular array of
nine pairs of microtubules (9+0 arrangement) (Figure 2.3).

Cilia with this

configuration are generally immotile, with the exception of embryonic node cilia
that direct morphogen flow which is important for left-right axis (L/R) specification
(176, 179).

Figure 2.3 Illustration of primary cilia. Primary or monocilia are a distinct type of cilium
and are responsible for the establishment of L/R asymmetry in early embryos. Primary cilia
are also found in various organs, including skin, kidney (renal tubule epithelium) and blood
vessels (endothelium) where their functions are largely unknown. (Illustration courtesy of Dr.
Stephen Fish, Department of Anatomy, Cell and Neurobiology, Joan C. Edwards School of
Medicine, Marshall University)

Primary cilia are a common feature of polarized epithelial cells in
eukaryotes and are thought to serve either a chemosensory or mechanosensory
function. Primary cilia often contain high concentrations of receptors and are
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ideally positioned to interact with the environment, as with the odorant receptors
on olfactory cilia or the highly specialized cone and rod photoreceptors that
respond to light (215). In fact, cilia are thought to contain more than 200 proteins
that maintain their formation and function (62).
Renal cilia project into the tubule lumen from the apical (luminal) surface
of all renal tubular cells except the intercalated cells of the collecting duct (181)
(Figure 2.4).

Figure 2.4 Primary cilia extend into the renal tubule lumen. In the kidney, cilia are
present throughout much of the nephron and collecting duct. Cilia project from the apical
surface of the epithelia into the tubule lumen, where they are optimally positioned to function
in a sensory capacity. (Illustration courtesy of Dr. Stephen Fish, Department of Anatomy,
Cell and Neurobiology, Joan C. Edwards School of Medicine, Marshall University)

Electron microscopy of the rat nephron has detected the presence of
primary cilia on cells of the parietal wall of the renal corpuscle, the proximal
tubules, the thin limb of Henle’s loop, the distal tubule, and the collecting duct
(68, 259). These cilia have been shown to reversibly bend in response to lateral
fluid shear forces, as visualized by real-time video recorded under conditions that
resemble actual tubule flow rates (203). Fluid shear-force bending of the primary
cilia of Madin-Darby canine kidney (MDCK) cells has been shown to increase
intracellular calcium, from both extracellular and intracellular sources, and to
transmit these signals to adjacent cells through gap junctions (203). Deciliation

23

by chloral hydrate treatment abolishes flow-induced calcium increases but does
not affect calcium mobilization in response to mechanical cell-surface stimulation,
indicating that cilia are mechanosensory flow sensors (204). This flow-induced
increase in intracellular calcium also caused membrane hyperpolarization and
increased potassium conductance (204).
In addition to mechanosensation, it is possible that renal cilia may function
in a chemosensory capacity, such as with cilia found on olfactory neurons of
mammals and in Caenorhabditis elegans (132, 222, 228, 259). If renal cilia do
act as sensors in the tubule lumen, the cilium length may be a critical factor in
signaling efficacy. A few mouse mutants for PKD have shortened or absent
cilium but this is not a common denominator among all mouse models for PKD
that have defects in cilia proteins (161, 179, 191, 213).
The synthesis of primary cilia involves the process of intraflagellar
transport (IFT) in which large particles or “rafts” containing protein cargo are
transported bidirectionally along the ciliary axoneme (192).

The anterograde

movement of proteins along the axoneme is mediated by kinesin-II, a
heterotrimeric protein composed of two motor subunits (KIF3A and KIF3B) and
one non-motor subunit (KAP). Conventional knockout mice that completely lack
KIF3A fail to synthesize cilia in the embryonic node and exhibit randomization of
left-right symmetry and structural abnormalities of the neural tube, pericardium,
branchial arches, and somites (147, 249). Tissue-specific Cre-loxP inactivation
of Kif3a in renal tubular epithelial cells results in viable offspring with normalappearing kidneys at birth. However, cysts begin to develop in the kidneys at
postnatal day 5 and cause renal failure by postnatal day 15. The cystic epithelial
cells were found to lack primary cilia and exhibit increased proliferation and
apoptosis, apical mislocalization of the epidermal growth factor receptor (EGFR),
and increased expression of β-catenin, c-Myc and p21CIP1 (137). These results
demonstrate that the absence of renal cilia produces both the clinical and
molecular findings associated with PKD.
A number of groups have reported the possible involvement of genes
associated with PKD in either the assembly or function of cilia in mice and
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Caenorhabditis elegans. The first evidence for the ciliocentric theory of PKD
pathogenesis was provided by the orpk mouse model. The product of this gene,
polaris, is localized in the axoneme and basal body of primary cilia and is
required for ciliary assembly (287). Similarly, the inv mouse model for PKD also
has a connection to primary cilia. Several isoforms of the inversin protein have
been described and have been localized to primary apical cilia, cell-cell adhesion
sites and the nucleus (157, 178).
The cpk mouse model for PKD has also been linked with cilia. The gene,
Cys1, encodes cystin-1, has been localized in the axonemal region of primary
cilia and partially overlaps with the localization of polaris (108). Interestingly, cpk
mutants have PKD despite structurally normal cilia (89, 213).
A further link between cilia defects and PKD is provided by the Pkd1-/LacZ
mouse, in which a targeted deletion of exon 1 was generated using a LacZ
“promoter trap” (197).
-/Lac

homozygous for Pkd1

Pkd1 is localized to renal primary cilia and mice
develop renal and pancreatic cysts.

Parallel work in C. elegans identified orthologues of PKD1 (lov-1, for
location of vulva) and PKD2 (pkd-2), whose protein products were found
specifically in the cilia or male sensory neurons co-localizing with OSM-5, an
orthologue of polaris, and IFT88, the orthologue of an intraflagellar transport
protein in Chlamydomonas (15, 99, 210). Mutations in lov-1 or pkd-2 seemed to
affect ciliary function, whereas osm-5 (osm, for osmotic avoidance) mutations
affected ciliary structure. These discoveries prompted researchers to question
whether the mammalian polycystins reside in the cilia of renal epithelial cells.
Studies have demonstrated that polycystin-1 and polycystin-2 co-localize
to the primary cilia of cultured kidney cells and mouse kidney tubule cells in vivo
(193).

These two proteins are thought to work together to mediate

mechanosensation (172, 284).

This was demonstrated by showing that the

calcium flux induced by fluid-flow ciliary bending did not occur in polycystin-1 null
cells or when cells were treated with polycystin-1 or polycystin-2 blocking
antibodies (172). Although the cellular functions of the polycystins are unknown,
there is evidence suggesting that polycystin-1 (PC1) (3) is a receptor that
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regulates polycystin-2 (PC2) calcium channel activity (53, 189, 190). By acting
as a ciliary mechanoreceptor, PC1 may sense luminal flow rates through ciliary
bending and signal morphologically relevant information through a number of
cellular signaling pathways to establish and maintain appropriate luminal
dimensions. Activated by signals from PC1, PC2 would then act as a tensiongated ion channel to generate an influx of calcium (33).

Calculations have

suggested that as few as one polycystin-2 molecule per cilium is sufficient to
trigger the measured calcium influx in MDCK cells (204). Loss or dysfunction of
PC1 or PC2, or cilia dysfunction in general, would impair the mechanosensing
capability of epithelial cells, causing defects in cellular differentiation and tubular
integrity that in turn leads to cyst formation.
The potential connection between cilia and PKD is intriguing. Elucidating
the function of primary cilia and their association with PKD will require a detailed
characterization of proteins involved in ciliogenesis and cilia function, as well as
the development of reagents and assays to test the role of primary cilia in renal
physiology.
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Vertebrate Left-Right Asymmetry
The establishment of the three body axes – anterior-posterior (A/P),
dorsoventral (D/V), and left-right (L/R) – is central to the organization of the
vertebrate body plan. A distinctive and essential feature of the vertebrate body is
a pronounced left-right asymmetry of internal organs and the central nervous
system. L/R axis determination is determined last, and consequently, defects
that arise from abnormal L/R patterning are less severe than A/P or D/V defects,
making experimental observations much easier (95).
In the process of left-right (L/R) axis formation in the mouse, the
embryonic node plays a critical role in the initial breaking of L/R symmetry (95).
The current model for the establishment of left-right axis asymmetry depends
upon the motility of primary cilia in the embryonic node to generate a net leftward
flow of extra-embryonic fluid to ultimately create a morphogen gradient around
the node.

This morphogen gradient is proposed to provide a signal for

subsequent asymmetric gene expression at the lateral plate mesoderm (95).
These signals for "left" and "right" are ultimately interpreted by organ primordia to
establish asymmetry of the visceral organs. Complex activating and inhibiting
interactions involving TGF-β family members, as well as homeobox transcription
factors, mediate these asymmetric patterns of gene expression (131).
The investigation of the mechanisms regulating left-right axis patterning in
model organisms has resulted in the characterization of human mutations
associated with left-right axis malformations. These observations indicate that
the loss of primary cilia function on the embryonic node results in the
randomization of visceral organs (26). This is observed in Kartagener syndrome
in which loss of cilia motility can result in random laterality of heart looping where
the heart is on the wrong side of the midline.

This loss of motility is also

responsible for situs inversus viscera (mirror image reversals in the orientation of
internal organs), bronchiectasis, sinusitis, and infertility (2). These patients have
mutations in genes encoding components of the ciliary motor, including defects in
dynein intermediate chains and dynein heavy chains (246).
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There is a growing body of evidence that links ciliary dysfunction,
embryonic left-right patterning defects and cystic disease of the visceral organs,
e.g., kidney, liver and pancreas. Polaris is one of many proteins that appear to
function in ciliogenesis and L/R body axis determination (161). A targeted null
mutation in Tg737, Tg737∆2-3βGal, results in complete loss of nodal cilia, left-right
axis asymmetry defects, failure of the neural tube to close, limb patterning
defects, and embryonic lethality (161, 251). In contrast, homozygosity for the
Tg737orpk hypomorphic allele results in renal, biliary and pancreatic cysts (251).
Mice homozygous for the Invs gene have both reversal of L/R visceral
asymmetries and renal cystic disease (158). Ultrastructural analysis of the cilia
of inv homozygotes indicate that the nodal cilia are present and motile, but can
produce only very weak leftward nodal flow (179). Recent evidence has also
indicated that mice containing a knockout of the Kif3a gene fail to synthesize cilia
in the embryonic node and exhibit randomization of left-right asymmetry and
structural abnormalities of the neural tube, pericardium, branchial arches and
somites (147, 249). However, tissue-specific inactivation of Kif3a in the kidney
results in severe PKD. The cyst epithelium lack cilia and exhibit increased cell
proliferation and apoptosis (137). Finally, targeted null mutations in Pkd2 result
in right pulmonary isomerism, randomization of embryonic turning, heart looping
and abdominal situs (197).
Currently, the common mechanism that links cilia, L/R asymmetry, and
PKD is still unknown. Further studies of cilia formation and function might yet
reveal a fundamental mechanism that underlies both L/R asymmetry and PKD
pathogenesis. Establishing clinical treatment for PKD will be greatly facilitated by
an understanding of how individual gene products participate in the disease
pathway.
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Summary
Polycystic kidney disease (PKD) is a common genetic cause of chronic
renal failure in children and adults, and is characterized by the accumulation of
fluid-filled cysts in the kidney (118). Renal cysts originate from the epithelia of
the nephrons and renal collecting system and are lined by a single layer of
continuous epithelium that has higher rates of cellular proliferation and are less
differentiated than normal tubular cells. Abnormalities in gene expression, cell
polarity, fluid secretion, apoptosis, and extracellular matrix have also been
described in PKD (117, 118). A number of genes in humans and animal models
have been identified that, when mutated, cause PKD.

Despite the growing

number of genetic mutations attributed to the formation of cysts in the kidney, the
pathogenic mechanisms behind PKD still remain elusive. In order to understand
how individual gene products participate in cyst formation and disease
pathogenesis, a detailed characterization of PKD-susceptibility genes and the
proteins that they encode is required. The objective of the following body of
research is to characterize the jcpk mouse model for polycystic kidney disease
(PKD) through both genetic and molecular analyses.

The jcpk locus was

previously localized to a 1 cM region located on mouse Chromosome 10 (28).
Two other mouse models, bpk and 67Gso, have been shown to be allelic to jcpk
through complementation analysis (90, 206).

The purpose of the following

research is 1) to identify the PKD disease-causing gene shared by the jcpk, bpk
and 67Gso mouse models; 2) to use molecular analyses to evaluate the mRNA
and protein expression of jcpk; and 3) to begin to establish a role for the jcpk
gene in the context of current theories of PKD pathogenesis.

No specific

treatments for PKD currently exist, so it is hoped that a more complete
understanding of the molecular pathogenesis of this disease will identify novel
therapeutic strategies.
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CHAPTER III
MATERIALS AND METHODS

Genetic and Physical Mapping
Mouse Strains
Mice used for these studies were bred at the Joan C. Edwards School of
Medicine, Marshall University, Huntington, WV.

The jcpk mutation was first

identified during chlorambucil mutagenesis experiments (67).

Male (101/Rl x

C3H)F1 mice were treated with 10 mg/kg of chlorambucil. Treated males were
then mated with Tester females. The progeny of this cross were intercrossed
twice so that recessive visible mutations could be recovered (67). The PKD
phenotype was recognized by a grossly enlarged abdomen appearing in 3 to 10day old mice (66). The jcpk mutation has been backcrossed at least 40 times to
the C57BL/6 (B6) mouse strain. B6 mice were purchased from The Jackson
Laboratory (Bar Harbor, Maine). The 101/Rl mice were obtained from The Oak
Ridge National Laboratory (Oak Ridge, Tennessee). Both B6 and 101/Rl were
maintained at the Marshall University Animal Resource Facility, Huntington, WV.
Mice were bred for colony maintenance and as a source of tissues for DNA, RNA
and protein analyses. Animals were observed from birth for signs of polycystic
kidney disease and were euthanized at obvious signs of discomfort.
Heterozygous mice carrying the waved-2 mutation (a/a Egfrwa2/J) were
purchased from The Jackson Laboratory (Bar Harbor, Maine).

Mouse waved-2

(wa2) was first identified as a mutation in the Egfr gene in an “abnormal corpus
callosum” stock at the Bussey Institution (141).

The waved-2 mutation is

inherited as an autosomal recessive trait. Matings between mice heterozygous
for the jcpk mutation and homozygous for the wa2 mutation generated compound
heterozygous animals. Compound heterozygous females were backcrossed to
male mice homozygous for the wa2 mutation to produce mice that were
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heterozygous for the jcpk allele and homozygous for the wa2 allele.

Male

offspring that were heterozygous for jcpk and homozygous wa2 were mated to
females that were heterozygous for both alleles to generate double mutant
animals. Crosses involving female wa2/wa2 homozygotes were avoided due to
impaired lactation (71). The jcpk mutation was determined to be present in mice
using genotyping assays discussed below and the wa2/wa2 homozygotes were
recognized phenotypically by their wavy coat and curly whiskers that can be
observed as early as 2-3 days after birth (71). All mice were maintained under a
17 hour light - 7 hour dark cycle and fed Purina™ Rodent Chow 5001. Pregnant
and lactating mice were fed Purina™ 5K67 NIH Rat and Mouse Autoclavable
Diet. Mice were given non-sterile, non-filtered water and maintained in standard
rodent cages at ambient temperature. All procedures performed on the above
mice were approved by the Marshall University Institutional Animal Care and Use
Committee (IACUC).

Genomic DNA Extraction
Genomic DNA was extracted from tail biopsy and isolated tissues by
several methods. Tail DNA was isolated based on a simplified mammalian DNA
isolation procedure (135).

Tail biopsies of no longer than 0.5 cm were

transferred immediately to a 1.5 ml tube containing 0.5 ml of lysis buffer (100 mM
Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, and 100 µg/ml
Proteinase K) immediately upon removal. The tubes were then transferred to a
rotating shaker and agitated at 200 rpm at 55°C overnight. Following incubation,
the tubes were vortexed and centrifuged at maximum speed for 10 minutes. The
supernatants were transferred to pre-labeled 1.5 ml tubes containing 0.5 ml of
isopropanol. DNA was recovered by centrifugation at maximum speed for 15
minutes at 4°C. Pellets were suspended in 50 µl of sterile dH2O.
Genomic DNA was also extracted using the HotSHOT DNA extraction
procedure (260). A small snip of mouse tail was removed using a sterile scalpel
blade while mice were under anesthesia. The snip of mouse tail was then added
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to 75 µl of alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH 12) and
incubated for 30 minutes at 94°C. After incubation, 75 µl of neutralizing buffer
(40 mM Tris-HCl, pH 5) was added. Genomic DNA from mouse tissues was
extracted using the Wizard® Genomic DNA Purification kit (Promega, Madison,
WI).
Blood spots were also collected for DNA analysis. Freshly snipped mouse
tails were touched to 3M Whatman filter paper to generate spots of blood
followed by cauterization of the tail wound. The spots were allowed to air dry
followed by a 15 minute wash in methanol to preserve the blood on the filter
paper.

The spots were allowed to air dry again and were stored at room

temperature. The dried spots were then cut from the Whatman paper and used
for genotyping.

Genotyping
The polymorphic marker D10Mit42 was found to be genetically linked to
the jcpk mutation and was used to initially genotype mice prior to gene
identification (66).
The following primers were used:
F: 5’GCATTCAGAAGCTGGAAAGG3’
R: 5’TGCCCAGCATATGTTTAAAGG3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. Tail snips or blood spots prepared as above were boiled for ten
minutes in 10 ul of sterile dH2O and used as genomic DNA sources. The forward
primer of D10Mit42 was radioactively labeled with γ-[32P]dATP by T4
polynucleotide kinase for 30 minutes at 37°C, then 10 minutes at 65°C. A 25 ul
PCR reaction containing 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3,
100 mM KCl, 32 µg/ml BSA, 400 µM of each dNTP), 0.25 µl 10 µM reverse
primer, 1µl Taq DNA polymerase (5 U/µl), and 1 µl 50 ng/µl DNA was amplified
under the following conditions: 2 minutes at 97°C; 25 cycles of 95°C for 30
seconds, 56°C for 30 seconds, and 72°C for 30 seconds, with a final extension at
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72°C for 7 minutes. Fifty nanograms of purified genomic DNA from C57BL/6J,
101/Rl, and Tester were also labeled and amplified as controls.

The PCR

products were then denatured at 95°C for 5 minutes and were separated by
electrophoresis in 1X TBE on 5% denaturing polyacrylamide gels at 60 watts for
1 hour. Gels were dried on a gel dryer at 80°C for 15 minutes. The bands were
detected using autoradiography: the gel was exposed to X-ray film in cassettes
containing an intensifying screen and stored overnight at -80oC. Mice identified
as heterozygotes based on this linkage analysis were backcrossed to known
heterozygotes (+/jcpk) of the opposite sex to confirm the presence of the jcpk
mutant allele.
Once the jcpk gene was identified, an allele-specific mutation assay was
developed for genotyping purposes. Genomic DNA was extracted from tail snips
using the HotSHOT DNA extraction protocol as described previously. A 30 ul
PCR reaction containing 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3,
100 mM KCl, 32 µg/ml BSA, 400 µM of each dNTP), 0.25 µl 10 µM each primer,
1µl Taq DNA polymerase (5 U/µl), and 10 µl of the tail prep DNA extracted by the
HotSHOT method was amplified under the following conditions: 40 cycles of
92°C for 1 minute, 57°C for 1 minute and 72°C for 2.5 minutes.
The following primers were used for the amplification:
F: 5’CCTTTCTTGGATTTAGCCCC3’;
R: 5’CTCCGAGGACGATCTGGTGG3’.
Primers were sythesized by the Marshall University DNA Core Facility,
Huntington, WV.
Following PCR, 15 µl of the amplification reaction was used for
amplification product separation on a 1% agarose gel containing 0.5 µg/ml of
ethidium bromide.

A 187 bp product is visible upon separation by gel

electrophoresis in 1X TAE buffer, at 100 V for 30 minutes. The jcpk mutation
eliminates a DdeI restriction enzyme site in the 187 bp PCR product. Therefore,
20 µl of the previous PCR reaction mix was used in an endonuclease restriction
digest reaction performed overnight with 10 units of DdeI at 37°C (New England
BioLabs, Inc., Beverly, MA).

The restriction digestion was analyzed by gel
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electrophoresis on a 3% agarose gel containing 0.5 µg/ml of ethidium bromide, in
1X TAE at 100 V for 30 minutes. Homozygous normal mice (wild type) have two
bands that are 115 and 72 bp in length. Homozygous affected mice (jcpk/jcpk)
do not have the DdeI restriction site and have a single 187 bp band.
Heterozygous animals (+/jcpk) have three bands:

a 187 bp fragment

corresponding to the jcpk allele and two fragments of 115 and 72 bp that
correspond to the wild type allele.

High Resolution Genetic Mapping
In order to significantly narrow the region on mouse Chromosome 10
thought to contain the jcpk gene, the polymorphic markers 393H9SP6RPT and
282P18T7RPT were analyzed by radioactively labeling 12 µM of one PCR primer
with γ-[32P]dATP using T4 polynucleotide kinase in a 12 µl reaction (Invitrogen,
Carlsbad, CA) for 30 minutes at 37°C and then 65°C for 10 minutes.

Fifty

nanograms of purified genomic DNA from jcpk recombinant animals (28),
C57BL/6J, 101/Rl, C3H/HeJ, CAST/Ei, and BALB/c were used for 30 ul PCR
reactions containing 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3, 100
mM KCl, 32 µg/ml BSA, 400 µM of each dNTP), 0.25 µl 10 µM each primer, and
1µl Taq DNA polymerase (5 U/µl) and 0.24 µl of the kinase reaction from above.
PCR was performed under the following conditions: 2 minutes at 97°C; 25 cycles
of 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds; with a final
extension of 72°C for 7 minutes. The radioactively labeled amplification products
were denatured by addition of 6 µl of Stop Buffer (80% formamide, 50 mM TrisHCl (pH 8.3), 1 mM EDTA, 0.1% (wt/vol) xylene cyanol, and 0.1% (wt/vol)
bromophenol blue) followed by incubation at 95oC for 5 minutes.

Prior to

separation of samples, 5-6% denaturing polyacrylamide gels in 1X TBE were
pre-run at a constant of 60 watts for greater than 15 minutes. Three µl of each
denatured sample was then loaded on the pre-run gels followed by gel
electrophoresis at 60 watts.

Gels were dried on a gel dryer at 80°C for 15

minutes and differences in control and recombinant PCR products were detected
using overnight exposure to X-ray film at -80°C with an intensifying screen. Size

34

differences between B6 and 101/Rl were used as controls and were compared to
jcpk recombinant animals in order to determine the position of both
393H9SP6RPT and 282P18T7RPT relative to known markers on the genetic
map representing the jcpk critical region on mouse Chromosome 10. Primer
sequences for 393H9SP6RPT are as follows:
F: 5’CCAGGAGGTGAAGGAGAGCA3’
R: 5’GCTGGAAAACTGCCATGACC3’.
Primer sequences for 282P18T7RPT are as follows:
F: 5’CTTGGTCTCCTAATGCCTGC3’
R: 5’TGTATTGCATAACCCCAGCA3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV.
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Physical Mapping
Construction of the physical map representing the region on mouse
Chromosome 10 thought to contain the jcpk gene was initially performed by
PCR-based screening of two different mouse whole-genome BAC libraries.
Analysis of the CITB BAC library (Research Genetics, Huntsville, AL) and the
Mouse ES-129/SvJ BAC library (Genome Systems, St. Louis, MO) was
performed according to manufacturer’s protocols.

Positive BAC clones were

identified from either of the above libraries and subsequently analyzed by PCR
for marker content. BAC end nucleotide sequences were determined by isolating
and subcloning the ends of the BACs into an appropriate high copy number
plasmid vector followed by sequence analysis of the subclone, or alternatively,
direct sequence analysis of the BAC was performed to determine the nucleotide
sequence on the ends of the BACs. Primers were designed based on these BAC
end sequences and the libraries were re-screened with the new primers.
The RPCI-23 mouse whole-genome C57BL/6 BAC library (Research
Genetics, Huntsville, AL) was screened using a procedure known as multiplex
oligonucleotide hybridization or “overgo” (32).

Overgo is a genomic library

screening method that relies on the design of highly specific 3'-overlapping
oligonucleotide (overgo) probes comprised of two 24 base oligonucleotides with
an 8 base pair (bp) overlap. The overgo probes are labeled by adding radioactive
nucleotide monophosphates to the 3'-recessed ends.

These probes are

multiplexed and used to quickly and efficiently screen an entire mouse wholegenome library in a single step. A large number of BACs can be identified at one
time instead of using several rounds of PCR amplification as required in other
screening methods.
To obtain RCPI-23 BAC end sequence information in order to design
overgo primers for library screening, the BAC end sequence annotation database
at

http://www.tigr.org/tdb/bac_ends/mouse/bac_end_intro.html

was

used.

Downloaded sequences were processed through the computer software
RepeatMasker (http://genome.wustl.edu/gsc/repeatmasker) to eliminate regions
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containing repetitive elements and by analysis of the non-redundant sequence
database at www.ncbi.nih.gov using the Basic Local Alignment Search Tool
(BLAST) (5) to insure that the regions used for overgo primer design were
unique. Sequence-specific overgo primers were designed using an interactive
website (http://genome.wustl.edu). Primer sequences for the overgo primers can
be found in Appendix A. All primers were synthesized by the Marshall University
DNA Core Facility, Huntington, WV.
All overgo probes were radioactively labeled and used simultaneously to
screen the entire RPCI-23 library spotted on seven Hybond nylon membranes
(Research Genetics, Huntsville, AL). Each membrane contained 27,648 unique
BAC DNAs spotted in duplicate. Overgo probes were radioactively labeled in a
reaction containing 3 µl of overgo primer mix (10 pmol/µl of each primer), 1.5 µl
of BSA (2 mg/ml), 2 µl α-[32P]dATP (3000 Ci/mmol, 10 mCi/ml), 2 µl α-[32P]dCTP
(3000 Ci/mmol, 10 mCi/ml), 2 µl of Klenow fragment (2 U/ul), 13.5 µl of sterile
dH2O and 6 µl of OLB (1:2.5:1.5 ratio of solutions A:B:C). Individual solution
components are as follows: Solution O (1.25 M Tris-HCl, pH 8.0, 125 mM MgCl2),
Solution A (1 ml Solution O, 18 µl 2-mercaptoethanol, 5 µl 0.1 M dTTP, 5 µl 0.1
M dGTP), Solution B (2 M HEPES-NaOH, pH 6.6), and Solution C (3 mM TrisHCl, pH 7.4, 0.2 mM EDTA) (32). The labeling reaction was incubated at room
temperature for two hours.

Unincorporated nucleotides were removed using

Sephadex NICK™ columns (Amersham Biosciences, Piscataway, NJ). Separate
overgo labeling reactions were combined into one NICK™ column to provide a
single mixed reaction.

The seven nylon membranes containing the spotted

BACs were then separated into two hybridization bottles (30 cm x 4 cm).
Membranes were wet with warmed 1X SSC and layered onto hybridization mesh.
All filters were rolled together in the same direction and inserted into two
hybridization bottles. With the cap on, the bottles were rotated manually to allow
the membranes and mesh to unroll in the bottle. The 1X SSC was removed and
replaced with 30 ml of pre-warmed sodium phosphate hybridization buffer (0.5 M
sodium phosphate, 1% BSA, 1 mM EDTA, pH 8.0 and 7% SDS). Membranes
were pre-hybridized for 2 hours at 60°C with constant rotation in a hybridization
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oven. After pre-hybridization, 5 ml of hybridization buffer from each bottle was
removed and pooled in a 25 ml conical tube. The labeled probe mixture was
denatured by boiling for 10 minutes. The probe mixture was then added to the
10 ml of hybridization buffer, mixed and 5 ml of this mixture was returned to each
hybridization bottle. The membranes hybridized at a temperature of 60°C for a
minimum of 18 hours.
After incubation at 60°C, the hybridization solution was removed and each
bottle was filled with room temperature 4X SSC, 0.1% SDS. The bottles were
then returned to the hybridization oven and rotated for 30 minutes at 60°C. The
membranes were transferred to a large plastic container on a rotary shaker and
washed in the following manner: 1.5X SSC, 0.1% SDS at 58°C for 30 minutes
where the hybridization mesh was left between the membranes; 0.75X SSC,
0.1% SDS at 58°C for 30 minutes with the mesh removed between the
membranes. Both washes were rotated at a constant speed of 30 rpm. The
membranes were then sealed in plastic bags and attached to individual 3M
Whatman sheets. The membranes were exposed to X-ray film at -80°C without
an intensifying screen for 12-16 hours.

Positive clones were identified and

purchased as glycerol stocks (Research Genetics, Huntsville, AL). BAC DNA
used for analysis was isolated using the QIAGEN plasmid DNA extraction kit
(QIAGEN, Inc., Valencia, CA).
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Slot Blot Analysis
To determine which BACs contained a specific overgo probe sequence,
slot blot hybridization analysis was performed. Briefly, 500 ng of each purified
BAC DNA suspended in sterile dH2O was denatured with 0.1 volume of 1 N
NaOH for 5 minutes in a boiling water bath and immediately put on ice. One
volume of 2 M ammonium acetate, pH 7, was then added to neutralize the
denatured sample. A nylon membrane and two sheets of 3M Whatman paper for
each blot were pre-wet in deionized water and then soaked in 6X SSC prior to
use.
Slot blots were produced using the standard manufacturer’s protocol
provided with the slot blotting manifold (Schleicher and Schuell, Keene, NH).
Individual slots were washed with 6X SSC on constant low vacuum
(~1ml/minute). With the vacuum still on, the BAC DNA sample was applied and
filtered on low vacuum. BAC DNA was immobilized on the nylon membranes by
UV irradiation at 120mJ/cm2.
Membranes were then pre-hybridized at 60°C in 20 ml of HyperHyb™
(Research Genetics, Huntsville, AL) for 30 minutes with constant rotation.
Individual overgo probes were radioactively labeled as previously described
followed by individual NICK™ column (Amersham Biosciences, Piscataway, NJ)
purification. Probes were denatured by boiling for 10 minutes. The membranes
were hybridized with each probe for 2 hours at 60°C with constant rotation.
Membranes were then washed with 1.5X SSC, 0.1% SDS at 58°C for 10
minutes; 0.75X SSC, 0.1% SDS at 58°C for 5 minutes followed by overnight
exposure with X-ray film at -80°C. Membranes were scored for the presence or
absence of a specific marker in order to position BACs onto the physical map.

PCR Amplification
BAC identification by slot blot hybridization analysis was confirmed by
PCR amplification using BAC end specific primers and a panel of 100 ng/ul of
purified BAC DNAs as well as human, CAST/Ei, BALB/c, 101/Rl, B6, 129aa and
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hamster A23 genomic DNA. Primer sequences can be found in Appendix B. All
primers were designed using Primer3 computer software (218) and synthesized
by the Marshall University DNA Core Facility, Huntington, WV. A 30 ul PCR
reaction containing 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3, 100
mM KCl, 32 µg/ml BSA, 400 µM of each dNTP), 1µl Taq DNA polymerase (5
U/µl), 0.25 µl 10 µM each primer and 1 µl 100 ng/µl DNA was amplified under the
following conditions: 97°C for 2 minutes; 35 cycles of 95°C for 30 seconds, the
primer-specific annealing temperature for 30 seconds, and 72°C for 30 seconds;
with a final extension of 72°C for ten minutes.

Amplification products were

resolved on 2% agarose gels containing 0.5 µg/ml ethidium bromide, in 1X TAE
at 100 V for 30 minutes. The presence or the absence of bands was noted as
well as any size differences.

If differences between 129aa mouse and A23

hamster DNA were present, these markers were also evaluated by radiation
hybrid mapping.

Radiation Hybrid Mapping
Radiation hybrid (RH) mapping is another technique with which to order
DNA markers with respect to one another on a mouse chromosome.

X-ray

fragmented mouse genomic DNA (129aa) is recovered in hamster (A23) cells to
produce hybrid clones. Approximately 100 clones are developed that represent
the whole-mouse genome. These clones are analyzed by PCR to determine the
presence or absence of specific mouse DNA markers (45). DNA from each of
100 hybrid clones from the mouse T31 radiation hybrid panel (Research
Genetics, Huntsville, AL) was used for construction of a radiation hybrid map of
mouse Chromosome 10 (149). PCR amplification was performed under standard
conditions with 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3, 100 mM
KCl, 32 µg/ml BSA, 400 µM of each dNTP), 0.25 µl 10 µM each primer, 1µl Taq
DNA polymerase (5 U/µl), 25 ng of DNA (55). A 30 µl PCR reaction was
amplified at 97°C for 2 minutes; 35 cycles of 95°C for 30 seconds, the
appropriate annealing temperature for a given primer set for 1 minute, 72°C for 1
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minute; and a final extension step of 72°C for 7 minutes. Amplification products
were separated on 3% agarose gels containing 0.5 µg/ml ethidium bromide, in
1X TAE at 100 V for 30 minutes.
For each locus, the 100 cell lines were typed for the presence or absence
of a mouse-specific amplification product. Every locus was independently typed
a minimum of three times in each cell line. Data for each locus was combined
and analyzed with other loci using the computer analysis software RHMAP (20).
The primer sequences for all D10Mit markers and M-02039 were obtained and
are available at http://www-genome.wi.mit.edu.
other typed loci are in Appendix C.

The primer sequences of all

All primers used for RH analysis were

synthesized by the Marshall University DNA Core Facility, Huntington, WV.

BAC Overlap Estimation
Nucleotide sequence overlap between BAC clones was assessed by
determining common markers and by comparing BAC Hind III and EcoR I (New
England BioLabs, Inc., Beverly, MA) restriction digestion patterns analyzed by
gel electrophoresis on 1% agarose gels separated in 1X TBE overnight at 20 V.
Gels were stained with 0.5 µg/ml ethidium bromide. Gel images were captured
using the Gel Doc Imaging System (Bio-Rad, Hercules, CA).

DNA Sequencing
In order to identify potential gene candidates for the jcpk gene, six BACs
between the genetic markers D10Mit115 and 282P18T7 (RP23-310N21, RP23395K5, RP23-337L15, RP23-440N1, RP23-348F2, and RP23-282P18) were
chosen and sequenced in their entirety as part of the NHGRI BAC sequencing
program.

Sequences were analyzed using a number of gene identification

programs

including

GrailEXP

v3.2

(http://compbio.ornl.gov),

GENSCAN

(http://genes.mit.edu/GENSCAN.html) and Ensembl (www.ensembl
.org). Genomic DNA and cDNA sequence analysis of the Bicc1 gene in wild type
strains B6, 101Rl, and DBA/2J as well as in the mutant jcpk strain was performed
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at Marshall University, Huntington, WV. Primers used for sequence analysis can
be found in Appendix D. All primers were synthesized by the Marshall University
DNA Core Facility, Huntington, WV.
Ensembl was used to obtain additional information on Bicc1 and its
intron/exon structure.

Sequence homology between mouse and human

sequences was determined by comparing both the mouse and human
chromosome sequence databases (www.ncbi.nih.gov) using the Basic Local
Alignment Search Tool (BLAST) (5).

42

Gene Identification
EST Candidate Analysis
A number of expressed sequence tags (ESTs) were evaluated as possible
candidates for the jcpk gene. EST clones have been designated by GenBank
accession numbers. I.M.A.G.E clones were obtained from Research Genetics,
Huntsville, AL. Several ESTs were identified by BLAST analysis of BAC end
sequences obtained from the TIGR annotation database (http://www.tigr.org).
EST-specific PCR primers were designed using the available sequence
information. All primers were synthesized by the Marshall University DNA Core
Facility, Huntington, WV.

Slot blot analysis was performed as previously

described using nylon membranes containing purified BAC DNA and
radioactively labeled EST-specific PCR products as probes to determine the
position of the ESTs within the jcpk critical region.
ESTs determined to be within the jcpk critical region were further analyzed
by Northern blot analysis. Total RNA from the kidneys and livers of normal adult
B6 and 7-day old jcpk/jcpk animals was isolated using the RNAeasy kit with oncolumn DNase I digestion (QIAGEN, Inc., Valencia, CA) or by using Trizol
Reagent (Invitrogen, Carlsbad, CA). Briefly, 50-100 mg of frozen tissue was
homogenized on ice in 1 ml of Trizol Reagent. The sample was incubated at
room temperature for 5 minutes to completely dissociate nucleoprotein
complexes. Two hundred microliters of chloroform was added and the tubes
were vortexed for 15 seconds and incubated at room temperature again for 2-3
minutes.

Samples were centrifuged at 12,000 x g for 15 minutes at 4°C.

Following centrifugation, the aqueous layer was removed and the RNA
was precipitated by the addition of 500 µl isopropanol. Samples were incubated
on ice for 10 minutes and the samples were centrifuged at 12,000 x g for 10
minutes at 4°C.

The RNA pellet was washed with cold 75% ethanol and

collected by centrifugation at 12,000 x g for 5 minutes at 4°C. The pellet was
dried and resuspended in 100 µl of nuclease-free water (Ambion, Austin, TX).
Genomic DNA contamination was removed using the DNA-free kit (Ambion,
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Austin, TX). Northern blots were prepared with 20-30 µg of total RNA on
Hybond N+ membranes (Amersham Biosciences, Piscataway, NJ) using a
standard protocol for Northern analysis (70).

RNA was separated on a

denaturing formaldehyde 1% agarose gel in 1X MOPS/EDTA buffer at room
temperature overnight at 20 V. Probes were made by isolating plasmid inserts
from I.M.A.G.E. clones by restriction enzyme digestion.

Products of the

restriction digestions were separated on 1% agarose gels containing 0.5 µg/ml
ethidium bromide, in 1X TAE at 100 V for 30 minutes. The isolated I.M.A.G.E
clone inserts were cut from the gel and purified using the Gel Extraction
Purification Kit (QIAGEN, Inc., Valencia, CA). The concentration of the plasmid
inserts was estimated by agarose gel electrophoresis and comparison with a low
mass ladder (Invitrogen, Carlsbad, CA).
Radioactive probes were prepared by labeling 100 ng of purified insert
with α–[32P]dCTP for 2 hours using the Random Primers DNA Labeling System
(Invitrogen, Carlsbad, CA).

Unincorporated radionucleotides were removed

using NICK™ columns (Amersham Biosciences, Piscataway, NJ). Blots were
placed in hybridization buffer (50% formamide, 10% 50X Denhardt’s solution,
10% 20X SSC, 10% Dextran SO4, 0.5% SDS) and pre-hybridized at 42°C for 1
hour. Probes were boiled with 1 mg of salmon sperm DNA solution (Invitrogen,
Carlsbad, CA) for 10 minutes. The denatured probes were added to the blots
and hybridized at 42°C overnight with constant rotation in a hybridization oven.
Northern blots were washed two times in 2X SSC, 0.1% SDS at 55°C for 15
minutes and one time in 0.1X SSC, 0.1% SDS at 55°C for 15 minutes. Blots
were wrapped in clear plastic wrap and exposed to X-ray film at -80°C for 1-4
days with an intensifying screen.
ESTs localized to the region of mouse Chromosome 10 between
D10Mit115 and D10Mit173 were also mapped in a standard PCR reaction using
a panel of purified BAC DNAs covering the entire critical region. A 30 ul PCR
reaction containing 2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3, 100
mM KCl, 32 µg/ml BSA, 400 µM of each dNTP), 0.25 µl 10 µM each primer, 1µl
Taq DNA polymerase (5 U/µl), and 100 ng of DNA was amplified under the
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following conditions: 97°C for 2 minutes; 35 cycles of 95°C for 30 seconds, the
primer-specific annealing temperature for 30 seconds, and 72°C for 30 seconds;
with a final extension of 72°C for ten minutes.

Amplification products were

separated on 1% agarose gels containing 0.5 µg/ml ethidium bromide, in 1X TAE
at 100 V for 30 minutes.
All primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. The following primers were used for PCR:
AW260721 (I.M.A.G.E. 23316553)
F: 5’CCAACTACGACAGAGGAAATGGA3’
R: 5’CCTTCTGAAACTTCTTAGTCCTGTTGA3’;
BB498314
F: 5’TTGGGGTCCACATTCAGTCA3’
R: 5’TGATGCTATTGGGGAGACTGG3’;
AI956350 (I.M.A.G.E. 2136285)
F: 5’TTGCCAATGACTGTTCGTGG3’
R: 5’TCCTTGATGGAAGGCTGCAT3’;
AA674570 (I.M.A.G.E. 1003910)
F: 5’CTTTGGCAGAAGGGGTGAGC3’
R: 5’GCCAGGCTACAGTTACAGCTCC3’.

Southern Blot
ESTs were also mapped by Southern blot analysis. Amplification products
from PCR using the above primer sets were radioactively labeled with the
Random Primers Labeling System (Invitrogen, Carlsbad, CA) and used to probe
nylon membranes containing purified BAC DNA digested with the restriction
enzymes Hind III or EcoR I (New England BioLabs, Beverly, MA). Blots were
hybridized at 42°C overnight in hybridization buffer (50% formamide, 10% 50X
Denhardt’s solution, 10% 20X SSC, 10% Dextran SO4, 0.5% SDS) and washed
with 2X SSC, 0.1% SDS at 55°C for 15 minutes then 0.1X SSC, 0.1% SDS at
55°C for 10 minutes. Blots were placed in plastic bags and exposed to X-ray film
overnight at -80°C with an intensifying screen.
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Mutation Detection
RT-PCR analysis to determine if mutations exist in the coding region of
Bicc1 was performed using the Superscript One-Step RT-PCR System
(Invitrogen, Carlsbad, CA) with 0.25 µl 10 µM each primer and 500 ng of purified
total RNA from 101/Rl (+/+), +/jcpk, and jcpk/jcpk mouse kidneys under the
following conditions: 45°C for 30 minutes, 94°C for 2 minutes; 40 cycles of 94°C
for 30 sec, 64°C for 45 sec, 72°C for 1 minute; and 72°C for 10 minutes. The
following primers were used:
F: 5’CTCCGAGGACGATCTGGTGG3’
R: 5’TCTGGGAAGTGGATGTGGCA3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. Amplification products were separated on a 2% NuSieve (FMC
Corporation, Philadelphia, PA) gel containing 0.5 µg/ml ethidium bromide, in 1X
TAE at 80 V for 45 minutes. Images were captured on the GelDoc Imaging
System (Bio-Rad, Hercules, CA).

Reverse Transcription
A 20 µl reverse transcription reaction was performed with 2.0 µg of total
mouse kidney RNA extracted from 4-day old mice along and 1 µl of 100 uM
random hexamers (MU DNA Core Facility, Huntington, WV), and 1 µl of 10 mM
dNTP mix (Sigma-Aldrich, St. Louis, MO). The mixture was heated to 65°C for 5
minutes and then placed on ice. To the tube, 4 µl of 5X First Strand Buffer
(Invitrogen, Carlsbad, CA), 2 µl of 0.1 M DTT, and 1 µl of RNaseOUT
Recombinant Ribonuclease Inhibitor (40U/µl) (Invitrogen, Carlsbad, CA) were
added and the reaction was incubated at 25°C for 10 minutes, and then at 37°C
for 2 minutes.

One microliter of M-MLV Reverse Transcriptase (200 U/µl)

(Invitrogen, Carlsbad, CA) was then added and the mixture was incubated at
37°C for 50 minutes and finally 70°C for 15 minutes.
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Alternative Transcripts
For the detection of alternative transcripts for Bicc1 in mouse ESTs and
mouse kidney cDNA, the following primers were used:
F: 5’GTGCCCGAAGGAAAATGCTG3’
R: 5’GCAGGCGAGTGCAGTGAAGA3’.
Primers were synthesized by the Marshall University DNA Core Facility.

The

following ESTs were used in the PCR analysis in order to determine if alternative
transcripts exist:

AW240366 (I.M.A.G.E. 2655954), BF785275 (I.M.A.G.E.

4236691) and AI595208 (I.M.A.G.E. 493392). A 30 ul PCR reaction containing
2X PCR buffer (3 mM MgCl2, 20 mM Tris-HCl, pH 8.3, 100 mM KCl, 32 µg/ml
BSA, 400 µM of each dNTP), 0.25 µl 10 µM each primer, 1µl Taq DNA
polymerase (5 U/µl), and either 50 ng of purified plasmid DNA or 5 µl of cDNA
(as described in Reverse Transcription) was amplified under the following
conditions: 35 cycles of 97°C for 2 minutes, 97°C for 30 seconds, 60°C for 30
seconds, and 72°C for 30 seconds; with a final extension of 72°C for 10 minutes.
Amplification products were separated on 2% NuSieve (FMC Corporation,
Philadelphia, PA) agarose gels containing 0.5 ug/ml ethidium bromide, in 1X TAE
at 80 V for 45 minutes.
Determination of alternative transcripts for Bicc1 was also performed by
RT-PCR analysis using the above primers and the Superscript™ One-Step RTPCR kit (Invitrogen, Carlsbad, CA). Total RNA was extracted from adult mouse
brain, testis, liver, kidney and 7-day old jcpk/jcpk kidney, and amplified under the
following conditions: 45°C for 30 minutes, 94°C for 2 minutes; 40 cycles of 94°C
for 30 seconds, 60°C for 45 seconds, and 72°C for 1 minute; and a final
extension of 72°C for 10 minutes. Amplification products were separated on 22.5% agarose gels containing 0.5 ug/ml ethidium bromide in 1X TAE at 80 V for
45 minutes. Images were captured using the GelDoc Imaging System (Bio-Rad,
Hercules, CA).
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RNA Analysis
Northern Blot Analysis
To determine the size and tissue expression of Bicc1 mRNA,
prefabricated Northern blots were commercially obtained (CLONTECH, Palo
Alto, CA) and hybridized with the full-length insert of AW240366 (I.M.A.G.E clone
2655954).

The Northern blots contained purified poly A+ RNA from various

mouse tissues that was separated on a denaturing formaldehyde 1.0% agarose
gel, transferred to a nylon membrane and fixed with UV irradiation. The isolated
cDNA insert from AW240366 was radioactively labeled using the Random
Primers Labeling System (Invitrogen, Carlsbad, CA). Unincorporated nucleotides
were removed using NICK™ columns (Amersham Biosciences, Piscataway, NJ).
Northern blots were hybridized using ExpressHyb™ (CLONTECH, Palo Alto, CA)
according to the manufacturer’s instructions.

RT-PCR Analysis
Embryonic expression of Bicc1 was determined by RT-PCR analysis using the
following primers:
F: 5’CAGGAAGAAACTCGAGGCCA3’
R: 5’AATGTGGCCTGGGCAGTAGA3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. RT-PCR analysis was performed using the Superscript™ OneStep RT-PCR System (Invitrogen, Carlsbad, CA) with 0.25 µl 10 µM each primer
and 100 ng of purified total RNA from adult mouse or whole embryos at
embryonic days 5 and 10.

Amplification proceeded under the following

conditions: 45°C for 30 minutes, 94°C for 2 minutes; 40 cycles of 94°C for 15
sec, 59°C for 30 sec, 72°C for 2 minutes; and a final extension of 72°C for 10
minutes. Amplification products were separated on a 2% agarose gel containing
0.5 ug/ml ethidium bromide in 1X TAE buffer at 100 V for 30 minutes. Images
were captured on the GelDoc Imaging System (Bio-Rad, Hercules, CA).
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Dot Blot Analysis
Dot blot analysis for embryonic expression of Bicc1 was also performed
using a commercially available dot blot containing poly A+ RNA extracted from 7day, 11-day, 15-day and 17-day mouse embryos (CLONTECH, Palo Alto, CA).
The isolated insert from BF785275 (I.M.A.G.E. clone 4236691) was radioactively
labeled using the Random Primers Labeling System (Invitrogen, Carlsbad, CA).
Unincorporated nucleotides were removed using NICK™ columns (Amersham
Biosciences, Piscataway, CA). The slot blot was hybridized using ExpressHyb™
(CLONTECH, Palo Alto, CA) according to the manufacturer’s indications.
Images were collected using the Typhoon 8600 Image Capture System
(Amersham Biosciences, Piscataway, NJ).

Densitometry analysis was

performed using ImageQUANT software (Visual Molecular Dynamics, Urbana,
IL).

Real-time PCR
Expression of Bicc1 in 101/Rl and jcpk/jcpk kidney tissues was determined
by real-time PCR analysis with TaqMan™ (Applied Biosystems, Foster City, CA)
amplification detection. The following primers were designed for amplification:
F: 5’GTTACCGATTGCCGGGATT3’
R: 5’GTTTGTGAGATGTGCTGAATGGA3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington,

WV.

A

single

Taqman™

probe

was

designed,

5’FAM-

TCCAGCCAGTCCCCGATCCCA-TAMRA3’, with 6-FAM at the 5’ end and
TAMRA at the 3’ end in order to detect amplicon quantity on the iCycler™ Realtime PCR system (Bio-Rad, Hercules, CA). The following conditions were used
in a standard 30 µl PCR reaction containing 100 nM of each primer, 200 nM of
the fluorescent probe, 3.0 mM MgCl2, 300 uM dNTP mix (Sigma-Aldrich, St.
Louis, MO), 10X PCR Reaction Buffer (Applied Biosystems, Foster City, CA), 1 µl
Taq DNA polymerase (5U/µl) and 2 µl of normal or jcpk/jcpk kidney cDNA (as
described in Reverse Transcription): 95°C for 5 minutes; 40 cycles of 95°C for 15
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seconds and 57°C for 1 minute. No extension step was included and optical data
was taken at the 57°C annealing step.

Four replicates of each sample were

included and the entire amplification procedure was repeated in triplicate. Eight
different standards were included in triplicate representing 102 to 109 DNA
molecules per reaction tube. These standards were serial dilutions of a known
amount of the 3 kb cDNA insert of AW240366 and were amplified along with the
experimental tubes.

Data was analyzed using SigmaPlot statistical software

(SSPS Inc., Chicago, IL).
Real-time PCR with SYBR Green (FMC Corporation, Philadelphia, PA)
was used to compare Bicc1 mRNA expression in age-matched BALB/c and
bpk/bpk kidneys. The following primers were used in the analysis:
F: 5’CAAGCGGCAGACGGTTGAGC3’
R: 5’GGACATATGTTGGCTGCGAGGC3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. The following conditions were used in a 30 ul PCR reaction
containing 100 nM of each primer, 3.0 mM MgCl2, 300 uM dNTP mix (SigmaAldrich, St. Louis, MO), 2 µl of cDNA (as described in Reverse Transcription), 1µl
Taq DNA polymerase (5U/µl) and 2 µl of SYBR Green (1:10,000 stock) at a
1:20,000 dilution: 95°C for 5 minutes; 40 cycles of 95°C for 30 seconds, 65°C for
30 seconds and 72°C for 1 minute.
extension step.

Optical data were taken at the 72°C

Four replicates of each sample were included and the entire

amplification procedure was repeated in duplicate.

Eight different standards

were included in duplicate representing 102 to 109 DNA molecules per reaction
tube. These standards were serial dilutions of the quantified gel-extracted PCR
product for the particular gene analyzed. This product was used as a template
and amplified along with the experimental tubes.

Data was analyzed using

SigmaPlot statistical software (SSPS Inc., Chicago, IL).
Real-time PCR analysis of Egfr, Egf and Tgf-α mRNA expression was
performed as described above with the following primers:
Egfr
F: 5’ TGCCAGAAATTGACCAAAAT3’
R: 5’ CTTCGTAGTAGTCAGGCCCA3’;
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Egf
F: 5’AAACCAGGCTGATGATGGTA3’
R: 5’ACCGTCCAGTGAAGAAGACA3’;
Tgf-α
F: 5’TAGCGCTGGGTATCCTGTTA3’
R: 5’ACACATGCTGGCTTCTCTTC3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. Tissues used for this analysis were age-matched progeny from
+/jcpk X +/jcpk crosses.

Real-time PCR analysis with SYBR Green (FMC

Corporation, Philadelphia, PA) was used to compare gene expression of Egfr,
Egf, and Tgf-α in age-matched +/+, +/jcpk and jcpk/jcpk kidneys. The following
conditions were used in a standard 30 µl PCR reaction containing 100 nM of
each primer, 3.0 mM MgCl2, 300 uM dNTP mix (Sigma-Aldrich, St. Louis, MO), 1
µl Taq DNA polymerase (5U/µl), 2 µl of cDNA and 2 µl of SYBR Green (1:10,000
stock) at a 1:20,000 dilution: 95°C for 5 minutes; 40 cycles of 95°C for 30
seconds, 65°C for 30 seconds and 72°C for 1 minute.

Optical data were taken

at the 72°C extension step. Four or five replicates of each sample were included
and the entire amplification procedure was repeated in duplicate or triplicate.
Eight different standards were included in duplicate or triplicate.

These

standards were serial dilutions of the quantified gel extracted PCR product
depending on the gene analyzed and used as an indicator of DNA copy number.
This product was used as a template and amplified along with the experimental
tubes.

Data was analyzed using SigmaPlot statistical software (SSPS Inc.,

Chicago, IL). For real-time characterization of expression of other PKD-causing
genes, the following primers were used:
Pkd1
F: 5’TATAGCTGGACAGCGCAGCA3’
R: 5’CAGGCCAGGTGTAGCAAAGG3’;
Pkd2
F: 5’CCATGAGCCAGCTCTCCACAA3’
R: 5’GGCCCCAAAACTCGGTTAGC3’;
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cpk (Cys1)
F: 5’ACGCCTGCTGGATCAGTTGC3’
R: 5’TGCTCGCCATGAGCTCCTCT3’;
Invs
F: 5’CCTGCCAGCCTGGTGTTTAG3’
R: 5’TGTGGCCTGGTCACCAAGTA3’;
orpk (Tg737)
F: 5’TCCTGGTGAGACAACGAGAGC3’
R: 5’CCGATCTCCAATGGCAAAAC3’;
jck (Nek8)
F: 5’GTCCCCTGAGGTTGCCAATG3’
R: 5’AATGGTGGGCTGGCTGATGT3’;
kat (Nek1)
F: 5’TGGGACAGTGCAGCTTGGAGA3’
R: 5’TGAGACAGCAAGCTGCGGAGA3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV.

Reaction components and amplification were the same as

described previously.

Microarray
For microarray analysis, two sets of frozen kidney tissues: three 8-day old
B6 kidneys and one 8-day jcpk/jcpk kidney were sent to CLONTECH
Laboratories (Mt. View, CA) and used to identify differences in gene expression
between B6 and jcpk/jcpk kidneys.

The Atlas Mouse 1.2 Microarray used

contained over 1,176 different genes (CLONTECH, Mt. View, CA).
Alterations in gene expression detected by microarray were confirmed by
real-time PCR analysis using SYBR Green (Sigma-Aldrich, St. Louis, MO) as a
fluorescent indicator of product amplification. The following conditions were used
in a standard 30 µl PCR reaction containing 100 nM of each primer, 3.0-4.0 mM
MgCl2, 1 µl Taq DNA polymerase (5U/µl), 300 uM dNTP mix (Sigma-Aldrich, St.
Louis, MO), 2 µl of cDNA and 2 µl of SYBR Green (1:10,000 stock) at a 1:20,000
dilution: 95°C for 5 minutes; 40 cycles of 95°C for 30 seconds, the appropriate
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annealing temperature for 30 seconds and 72°C for 1 minute. Optical data were
taken at the 72°C extension step. Four replicates of each sample were included
and the entire amplification procedure was repeated in duplicate. Eight different
standards were included in duplicate. These standards were serial dilutions of
quantified gel extracted PCR product. This product was used as a template and
amplified along with the experimental tubes and represented DNA copy number.
Data was analyzed using SigmaPlot statistical software (SSPS Inc., Chicago, IL).
The primers used for real-time analysis are as follows:
ErbB2 (L47239)
F: 5’ATGATGACATGGGGGAGCTG3’
R: 5’GCAGTCCTTTGGTTACCCCC3’;
Pax2 (X55781)
F: 5’CTCAGGCAACCCATACAGCCR’
R: 5’CGACAGGGTGATGAGAAGGG3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV.

53

Protein Analysis
Protein Isoform Characterization
In silico analysis was used to structurally characterize the various isoforms
of the Bicc1 protein. These tools are located at www.expasy.org and include
PeptideMass (207, 273) and EMBOSS (194, 195).

Antibody Production
In order to characterize the Bicc1 protein, an anti-Bicc1 polyclonal
antibody was raised in rabbit against a recombinant fusion protein containing the
first 81 amino acids of the mouse Bicc1 protein.

A blunt-end 247 bp PCR

product of the first two exons of the Bicc1 gene was produced in a 50 µl PCR
reaction containing 1 µl of Pfx DNA polymerase (Invitrogen, Carlsbad, CA), 100
ng of the purified plasmid AW240366, 1 mM MgSO4, 10X Pfx Amplification
Buffer (Invitrogen, Carlsbad, CA), 0.3 µM each primer, and 0.3 mM each dNTP.
Primers used to generate the construct from the template are as follows:
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’CTTCTGAAAAAAGTCTTCCCC3’.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV. PCR was performed under the following conditions: 2 minutes
at 94°C and 35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 3 minutes.
The PCR product that was produced was gel purified using the QIAGEN gel
extraction kit (QIAGEN, Inc., Valencia, CA) and directionally ligated into the
Champion™ pET101/D-TOPO expression vector (Invitrogen, Carlsbad, CA)
containing both V5 and 6X Histidine epitopes.

Plasmid ligation reactions were

used to transform TOP10 chemically competent E. coli (Invitrogen, Carlsbad, CA)
which were plated onto Luria-Bertani (LB) agarose plates containing 100 ug/ml of
ampicillin (Fisher Scientific International, Hampton, NH). Isolated colonies were
screened based on insert size which was determined by restriction digestion with
SacI and XbaI (New England Biosystems Inc., Beverly, MA). Clones containing
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the correct inserts were grown overnight and extracted with the QIAGEN Plasmid
DNA extraction kit (QIAGEN, Inc., Valencia, CA).

Sequence analysis of the

isolated plasmid DNA was performed on an ABI 310 sequence analyzer (Applied
Biosystems, Foster City, CA) using vector-specific primers to determine
orientation of the insert. The following primers were used:
T7 Forward: 5´-TAATACGACTCACTATAGGG-3´
T7 Reverse: 5´-TAGTTATTGCTCAGCGGTGG-3.
Primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV.
A recombinant plasmid containing an in-frame Bicc1 insert was
transformed into BL21 (DE3) chemically competent E. coli (Invitrogen, Carlsbad,
CA) and grown overnight in 10 ml of Luria-Bertani (LB) media containing 100
µg/ml of ampicillin and 1% glucose at 37°C, 200 rpm on a rotating shaker. Three
ml of the overnight culture were used to seed 250 ml of LB containing 100 µg/ml
of ampicillin and 1% sterile glucose. Cultures were grown for two hours or until
an A600 of 0.4-0.6 was reached. Protein expression was induced with 1.0 M
isopropyl-β-D-thiogalactoside (IPTG) (Fisher Scientific International, Hampton,
NH) at a final concentration of 0.5 mM. Induced cultures were grown overnight
and pelleted by centrifugation at 5,000 rpm for 15 minutes at 4°C. Cell pellets
were resuspended in a volume of 5 ml/gram weight of pellet in denaturing lysis
buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 8M Urea, pH 8.0), sonicated on ice for
1 minute, and incubated on a rotating shaker at 4°C for 30 minutes. Lysates
were sonicated again for 1 minute and incubated at 4°C for another 30 minutes
with rotation. Lysates were then centrifuged at 4°C at 16,000 rpm for 20 minutes
to produce a cleared cell lysate.
The cleared cell lysates were concentrated to a volume of approximately 5
ml using Centriprep-50 spin columns (Millipore, Billerica, MA). The cleared cell
lysates were further purified by Ni+-NTA resin chromatography under denaturing
conditions (QIAGEN, Inc., Valencia, CA). Proteins were eluted under low pH.
Eluted protein was further purified using YM-10 Centricon centrifugal filter
devices (Millipore, Billerica, MA).

The Centricon devices were centrifuged at
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5,000 rpm for 1.5 hours at 10°C in a fixed angle rotor.

Complete protease

inhibitor (Roche, Indianapolis, IN) was then added to the concentrated proteins at
a concentration of 1 tablet per 50 ml of elution buffer.
Eluted proteins were separated on 15% SDS-PAGE gels at 200 V for 45
minutes in 10X SDS PAGE running buffer. Gels were then stained with the
GelCode® E-Zinc™ Reversible Stain kit (Pierce Biotechnology, Inc., Rockford,
IL) and the 18 kDa Bicc1 fusion protein was cut from the gel. Gel fragments
were de-stained with GelCode® E-Zinc™ Eraser (Pierce Biotechnology, Inc.,
Rockford, IL) and electro-eluted in volatile elution buffer (50 mM ammonium
bicarbonate, 0.1% SDS) at 15 V for 6 hours. The concentration of the eluted
fusion protein was determined by the BCA assay (Sigma-Aldrich, St. Louis, MO).
Purified, concentrated fusion protein was sent to a commercial facility for
polyclonal Bicc1 antibody production (Covance, Inc., Princeton, NJ).

Total Protein Isolation
In order to determine the expression of the Bicc1 protein, total protein was
isolated from whole organs that had been snap frozen in liquid nitrogen and
stored at -80°C. Frozen organs were placed in 300 ul of ice cold RIPA buffer
(150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris,
and 10mM EDTA) containing 1 µl of a complete protease inhibitor solution made
by dissolving one complete protease inhibitor tablet (Roche, Indianapolis, IN) in
25 ml of RIPA buffer. Tissue was ground using a motorized homogenizer (UltraTurrax, Fisher Scientific International, Hampton, NH) for 30 seconds and then
placed on ice. Keeping the sample on ice, the tissue sample was sonicated at
intensity level six with two or three 10-15 second bursts for a total of 30 seconds
using the Misonex 110VAC XL2000 Ultrasonic Cell Disruptor (Fisher Scientific
International, Hampton, NH).

The sample was then incubated on ice for 15

minutes. The sample was sonicated again for 30 seconds and placed on ice for
another 30 minutes. The sample was then centrifuged for 10 minutes at 15,000
rpm at 4°C. The supernatant was transferred to a new tube and treated with
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DNase I (10U) (QIAGEN, Inc., Valencia, CA) and RNase A with a final
concentration of 40 µg/ml (Sigma-Aldrich, St. Louis, MO) for 15 minutes at room
temperature.

Protein concentration was determined using the BCA assay

(Sigma-Aldrich, St. Louis, MO).

Western Blot (Immunoblot) Analysis
Protein-containing lysates were resolved on sodium dodecyl sulfate
(SDS)-10% polyacrylamide gels and transferred to nitrocellulose membranes
(Bio-Rad, Hercules, CA). Membranes were incubated in a blocking solution of
1X PBS (0.9% NaCl, 10 mM sodium phosphate, pH 7.4) and 5% nonfat milk
overnight at 4°C.

The membranes were then rinsed two times at room

temperature for 15 minutes in blotting solution (PBS-0.5% nonfat milk), and then
incubated with primary Bicc1 antibody in blotting solution overnight with
continuous rotation at 4°C. The Bicc1 polyclonal primary antibody was used at a
concentration of 1:40,000.

Membranes were washed two times at room

temperature for 15 minutes each in blotting solution.

Bound antibody was

detected with a horseradish peroxidase-conjugated anti-rabbit immunoglobulin G
secondary antibody (Sigma-Aldrich, St. Louis, MO).

The secondary antibody

was used at a concentration of 1:40,000 for 1 hour in blotting solution with
continuous rotation.

The membranes were washed two times with blotting

solution at room temperature for 15 minutes with continuous rotation. The protein
bands were visualized on X-ray film by the enhanced chemiluminesence (ECL)
Western blotting detection kit (Amersham Biosciences, Piscataway, NJ).

Multiple Sequence Analysis
The putative protein domains of the Bicc1 protein were identified using the
web interface PROSITE (233). Protein characteristics were determined using
ProtParam (134).

Protein sequences for the multialignment analysis were

retrieved from the NCBI protein database (208). GenBank accession numbers
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for the multiple alignment analysis of Bicaudal-C are as follows: Mus muscularis
(NP_113574); Homo sapiens (human) (AC012168); Rattus norvegicus (rat)
(XP342127); Drosophila melanogaster (fruitfly) (S55051); and Xenopus laevis
(frog)

(AAF69826);

Caenorhabditis

elegans

(nematode)

(NP_502067);

Caenorhabditis briggsae (nematode) (CAE61995); Danio rerio (zebrafish)
(ENSDARP00000024970 at

www.ensembl.org; Fugu rubripes (pufferfish)

(Q99MQ1); and Anopheles gambiae (mosquito) (ENSANGP00000012257 at
www.ensembl.org).

Alignments were generated using the GeneStream

alignment program (Multalign) (196).
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RNA Binding Study
Generation of Recombinant Proteins
In order to determine the in vitro RNA binding ability of Bicc1, Bicc1 fusion
proteins containing different combinations of Bicc1 protein structural domains
were constructed as detailed in Antibody Production. The cDNA template used
to generate the various PCR products was cDNA clone AW240366. Primers
used to generate each plasmid construct containing both V5 and 6X Histidine
epitopes are as follows:
Full-length (amino acids 1-934)
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’GAGATTGCCAGCAGCATTTTCCCT3’;
Bicc1jcpk (amino acids 1-93)
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’CAGCACCAAAGGAAGCAGCTCCCG3’;
KH1 (amino acids 1-132)
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’GCTTTTTGTGTCTAAGACAGAC3’;
KH2 (amino acids 125-209)
F: 5’CACCATGTCTGTCTTAGACACA3’
R: 5’CAGCACCAAAGGAAGCAGCTCCG3’;
KH1+KH2 (amino acids 1-209)
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’CAGCACCAAAGGAAGCAGCTCCG3’;
KH3 (amino acids 272-407)
F: 5’CACCATGCTGTTGGAACACCTT3’
R: 5’TAAGGCATTTCGCTCAACACT3’;
KH2+KH3 (amino acids 125-407)
F: 5’CACCATGTCTGTCTTAGACACA3’
R: 5’TAAGGCATTTCGCTCAACACT3’;
KH1+KH2+KH3 (amino acids 1-407)
F: 5’CACCATGGCCTCGCAGAGC3’
R: 5’TAAGGCATTTCGCTCAACACT3’.
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All primers were synthesized by the Marshall University DNA Core Facility,
Huntington, WV.

PCR products were gel extracted using the QIAGEN gel

extraction kit (QIAGEN, Inc., Valencia, CA) and directionally cloned into the
Champion™ pET101/D-TOPO expression vector, then transformed into TOP10
chemically competent E. coli (Invitrogen, Carlsbad, CA) as previously described
in Antibody Production.

Sequence analysis was performed on an ABI 310

sequence analyzer (Applied Biosystems, Foster City, CA) to determine
orientation of the inserts. T7 forward and T7 reverse primers were used for
sequence analysis. If the inserts were longer than 300 bp, nested primers were
used for sequence analysis.

Recombinant Protein Expression
Isolated plasmids containing the correct in-frame insert were transformed
into BL21 (DE3) chemically competent E. coli (Invitrogen, Carlsbad, CA) and
induced with IPTG as previously described in the Antibody Production section
with minor alterations in the methodology. Plasmids transformed in BL21 (DE3)
cells were grown overnight in 20 ml of Luria-Bertani (LB) media plus 100 µg/ml
ampicillin and 1% sterile glucose at 37°C, 200 rpm on a rotating shaker. Five ml
of the overnight culture were used to seed 250 ml of LB containing 100 µg/ml
ampicillin and 1% sterile glucose.
To determine protein expression, 10 µl of the cleared bacterial cell lysates
were diluted in 10 µl of Laemmli sample buffer (Bio-Rad, Hercules, CA) and
boiled for 5 minutes. The samples were then loaded onto SDS-PAGE gels (10,
12 or 15% depending on protein size) and the proteins were separated at 200 V
for 45 minutes in 1X SDS PAGE running buffer. The separated proteins were
immunoblotted onto nitrocellose (Bio-Rad, Hercules, CA).

Membranes were

incubated in blocking solution overnight at 4°C with constant rotation.
Membranes were rinsed two times at room temperature for 15 minutes in blotting
solution. Membranes were then incubated in blotting solution with a horseradish
peroxidase-conjugated monoclonal antibody specific to the V5 epitope present
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on the fusion proteins derived from the pET101/D vector (Invitrogen, Carlsbad,
CA).

The anti-V5 antibody was used at a concentration of 1:5,000 with an

overnight incubation at 4°C with constant rotation. Membranes were washed
twice with blotting solution for 15 minutes at room temperature with continuous
rotation on a Belly Dancer™ (Stovall, Greensboro, NC). Proteins were visualized
on X-ray film using chemiluminescence (Amersham Biosciences, Piscataway,
NJ).

RNA-binding Assays
Binding assays to determine the function of the Bicc1 protein KH domains,
were performed with the concentrated cleared cell lysates for each recombinant
protein. Briefly, 200 µl of cleared cell lysate was added to 40 µl of 10X RNA
binding buffer (250 mM Tris-HCl, pH 7.4, 1.5 M NaCl, 10% Triton X-100, and
complete protease inhibitor cocktail (Roche, Indianapolis, IN), 158 µl of nucleasefree water (Ambion, Inc., Austin, TX), 1 µl of RNaseOUT (Invitrogen, Carlsbad,
CA), and 10 mg of beads.

The beads that were used were either poly(U)

Sepharose or Sepharose 4B (Sigma-Aldrich, St. Louis, MO). Reaction mixtures
were incubated at 4°C with constant rocking. Beads were pelleted at 13,000 rpm
for 2 minutes at 4°C and washed 3 times with cold 1X RNA binding buffer.
Between each rinse, the beads were briefly vortexed and centrifuged at 13,000
rpm for 2 minutes. The proteins were separated from the beads by adding 25 µl
of Laemmli sample buffer (Bio-Rad, Hercules, CA) and boiling for 5 minutes.
Samples were then loaded onto SDS-PAGE gels (10, 12 or 15% depending on
protein size) and the proteins were separated at 200 V for 45 minutes. The
separated proteins were transferred onto nitrocellulose and immunoblotted with a
horseradish peroxidase-tagged monoclonal primary antibody specific to the V5
epitope tag on the pET101/D-TOPO vector system (Invitrogen, Carlsbad, CA).
The V5 antibody was used at a concentration of 1:5,000 with an overnight
incubation at 4°C.

Proteins were visualized using chemiluminescence

(Amersham Biosciences, Piscataway, NJ).
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Asymmetry Study
Anatomical Analysis
In order to determine whether left/right specification defects exist in jcpk
homozygotes, mouse litters from jcpk heterozygous crosses were dissected 4-5
days after birth and observed for the presence of any anatomical defects in the
major organ systems.
in the study.

Only litters containing a polycystic pup(s) were included

A total of 149 mice were observed for the presence of L/R

patterning defects. If patterning defects were present, the visceral organs were
removed and preserved in 10% buffered formalin (Fisher Scientific International,
Hampton, NH). If defects were found, the organs of the remaining littermates
were also preserved in 10% buffered formalin for comparison. Defects were
noted and catalogued. Many litters without defects were saved for later tissue
analysis. These organs were snap frozen in liquid nitrogen and stored at -80°C.
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CHAPTER IV
RESULTS

Genetic and Physical Mapping
High Resolution Genetic Mapping
Previously, a high resolution genetic map was generated by the
integration of simple sequence length polymorphism (SSLP) markers and other
genetic markers to localize the jcpk gene to a 1 cM region on mouse
Chromosome 10 defined by the microsatellite markers D10Mit115 and
D10Mit173 (28). During the course of the work described here, two different
polymorphic markers within this region, 393H9SP6RPT and 282P18T7RPT, were
identified by sequence analysis and were used in fine mapping studies to
significantly narrow the original critical region (Figure 4.1). Both markers were
found to contain a variable number of tandem repeats among different mouse
strains. These markers were derived from the SP6 end of BAC RP23-393H9 and
the T7 end of BAC RP23-282P18. Fine genetic mapping of these two loci was
accomplished by genotyping using a mapping panel containing genomic DNA
from jcpk intercross recombinant animals (28).

Allele segregation of

393H9SP6RPT and 282P18T7RPT was compared to the strain distribution
pattern of the known recombinants from the mapping panel in order to position
these genetic markers within the genetic map. These two markers were found to
be genetically informative and were thereafter used to define the boundaries of
the minimal region thought to contain the jcpk gene (Figure 4.1).
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Ank3

D10Mit115

5’340N8 393H9SP6RPT 282P18T7RPT

Tfam

D10Mit173

Mmu 10
Region containing the jcpk gene
Figure 4.1 Genetic map of the 1-cM region containing the jcpk gene. This schematic
represents mouse Chromosome (Mmu) 10 with the centromere (circle) on the left. Previously,
the jcpk critical region was defined by the markers D10Mit115 and D10Mit173 (shown in blue)
(28). SSLP analysis significantly narrowed this region to an area defined by the markers
393H9SP6RPT and 282P18T7RPT (shown in red). Other genetic markers are shown for
reference. Hash marks indicate regions of the chromosome not shown.

Physical Mapping
A physical map representing the jcpk critical region on mouse
Chromosome 10 defined by the genetic markers D10Mit115 proximally and
D10Mit173 distally was constructed with 72 overlapping BACs (Figure 4.2). A
majority of the BACs used to construct the physical map were isolated from the
RCPI-23 (RP23) Mouse BAC Library which contains cloned genomic DNA from
an adult B6 mouse.

BACs from this library were isolated using a mapping

approach known as multiplex oligonucleotide hybridization or “overgo” (32). The
minimum tiling pattern covering the critical region defined by genetic marker
393H9SP6RPT

proximally

and 282P18T7RPT

distally

consists

of four

overlapping BACs (RP23-393H9, RP23-200D18, and RP23-282P18) ) (Figure
4.2).

Six BACs between D10Mit115 and 282P18T7RPT (RP23-310N21, RP23-

395K5, RP23-337L15, RP23-440N1, RP23-348F2, and RP23-282P18) (Figure
4.3) were sequenced in their entirety as part of the NHGRI BAC sequencing
program. Restriction endonuclease digestion with either EcoR I or Hind III has
indicated that the BACs in this region share considerable overlap
and Figure 4.5).

(Figure 4.4

This overlap is determined qualitatively by observing the

number of restriction fragments that each BAC shares with another BAC. If two
BACs contain a number of shared restriction fragments it is likely that these two
BACs overlap and therefore contain identical sequence within that region.
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Figure 4.2 Physical map of the jcpk region on mouse Chromosome 10. The order of the markers is indicated along the top line, which represents the
chromosome oriented with the centromere to the left of the map. Hash lines indicate breaks in the physical map. Markers in blue have also been placed on the
genetic map (Figure 4.1). The minimum area containing the jcpk gene is shaded in light red. BAC clones from the RCPI-23 library are indicated with the prefix
RP23- and are shown in black. BACs from the MIT/WI ResGen library are shaded in purple and BACs from the Genome Systems BAC Release I and II libraries
are highlighted in red. BACs sequenced as part of the NHGRI sequencing program are highlighted in yellow. Closed black circles indicate that a marker has been
tested and is present in the BAC; whereas open circles indicate the marker has not been tested. Triangles at the end of BACs indicate the SP6 end of the BAC
and squares indicate the T7 end of the BAC. The map is not drawn to scale.
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Figure 4.3 Minimum BAC tiling pattern covering the jcpk critical region. The order of the
markers is indicated along the top line, which represents the chromosome oriented with the
centromere to the left of the map. Hash lines indicate breaks in the physical map. Markers in
blue have also been placed on the genetic map (Figure 4.1). The minimum area containing the
jcpk gene is shaded in red. Six BACs were selected for sequence analysis as shown above.
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Figure 4.4 EcoR I restriction digestion of BACs within the physical map. EcoR I digestion
of selected BACs within the physical map. Note the number of restriction fragments each BAC
shares in common with other BACs within the physical map. A molecular size standard is present
in the last lane on the right with the sizes of each fragment indicated in base pairs (bp).
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Figure 4.5 Hind III restriction digestion of selected BACs. Restriction digestion of Hind III of
selected BACs within the physical map. Note the number of genomic DNA fragments that each
shares in common with the other BACs. A molecular size standard is included in the first lane on
the left with the sizes indicated in base pairs (bp) for each fragment.
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Radiation Hybrid Mapping
To complement physical mapping strategies to positionally clone the jcpk
gene, radiation hybrid (RH) mapping was employed to quickly order genetic
markers along mouse Chromosome 10.

The commercially available radiation

hybrid panel (T31) used in our study was created by exposure of mouse cells to
a high dose of X-ray irradiation in order to break mouse (strain 129aa)
chromosomes into several fragments. These broken chromosomal fragments
were recovered in hamster (strain A23) cells, and the resulting 100 mousehamster hybrid clones are available for analysis by a standard PCR assay to
determine the presence or absence of specific mouse DNA markers. The whole
genome mouse T31 radiation hybrid panel was used in this study because it
offers high resolution in that it has roughly 20-fold as many chromosomal breaks
as there would be crossovers in a similar number of mice (221). By estimating
the frequency of breakage, and thus the distance between markers, it is possible
to determine marker order in a manner analogous to meiotic mapping (45).
RH mapping data were submitted to the interactive auto RHMAPPER
v1.22

software

program

available

at

http://www.genome.wi.mit.edu/ftp

/pub/software/rhmapper/ (241). This computer program compares the generated
data with data from over 14,163 loci that has served as the basis of an RH map
of the entire mouse genome. Multipoint analysis was performed using the
software program RHMAP (20). This software program not only evaluates the
linkage of a particular marker to its nearest neighbor but its linkage to all other
markers within the data set.
Twenty-two D10Mit markers were used to construct the initial framework
RH map of mouse Chromosome 10. Additional mapped markers were derived
from nine BAC sequences, six expressed sequence tags (ESTs), six genes and
one anonymous marker (Figure 4.6). Sixteen of the D10Mit markers have also
been mapped by others and appear in The Jackson Laboratory T31 Mouse
Radiation Hybrid Database (http://www.jax.org/resources/documents/cmdata/
rhmap) which includes all publicly available RH data.
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All markers used to

construct the mouse Chromosome 10 RH map (Figure 4.6) had a LOD score
(logarithm of the likelihood ratio for linkage) greater than 5 when these markers
were mapped relative to the jcpk locus.
Radiation hybrid mapping has proven to be a valuable tool in evaluating
possible gene candidates for jcpk. For example, the expressed sequence tag
(EST) D10Ertd214e had previously been mapped to mouse Chromosome 10
near the region thought to contain the jcpk gene (127). However, based on RH
mapping data, this EST was placed distal to jcpk thus eliminating it as a possible
candidate for the jcpk gene. This placement is confirmed by physical localization
of D10Ertd214e within BACs that fall outside the jcpk critical region (Figure 4.2).
Together, these two maps give a detailed representation of the region containing
the jcpk gene.
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Figure 4.6 Radiation hybrid (RH) map of mouse Chromosome 10. The mouse chromosome is
oriented with the centromere at the top (black dot). The distance between loci is given in cR3000. Hash
marks indicate regions where the LOD score (logarithm of the likelihood ratio for linkage) between markers
is less than <4.0. Map order was generated using the software programs RHMAPPER (241) and RHMAP
(20).
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Gene Identification
Gene Candidate Analysis
Three expressed sequence tags (ESTs), AW260721, BB498314, and
AI956350, were identified between markers D10Mit173 and D10Mit115 by Basic
Local Alignment Search Tool (BLAST) analysis (5) of BAC end sequences found
in the TIGR BAC end annotation database (www.tigr.org).

The ESTs were

physically mapped using a combination of slot blot hybridization analysis and
PCR of a panel of purified BAC DNAs selected from all areas of the contig.
Northern blot analysis was also performed with wild type kidney and jcpk/jcpk
kidney mRNA to determine if any transcript differences were present.
AW260721 was originally discovered on the end sequence of BAC RP23430F6 and was found to map between markers 395K5T7 and 393H9SP6RPT.
This position places AW260721 outside the jcpk critical region defined by
393H9SP6RPT and 282P18T7RPT. As expected, Northern blot analysis showed
no differences in transcript size or expression in wild type versus jcpk/jcpk
kidneys. Therefore, AW260721 was eliminated as a candidate for jcpk.
AI956350 was originally discovered on the end sequence of BAC RP23337L15T7. Slot blot and southern blot analysis placed AI956350 at the T7 end of
RP23-337L15 proximal to 393H9SP6RPT, thus eliminating it as a candidate for
jcpk.

Northern blot analysis confirmed that there were no differences in

expression in wild type versus jcpk/jcpk kidneys.
The EST BB498314 was identified from nucleotide sequence from the
SP6 end of BAC RP23-307C12. Slot blot analysis determined that this EST
mapped between the markers 395K5T7 and 393H9SP6. Thus, BB498314 is
outside of the region thought to contain the jcpk gene. Northern blot analysis
showed no transcript or expression differences between wild type and jcpk/jcpk
kidneys.
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Gene Identification
Sequence analysis was performed on six BACs (RP23-310N21, RP23395K5, RP23-337L15, RP23-440N1, RP23-348F2, and RP23-282P18) (Figure
4.3) representing the region of mouse Chromosome 10 between markers
D10Mit115 and 282P18T7.

Using BLAST analysis (5) and the Ensembl

database (110), considerable overlap was found between the BAC sequences
within the region between markers 393H9SP6RPT and 282P18T7RPT.
Four of the above BACs (RP23-282P18, RP23-348F2, RP23-440N1 and
RP23-337L15) (Figure 4.3) that minimally cover the jcpk critical region between
markers 393H9SP6RPT and 282P18T7RPT were analyzed for the presence of
transcribed genes using a number of gene prediction programs including
GrailEXP v3.2 and GENESCAN. Within this region, only two partial transcripts
were identified by in silico analyses. These corresponded to two known ESTs,
BG062853 and BF785275, which were later determined to be part of a single
mouse gene, Bicc1.

This gene is the mouse orthologue of the Drosophila

melanogaster Bicaudal-C (Bic-C) gene (272).
Alignment of the Bicc1 Genbank mRNA sequence AF319464 with BAC
genomic DNA that had undergone sequence analysis revealed 21 separate
exons spanning three of the BAC genomic DNA inserts. Exons 1 and 2 were
found on RP23-282P18. Exon 1 contains an ATG start site and was determined
to be located approximately 80 kb upstream of exon 2. RP23-348F2 contained
exons 2 through 16. Exon 2 was found to be present on both RP23-282P18 and
RP23-348F2 and is approximately 51 kb away from exon 3.

RP23-440N1

contained nucleotide sequence for exons 10 through 21. The entire Bicc1 gene,
including exons and introns, spans a physical distance of over 234 kb as
estimated from nucleotide sequence data from both the Ensembl and TIGR
databases.

73

Mutational Analysis
To evaluate Bicc1 as the disease-susceptibility gene in the jcpk mouse
model for PKD, RT-PCR analysis using total RNA from 101/Rl (+/+), +/jcpk, and
jcpk/jcpk kidneys was performed on the coding region of the Bicc1 gene.
Primers were designed to evaluate each exon of the Bicc1 transcript. When a
RT-PCR primer set which generates a PCR product containing a portion of exon
1, all of exons 2-4 and a portion of exon 5 was used (Figure 4.7), a 70 bp
deletion was present when comparing +/+ and jcpk/jcpk RT-PCR products
(Figure 4.8). Both a wild type and jcpk/jcpk band were present in heterozygous
kidney.

EXON 1
Forward primer
GTCGGACCCCGGCTCCAACAGCGAGCGCAGCACCGACTCGCCGGTGGCCGG
CTCCGAGGACGATCTG
GTCGGACCCCGGCTCCAACAGCGAGCGCAGCACCGACTCGCCGGTGGCCGGCTCCGAGGACGATCTG
GTGGCCGCGGCGCCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCGCGTGGACAGGAAG
EXON 2
AAACTCGAGGCCATGCTCCAAG¦ CTGCAGCTGAAGGAAAAGGCCGAAGTGGGGAAGACTTTTTTCAGAA
EXON 3
G¦ ATCATGGAGGAGACAAACACGCAGATTGCATGGCCGTCCAAACTGAAGATCGGGGCTAAATCCAAGA
EXON 4
AAG¦ ATCCCCACATCAAGGTTTCTGGGAAGAAAGAGGATGTGAAGGAAGCCAAAGAAATGATCATGTCTG
EXON 5
TCTTAGACACAAAA¦ AGCAACCGCGTCACATTGAAGATGGATGTCTCGCACACGGAGCACTCCCACGTCA
TCGGCAAGGGTGGTAACAACATTAAAAAGGTCATGGAAGACACGGGCTGCCACATCCACTTCCCAGACT
Reverse primer
CCAA

Figure 4.7 RT-PCR analysis of exons 2-4 of the Bicc1 gene. Different exons are distinquished
by a green vertical line within the sequence. The forward primer used to evaluate the exons is
shown in red and the reverse primer is shown in blue. RT-PCR analysis in +/+ mice produces a
product that is 423 bp in length.

74

Figure 4.8 Mutation analysis of the Bicc1 gene. RT-PCR of Bicc1 transcripts using primers
that evaluate exons 2-4 (Figure 4.6) in 3-day old +/+ (Lane 2), +/jcpk (Lane 3), and jcpk/jcpk
(Lane 4) kidneys. A 100 bp ladder is shown in Lane 1. Lane 5 is a no-template control. A 70 bp
deletion was detected upon comparison of jcpk/jcpk versus +/+ tissues. The band in +/+ kidney
has a size of 423 bp, whereas the band in jcpk/jcpk tissue is 353 bp. Both bands are observed in
the heterozygous (+/jcpk) sample.

Nucleotide sequence analysis of the amplification products showed a
complete deletion of exon 3 in the mutant mRNA transcript (Figure 4.9). The
noncoding regions around exon 3 were then sequenced in 101/Rl wild type and
jcpk/jcpk kidney genomic DNA and a single base-pair change (G to A) in the
splice acceptor site of exon 3 was discovered (Figure 4.10). This mutation is
predicted to cause abnormal splicing, eliminating exon 3, and thereby joining
exon 2 to the acceptor site of exon 4. The resulting reading frameshift introduces
a premature stop codon in exon 4. Exon 3 is 70 nucleotides in size and accounts
for the differences seen by RT-PCR and sequencing analysis.
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EXON 1
CTCCGAGGACGATCTGGTGGCCGCGGCGCCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCG
CTCCGAGGACGATCTGGTGGCCGCGGCGCCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCG
Forward primer
EXON 2
CGTGGACAGGAAGAAACTCGAGGCCATGCTCCAAG¦ CTGCAGCTGAAGGAAAAGGCCGAAGTGGGGAAG
EXON 4
ACTTTTTTCAGAAG¦ ATCCCCACATCAAGGTTTCTGGGAAGAAAGAGGATGTGAAGGAAGCCAAAGAAATG
EXON 5
ATCATGTCTGTCTTAGACACAAAA¦ AGCAACCGCGTCACATTGAAGATGGATGTCTCGCACACGGAGCACT
CCCACGTCATCGGCAAGGGTGGTAACAACATTAAAAAGGTCATGGAAGACACGGGCTGCCACATCCACTTC
Reverse primer
CCAGACTCCAA

Figure 4.9 Sequence analysis of the Bicc1 transcript in jcpk/jcpk kidney tissue. Different
exons are distinquished by a green vertical line within the sequence. The forward primer used to
evaluate the exons is shown in red and the reverse primer is shown in blue. Sequence analysis
indicates a complete loss of exon 3 in the mRNA transcript. This deletion is 70 bp in length and
corresponds to that shown in Figure 4.7.
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NORMAL

JCPK/JCPK

Figure 4.10 Genomic sequence analysis of Bicc1 around exon 3. Both normal (+/+) and
jcpk/jcpk kidney tissues were used. Comparing +/+ (left) and jcpk/jcpk (right), a single point
mutation (G to A) was observed at the splice acceptor site of exon 3. This mutation produces a
frameshift that results in a premature stop codon.

Additional confirmation that Bicc1 is the disease-causing gene comes from
observations in the bpk and 67Gso PKD mouse models, both of which had been
demonstrated previously to be allelic to jcpk by complementation analyses (90).

76

In collaboration with Dr. Lisa Guay-Woodford (University of AlabamaBirmingham), RT-PCR analysis identified an insertion in the bpk allele of Bicc1
that is predicted to alter the terminal portion of the Bicc1 protein (41).

Through

fluorescent in situ hybridization (FISH) analysis done in collaboration with Dr.
Lisa Stubbs (Lawrence Livermore Laboratory, Livermore, CA), it was determined
that the translocation breakpoint on Chromosome 10 in 67Gso falls within a
region defined by two overlapping BACs RP23-348F2 and RP23-200D18 (40,
206). Since, both of these BACs are within the jcpk critical region and Bicc1 is
the only gene within that region, it is highly probable that the PKD phenotype in
67Gso mutant mice is due to disruption of the Bicc1 gene by the translocation
breakpoint.
Thus, it seems that three different mutations in the Bicc1 gene cause PKD
in three mouse models, jcpk, bpk, and 67Gso.

Alternative Transcripts
During sequence analysis of the EST BF785275, a previously unknown
exon in the Bicc1 transcript was discovered between exons 20 and 21 as defined
by Wessely et al. (272) (Figure 4.11). BLAST analysis was used to compare the
extra exon to the mouse EST database.

At least five ESTs (AW240366,

BF785375, AV170850, AA275580, and BY7635542) were found to contain this
extra exon.
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EXON 20
¦ATCGATCTTCAGACATTCCTCACCCTCACAGATCAGGATCTGAAGGAGCTGGGAATCACAACCTTTGGTGCCCGAAGGA
¦ATCG
ATCTTCAGACATTCCTCACCCTCACAGATCAGGATCTGAAGGAGCTGGGAATCACAACCTTTGGTGCCCGAAGGA
Forward primer
EXON 21
AAATGCTGCTGGCAATCTCAG¦TTTGTGACTCTGTTCAGATCCGCAACAAGATCCTGAGAGCTGCCAGGATTCTGTGAAC
AAATGCTGCTGGCAATCTCAG
EXON 22
CTTGGAATGTCAAAGAAAAAAG¦AGCTAAGTAAAAACCGAAGAAAACTTTTTGAACCACCAAACGCATCATGCACCTCCT
TCCTGGAAGGCGGAGCCAGTGGGAGGCTGCCTCGCCAGTATCATTCAGACATTGCGAGCGTCAGTGGCCGCTGGTAGCGG
TACCTTCTGGACACGCACCTGCTATCTTGCAAAGGTGGACACGATCCGTGGACAGTCTTCACTCACTCGCCTGCCCTTGG
Reverse primer
CACTCGGAGTGTCTGGTATCAGGACCAAAGTGTTGATTTCGTACCTGTACTTCATGGCCAAAAAAAAAAAAAAAA

Figure 4.11 Sequence analysis of the Bicc1 transcript. Different exons are distinquished by a
green vertical line within the sequence. The forward primer used to evaluate the exons is shown
in red and the reverse primer is shown in blue. Sequence analysis allowed identification of an
extra exon (designated exon 21).

This exon was also found in a Bicaudal-C human transcript (BF325944).
However, other mouse Bicc1 ESTs were found that did not contain this exon.
These ESTs included BI101203, AI595208, BM217996, AW488477, BY434239,
and AA276596. From these data it can be concluded that the original report by
Wessley et al. (272) indicating that mouse Bicc1 gene contains only 21 exons is
incomplete. Bicc1 has instead 22 exons.
Using primers within exons 20 and 22 designed to bridge exon 21, PCR
analysis confirmed that the extra exon is not only present in a number of these
ESTs, but is also present in +/+ and jcpk/jcpk kidney. As seen in Figure 4.12,
there are two amplification products differing by 80 nucleotides. Sequence
analysis of both transcripts confirmed that it was exon 21 that was the only
difference between these transcripts.
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Figure 4.12 PCR analysis to determine alternative transcripts for Bicc1. PCR analysis of
ESTs and tissues with primers spanning exons 20-22 of the Bicc1 gene. Lane 1: 100 bp ladder,
Lane 2: AI595208, Lane 3: AW340366, Lane 4: BF785275, Lane 5: No-template control, Lane
6: 101/Rl kidney cDNA (wild type), Lane 7: jcpk/jcpk kidney cDNA. Note that both wild type and
jcpk/jcpk kidney tissue contain the two transcripts.

Thus, data indicates that the Bicc1 gene has at least two alternatively spliced
transcripts: transcript A which contains exons 1-20 and 22, and transcript B
which contains exons 1-22. It is predicted that transcript A encodes a protein
with 977 amino acids, while transcript B has a premature stop codon in exon 21
and encodes a shorter protein of only 951 amino acids (Figure 4.13).
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PANEL A: Bicc1 protein from transcript A

MASQSEPGYLAAAQSDPGSNSERSTDSPVAGSEDDLVAAAPLLHSPEWSEERFRVDRK
KLEAMLQAAAEGKGRSGEDFFQKIMEETNTQIAWPSKLKIGAKSKKDPHIKVSGKKED
VKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEDTGCHIHFPDSN
RNNQAEKSNQVSIAGQPAGVESARARIRELLPLVLMFELPIAGILQPVPDPNTPSIQH
ISQTYSVSVSFKQRSRMYGATVTVRGSQNNTNAVKEGTAMLLEHLAGSLASAIPVSTQ
LDIAAQHHLFMMGRNGSNVKHIMQRTGAQIHFPDPSNPQKKSTVYLQGTIESVCLARQ
YLMGCLPLVLMFDMKEDIEVDPQVIAQLMEQLDVFISIKPKPKQPSKSVIVKSVERNA
LNMYEARKCLLGLESSGVSIATSLSPASCPAGLACPSLDILASAGLGLTGLGLLGPTT
LSLNTSATPNSLLNALNTSVSPLQSSSSGTPSPTLWAPPIANTASATGFSTIPHLMLP
STAQATLTNILLSGVPTYGHTAPSPPPGLTPVDVHINSMQTEGKNISASINGHVQPAN
MKYGPLSTSSLGEKVLSSNHGDPSMQTAGPEQASPKSNSVEGCNDAFVEVGMPRSPSH
SGNAGDLKQMLGASKVSCAKRQTVELLQGTKNSHLHGTDRLLSDPELSATESPLADKK
APGSERAAERAAAAQQKSERARLASQPTYVHMQAFDYEQKKLLATKAMLKKPVVTEVR
TPTNTWSGLGFSKSMPAETIKELRRANHVSYKPTMTTAYEGSSLSLSRSSSREHLASG
SESDNWRDRNGIGPMGHSEFSAPIGSPKRKQNKSREHYLSSSNYMDCISSLTGSNGCN
LNSCFKGSDLPELFSKLGLGKYTDVFQQQEIDLQTFLTLTDQDLKELGITTFGARRKM
LLAISELSKNRRKLFEPPNASCTSFLEGGASGRLPRQYHSDIASVSGRW
PANEL B: Bicc1 protein from transcript B

MASQSEPGYLAAAQSDPGSNSERSTDSPVAGSEDDLVAAAPLLHSPEWSEERFRVDRK
KLEAMLQAAAEGKGRSGEDFFQKIMEETNTQIAWPSKLKIGAKSKKDPHIKVSGKKED
VKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEDTGCHIHFPDSN
RNNQAEKSNQVSIAGQPAGVESARARIRELLPLVLMFELPIAGILQPVPDPNTPSIQH
ISQTYSVSVSFKQRSRMYGATVTVRGSQNNTNAVKEGTAMLLEHLAGSLASAIPVSTQ
LDIAAQHHLFMMGRNGSNVKHIMQRTGAQIHFPDPSNPQKKSTVYLQGTIESVCLARQ
YLMGCLPLVLMFDMKEDIEVDPQVIAQLMEQLDVFISIKPKPKQPSKSVIVKSVERNA
LNMYEARKCLLGLESSGVSIATSLSPASCPAGLACPSLDILASAGLGLTGLGLLGPTT
LSLNTSATPNSLLNALNTSVSPLQSSSSGTPSPTLWAPPIANTASATGFSTIPHLMLP
STAQATLTNILLSGVPTYGHTAPSPPPGLTPVDVHINSMQTEGKNISASINGHVQPAN
MKYGPLSTSSLGEKVLSSNHGDPSMQTAGPEQASPKSNSVEGCNDAFVEVGMPRSPSH
SGNAGDLKQMLGASKVSCAKRQTVELLQGTKNSHLHGTDRLLSDPELSATESPLADKK
APGSERAAERAAAAQQKSERARLASQPTYVHMQAFDYEQKKLLATKAMLKKPVVTEVR
TPTNTWSGLGFSKSMPAETIKELRRANHVSYKPTMTTAYEGSSLSLSRSSSREHLASG
SESDNWRDRNGIGPMGHSEFSAPIGSPKRKQNKSREHYLSSSNYMDCISSLTGSNGCN
LNSCFKGSDLPELFSKLGLGKYTDVFQQQEIDLQTFLTLTDQDLKELGITTFGARRKM
LLAISVCDSVQIRNKILRAARIL
Figure 4.13 Two protein isoforms are predicted for the Bicc1 gene. PANEL A: Putative
protein product from Bicc1 transcript A which does not contain exon 21. This protein contains
977 amino acids. PANEL B: Putative protein product of Bicc1 transcript B which contains exons
1-22. This protein contains only 951 amino acids. Differences between the two transcripts are
shown in red.
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RT-PCR and nucleotide sequence analysis of the bpk mutation identified a
two-base pair insertion in exon 22 of Bicc1 (41). This mutation is predicted to
extend the amino acid sequence of transcript A by 149 amino acids.

The

predicted amino acid sequence of transcript B would be unaffected by this
mutation, since the predicted stop codon in transcript B occurs in exon 21 prior to
the insertion mutation (Figure 4.14). This is different from the mutation in jcpk
which is predicted to truncate both protein isoforms (Figure 4.14). The
observation that the jcpk mutation affects both transcripts A and B; whereas bpk
affects only transcript A, may explain why affected jcpk animals have a more
severe phenotype and have an earlier onset of disease compared to affected bpk
mice. Future transcript-specific analyses are needed to explore this phenotypic
difference.
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PANEL A: Protein product from bpk mutation

MASQSEPGYLAAAQSDPGSNSERSTDSPVAGSEDDLVAAAPLLHSPEWSEERFRVDRK
KLEAMLQAAAEGKGRSGEDFFQKIMEETNTQIAWPSKLKIGAKSKKDPHIKVSGKKED
VKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEDTGCHIHFPDSN
RNNQAEKSNQVSIAGQPAGVESARARIRELLPLVLMFELPIAGILQPVPDPNTPSIQH
ISQTYSVSVSFKQRSRMYGATVTVRGSQNNTNAVKEGTAMLLEHLAGSLASAIPVSTQ
LDIAAQHHLFMMGRNGSNVKHIMQRTGAQIHFPDPSNPQKKSTVYLQGTIESVCLARQ
YLMGCLPLVLMFDMKEDIEVDPQVIAQLMEQLDVFISIKPKPKQPSKSVIVKSVERNA
LNMYEARKCLLGLESSGVSIATSLSPASCPAGLACPSLDILASAGLGLTGLGLLGPTT
LSLNTSATPNSLLNALNTSVSPLQSSSSGTPSPTLWAPPIANTASATGFSTIPHLMLP
STAQATLTNILLSGVPTYGHTAPSPPPGLTPVDVHINSMQTEGKNISASINGHVQPAN
MKYGPLSTSSLGEKVLSSNHGDPSMQTAGPEQASPKSNSVEGCNDAFVEVGMPRSPSH
SGNAGDLKQMLGASKVSCAKRQTVELLQGTKNSHLHGTDRLLSDPELSATESPLADKK
APGSERAAERAAAAQQKSERARLASQPTYVHMQAFDYEQKKLLATKAMLKKPVVTEVR
TPTNTWSGLGFSKSMPAETIKELRRANHVSYKPTMTTAYEGSSLSLSRSSSREHLASG
SESDNWRDRNGIGPMGHSEFSAPIGSPKRKQNKSREHYLSSSNYMDCISSLTGSNGCN
LNSCFKGSDLPELFSKLGLGKYTDVFQQQEIDLQTFLTLTDQDLKELGITTFGARRKM
LLAISELSKNRRKLFEPPNASCTSFLEGAEPVGGCLASIIQTLRASVAAGSGTFWTRT
CYLAKVDTIRGQSSLHSPALGTRSVWYQDQSVDFVPVLHGQKKKKKKKEREKRQEKCL
MFSCCHKSTKGRNAFINWQLDRICKMRVGLCFFLFTYITYALIFFFMVPKMKENFDIW
DARKLRSYFCWLELSWCLGIWKKK
PANEL B: Protein product from jcpk mutation

MASQSEPGYLAAAQSDPGSNSERSTDSPVAGSEDDLVAAAPLLHSPEWSEERFRVDRK
KLEAMLQAAAEGKGRSGEDFFQKIPTSRFLGRKRM
Figure 4.14 Predicted proteins encoded by the bpk and jcpk alleles. PANEL A: Predicted
protein encoded as a result of the bpk mutation. The mutation results in 170 novel amino acids
(shown in red) at the C-terminus and lengthens the protein by 149 amino acids. This mutation
affects only Bicc1 transcript A. PANEL B: Predicted protein encoded as a result of the jcpk
mutation. The mutation causes a frameshift resulting in a premature stop codon that produces a
protein that is only 93 amino acids in length. The amino acids that differ from the normal Bicc1
protein are shown in red. The jcpk mutation is expected to affect proteins translated from both
transcripts A and B.

Mouse-Human Homology
The human orthologue of Bicc1 was previously mapped to human 10q21
(272). Considerable homology exists between mouse and human sequences,
ranging from 80-96% in exon to exon comparisons (Table 4.1). The Bicc1 gene
is highly conserved in at least 9 different species. Ensembl database analysis
indicates that Bicc1 orthologues exist in human, Xenopus (frog), rat, Danio rerio
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(zebrafish),

Drosophila

(fruitfly),

Anopheles

(mosquito),

Caenorhabditis

(nematode) and Fugu (pufferfish). Such high conservation would suggest that
Bicc1 plays an important function in development or cell regulation across many
species.

Table 4.1 Exon to exon comparison of the mouse and human Bicaudal-C genes.
EXON

% HOMOLOGY

1

89

2

90

3

90

4

91

5

82

6

87

7

84

8

86

9

89

10

96

11

83

12

89

13

81

14

83

15

80

16

88

17

80

18

92

19

84

20

92

21

84

22

85

83

RNA Analysis
Tissue Expression of Bicc1
Previous work has indicated that mouse Bicc1 is predominantly expressed
in the adult kidney and heart, with low levels of expression evident in the testis
(272).

This expression was confirmed by Northern blot analysis using the

radioactively labeled EST AW240366 as a probe.

Bicc1 expression is the

strongest in the kidney with weak expression in the heart, lung, and liver (Figure
4.15).

Faint bands were also present in the brain and testis.

Interestingly,

experiments done by others did not observe expression in the brain, lung, or liver
(272). Northern blots in both experiments were probed with the cDNA insert from
AW240366.
1

2
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4

5

6

7

8
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9.5
7.5
k (5.9
kb)
5.9 kb
4.4
2.4

Figure 4.15 Tissue expression of Bicc1. Northern blot containing approximately 2 µg of poly
A+ RNA per lane from eight different mouse tissues. Blot was hybridized with a 3 kb cDNA probe
(AW240366). The probe detects an approximately 5.9 kb transcript (arrow). To the left is a size
marker indicating the size of bands in kilobases (kb). Lane 1: heart, Lane 2: brain, Lane 3: spleen,
Lane 4: lung, Lane 5: liver, Lane 6: skeletal muscle, Lane 7: kidney, Lane 8: testis.
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By Northern blot analysis, a Bicc1 transcript of approximately 5.9 kb in
length is detected. While the Bicc1 coding region itself is only 3.0 kb in length,
the size of the Bicc1 transcript is larger due to a relatively short 5’ untranslated
region and a long 3’ untranslated region. Because transcript A and transcript B
differ by only 80 nucleotides, they could not be individually distinquished by
Northern blot analysis.
Several other cell lines were examined for Bicc1 expression using EST
AW240366 as a probe (Table 4.2). Of the twelve cell lines analyzed, the Bicc1
gene was detected in two cell lines K-BALB (K-234) and Hepa 1-6 (Figure 4.16).
A low level of expression was also detected in the P19 cell line. P19 and KBALB are both embryonic cell lines, whereas Hepa 1-6 is a liver carcinoma cell
line. No detectable expression was found in the other cell lines which were
mostly of hematopoietic lineage.

This is consistent with the previous tissue

expression data. Comparing cell lines, Bicc1 is highly expressed in Hepa 1-6, a
liver carcinoma cell line. In Bicc1jcpk heterozygous mice, cysts are present in the
liver (41).
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Table 4.2 Description of cell lines examined for Bicc1 expression
Cell Line
PU5-1.8 (PU5-1R)

ATCC #
TIB61

Strain
BALB/c

RAW264.7

TIB71

BALB/c

K-BALB (K-234)
M-MSV-BALB/3T3
L-M

CCL163.3
CCL163.2
CCL1.2

BALB/c
BALB/c
C3H/An

P19

CRL1825

C3H/He

Hepa 1-6
R1.1

CRL1830
TIB42

C57L
C58/J

L1210

CCL219

DBA Subline212

P388D1

CCL46

DBA/2

P815

TIB64

DBA/2

NB41A3

CCL147

Tissue
Lymphoid Tumor,
Macrophage,
Monocyte
Monocyte,
Macrophage
Embryo, Fibroblast
Embryo, Fibroblast
Normal:
Subcutaneous
connective tissue,
Areolar and Adipose
Teracarcinoma,
Embryonal
Carcinoma, Embryo
Hepatoma, Liver
Lymphoma, Thymus,
T lymphocyte
Lymphocytic,
Leukemia
Lymphoma,
Macrophage,
Monocyte
Mastocytoma, Mast
Cell
Neuroblastoma, Brain,
Neuroblast

kb
9 .5
7 .5
( 5 .9 k b )

4 .4
2 .4

Figure 4.16 Expression analysis of Bicc1 in mouse cell lines.
Northern blot containing
approximately 1 µg of poly A+ RNA per lane from twelve different mouse cell lines (see Table
4.2). Lane 1: PU5-1.8, Lane 2: RAW264.7, Lane 3: K-BALB, Lane 4: M-MSV-BALB/3T3, Lane
5: L-M, Lane 6: P19, Lane 7: Hepa1-6, Lane 8: R1.1, Lane 9: L1210, Lane 10: P388D1, Lane
11: P815, Lane 12: NB41A3.
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It has been previously demonstrated by hybridization studies that
expression of Bicc1 appears early in development and can first be detected in
the embryonic node at the rostral tip of the primitive streak (272). It was also
shown that by embryonic day 13 (E13), Bicc1 mRNA is evident in the
metanephros, the limbs, and the mesenchyme of the lung (272).

Dot blot

analysis using the EST BF785275 as a probe was consistent with the above data
showing increasing embryonic expression starting at E7 (earliest time point
examined) through E15 with a leveling off of expression beyond this time point
(Figure 4.17). Similar results were seen by Northern blot analysis using the EST
probe AW240366 (Figure 4.17). RT-PCR analysis was performed on RNA from
staged whole mouse embryos and Bicc1 was detected as early as E5 (Figure
4.18).
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Figure 4.17 Embryonic expression of Bicc1. PANEL A: Slot blot analysis of embryonic
mRNA using the radioactively labeled EST BF785275 as a probe. Stages analyzed were E7,
E11, E15, and E17. Bicc1 expression increases as the embryo matures. Densitometry was
performed using the Typhoon Imaging System (Applied Biosystems, Foster City, CA). PANEL B:
Northern blot analysis of 2 ug embryonic mRNA using EST AW240366 as a probe. Lane 1: E7,
Lane 2: E11, Lane 3: E15, and Lane E17.
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1

2

3

4

5

Figure 4.18 RT-PCR analysis of embryonic mRNA. Analysis was performed using mRNA from
staged embryos and primers specific for the Bicc1 gene. Lane 1: 100 bp ladder, Lane 2: E5
mRNA, Lane 3: E10 mRNA, Lane 4: Adult B6 kidney, Lane 5: no template control.

Northern blot analysis using different Bicc1 ESTs as probes was
performed to determine the expression of Bicc1 in jcpk/jcpk affected kidneys
compared to normal controls (B6 or 101/Rl kidney). It was found that Bicc1 was
expressed in jcpk/jcpk kidney at a level that was indistinguishable from that of
controls (Figure 4.19). This situation is unusual, especially when considering that

1

2

3

5.9 kb

Bicc1

Gapdh

Figure 4.19 Northern blot analysis of Bicc1 in normal and affected kidney. The blot was
analyzed with a radioactively labeled probe for Bicc1. The blot was also probed for expression of
Gapdh as a loading control. Other blots with similar results were probed with ESTs BF785275,
AI595208, and AA086944. Lane 1: B6 (+/+) kidney, Lane 2: +/jcpk kidney, Lane 3: jcpk/jcpk
kidney. Similar bands are present in normal and affected kidney. The image is captured on the
Typhoon Image System (Applied Biosystems, Foster City, CA).
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the jcpk mutation produces a premature termination codon (PTC) which should
make the transcript susceptible to nonsense-mediated mRNA decay (NMD).
NMD has been shown to be a quality control mechanism developed by cells to
maintain homeostasis by destroying mRNA species which contain PTCs so that
only full-length proteins are produced (31). This is important since many times
mRNAs containing PTCs can be translated and have deleterious dominant
negative effects on the cell (226). Most mRNAs containing PTCs in their 5’
regions are degraded by NMD and are expressed at lower levels compared to
the normal transcript (47). Exon-skipping resulting in a PTC, as seen in the jcpk
mutation, is a common target for NMD. It is an unexpected observation that
Bicc1 would be expressed at normal levels in homozygous jcpk kidneys
compared to wild type controls given the presence of a PTC in the homozygous
jcpk transcripts. It is difficult to speculate why the Bicc1jcpk mRNA transcript is
not degraded by NMD.

Sequence and Northern blot analysis alone are not

enough to determine this mechanism, thus further study is required.

Real-time PCR Analysis of Bicc1 Gene Expression
A commonly used and more sensitive strategy for monitoring gene
expression is real-time PCR analysis.

This method monitors product

amplification by the use of fluorescently labeled probes or fluorescent dyes.
Specifically, Taqman™ PCR analysis was used to determine differences in Bicc1
gene expression in 3-day old +/+ and jcpk/jcpk littermates. Real-time analysis
determined that the Bicc1 gene is expressed at similar levels in jcpk/jcpk kidneys
as compared to the age-matched control (+/+) (Figure 4.20).

This data is

consistent with that seen in Northern blot analysis. Bicc1 gene expression was
also evaluated in bpk/bpk mice using real-time PCR analysis with SYBR Green
as a reporter (Figure 4.21).

No difference in gene expression was seen when

comparing bpk/bpk and BALB/c age-matched mice. This data was confirmed by
Northern blot analysis in collaboration with Dr. Lisa Guay-Woodford (41).
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Figure 4.20 Real-time PCR analysis of Bicc1 in jcpk/jcpk kidney. Taqman probes with either
FAM or VIC fluorophores were used to measure product amplification. PANEL A: A mean
quantity for each littermate was determined and those means were grouped as either normal
(+/+, N=2) or PKD affected (jcpk/jcpk, N=2) mice. An unpaired two-tailed t-test was performed on
the above groups. There was no significant difference between groups (P=0.101). PANEL B:
Amplification profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample
groups and standard groups are plotted on the same graph. PANEL C: Standard curve
generated from the BioRad iCycler software. Blue dots indicate standards and red squares
indicate unknown samples.
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Figure 4.21 Real-time PCR analysis of Bicc1 in bpk/bpk kidney. PANEL A: A mean quantity
for each littermate was determined and those means were grouped as either normal (+/+, N=2) or
PKD (jcpk/jcpk, N=2) affected mice. An unpaired two-tailed t-test was performed on the above
groups.
There was no significant difference between groups (P=0.826).
PANEL B:
Amplification profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample
groups and standard groups are plotted on the same graph. PANEL C: Standard curve
generated from the BioRad iCycler software. Blue dots indicate standards and red squares
indicate unknown samples.
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Real-time PCR Gene Expression Analysis of Other PKD Genes
A single, non-motile cilium is expressed on the apical surface of the
epithelium lining much of the nephron, the biliary tract, and the pancreatic ducts.
The proteins encoded by orpk (Tg737), Invs, Pkd1, Pkd2, and cpk (Cys1) have
been shown to be part of this primary cilia (99, 108, 172, 197). Mutations in
some of these genes result in shortened or nonfunctional cilia.

Moreover,

mutations in all of these genes result in PKD. Both jck and kat genes encode
NIMA (never in mitosis-A) kinases and when mutated, are also known to cause
PKD (Table 4.3).

Interestingly, the protein encoded by jck, Nek8, has been

shown to be associated with the developmental patterning protein, Bicaudal-D
(BicD), in the mouse (104). Using real-time PCR analysis, the expression of
these seven genes was evaluated in the jcpk mouse model for PKD to determine
if the mRNA expression of any of these genes is altered as a result of the jcpk
mutation.
Of the seven genes evaluated, only two were found to have altered
expression in jcpk/jcpk animals.

These results are summarized in Table 4.3.

The genes Pkd1, Pkd2, orpk (Tg737), Invs, and jck (Nek8) showed no difference
in expression when comparing homozygous normal and homozygous affected
kidneys (Figures 4.22 through 4.26). The cystic gene kat was found to have a 6fold decrease in gene expression in jcpk/jcpk mice when compared to control
mice (Figure 4.27). The expression of cpk was increased 3-fold in polycystic
mice versus control mice (Figure 4.28). It has not been determined whether
there are associations between the products of these genes and Bicc1. In vivo
analysis to test whether Bicc1 affects the expression of cpk and kat are needed
in order to determine the possible relationship between Bicc1 and these other
genes.
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Table 4.3 Real-time PCR analysis of PKD genes in jcpk/jcpk mice.

Gene

Mouse
Chromosome

Protein

Change in
Expression *

Pkd1

17

polycystin-1

none

Pkd2

5

polycystin-2

none

cpk (Cys1)

12

cystin

increased (3X)

Invs

4

inversin

none

orpk(Tg737)

14

polaris

none

jck (Nek8)

11

nek-8

none

kat (Nek1)

8

nek-1

decreased (6X)

*Represents change in gene expression in the kidneys of
polycystic jcpk/jcpk mice versus normal mice
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Figure 4.22 Real-time PCR analysis of pkd1 mRNA expression. Equal volumes of cDNA from
each of fifteen 4-day old mice were subjected to PCR using primers homologous to a specific
region of the mouse pkd1 gene. PANEL A: Template quantity analysis. Means were grouped as
(+/+), (+/jcpk), or (jcpk/jcpk) mice. The values shown represent the mean + standard error for
each groups (+/+ N = 5, +/jcpk N = 5, jcpk/jcpk N = 5) with 4 replicates for each animal. A oneway ANOVA was performed on the above groups. No significant difference between genotypic
groups was found (P = 0.681). PANEL B: Amplification profile plotting ∆RFU (relative
fluorescence units) versus cycle number. All sample groups were plotted on the same graph.
PANEL C: Standard curve generated from the iCycler software (BioRad, Hercules, CA). Blue
dots indicate standards and red squares indicate experimental samples.
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Figure 4.23 Real-time PCR analysis of pkd2 mRNA expression. Equal volumes of cDNA from
4-day old mice were subjected to PCR using primers homologous to a specific region of the
mouse pkd2 gene. The reporter used to detect product formation was SYBR Green (1:20,000
dilution). Four replicates of each cDNA sample were compared to amplification standards.
PANEL A: Template quantity analysis. Means were grouped as (+/+), (+/jcpk), or (jcpk/jcpk)
mice. The values shown represent the mean + standard error for each groups (+/+ N = 5,
+/jcpk N = 5, jcpk/jcpk N = 5). A one-way ANOVA was performed on the above groups. There
was no significant difference between genotypic groups (P = 0.313). PANEL B: Amplification
profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample groups are
plotted on the same graph. PANEL C: Standard curve generated from the iCycler software
(BioRad, Hercules, CA). Blue dots indicate standards and red squares indicate experimental
samples.
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Figure 4.24 Real-time PCR analysis of orpk mRNA expression. Equal volumes of cDNA from
each of fifteen 4-day old mice were subjected to PCR using primers homologous to a specific
region of the mouse orpk gene. The reporter used to detect product formation was SYBR Green
(1:20,000 dilution). Four replicates of each cDNA sample were compared to amplification
standards. PANEL C: Template quantity analysis. Means were grouped as (+/+), (+/jcpk), or
(jcpk/jcpk) mice. The values shown represent the mean + standard error for each groups (+/+
N = 5, +/jcpk N = 5, jcpk/jcpk N = 5). A one-way ANOVA was performed on the above groups.
There was no significant difference between genotypic groups (P = 0.865). PANEL B:
Amplification profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample
groups were plotted on the same graph. PANEL C: Standard curve generated from the iCycler
software (BioRad, Hercules, CA). Blue dots indicate standards and red squares indicate
experimental samples.
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Figure 4.25 Real-time PCR analysis of Invs mRNA expression. Equal volumes of cDNA from
4-day old mice were subjected to PCR using primers homologous to a specific region of the
mouse Invs gene. The reporter used to detect product formation was SYBR Green (1:20,000
dilution). Four replicates of each cDNA sample were compared to amplification standards.
PANEL A: Template quantity analysis. Means were grouped as (+/+), (+/jcpk), or (jcpk/jcpk)
mice. The values shown represent the mean + standard error for each groups (+/+ N = 5,
+/jcpk N = 5, jcpk/jcpk N = 5). A one-way ANOVA was performed on the above groups. There
was no significant difference between genotypic groups (P = 0.654). PANEL B: Amplification
profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample groups were
plotted on the same graph. PANEL C: Standard curve generated from the iCycler software
(BioRad, Hercules, CA). Blue dots indicate standards and red squares indicate experimental
samples.
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Figure 4.26 Real-time PCR analysis of jck mRNA expression. Equal volumes of cDNA from 4day old mice were subjected to PCR using primers homologous to a specific region of the mouse
jck gene. The reporter used to detect product formation was SYBR Green (1:20,000 dilution).
Four replicates of each cDNA sample were compared to amplification standards. PANEL A:
Template quantity analysis. Means were grouped as (+/+) or (jcpk/jcpk) mice. The values shown
represent the mean + standard error for each groups (+/+ N = 5, jcpk/jcpk N = 5). A one-way
ANOVA was performed on the two groups. There was no significant difference between
genotypic groups (P = 0.127). PANEL B: Amplification profile plotting ∆RFU (relative
fluorescence units) versus cycle number. All sample groups were plotted on the same graph.
PANEL C: Standard curve generated from the iCycler software (BioRad, Hercules, CA). Blue
dots indicate standards and red squares indicate experimental samples.
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Figure 4.27 Real-time PCR analysis of kat mRNA expression. Equal volumes of cDNA from
each of four 4-day old mice were subjected to PCR using primers homologous to a specific region
of the mouse kat gene. The reporter used to detect product formation was SYBR Green
(1:20,000 dilution). Four replicates of each cDNA sample were compared to amplification
standards. PANEL A: Template quantity analysis. Means were grouped as (+/+) or (jcpk/jcpk)
mice. The values shown represent the mean + standard error for each groups (+/+ N = 2,
jcpk/jcpk N = 2). A one-way ANOVA was performed on the two groups. There was a significant
difference between genotypic groups (P = <0.001). PANEL B: Amplification profile plotting ∆RFU
(relative fluorescence units) versus cycle number. All sample groups were plotted on the same
graph. PANEL C: Standard curve generated from the iCycler software (BioRad, Hercules, CA).
Blue dots indicate standards and red squares indicate experimental samples.
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Figure 4.28 Real-time PCR analysis of cpk mRNA expression. Equal volumes of cDNA from
each of four 4-day old mice were subjected to PCR using primers homologous to a specific region
of the mouse cpk gene. The reporter used to detect product formation was SYBR Green
(1:20,000 dilution). Four replicates of each cDNA sample were compared to amplification
standards. PANEL A: Template quantity analysis. Means were grouped as (+/+) or (jcpk/jcpk)
mice. The values shown represent the mean + standard error for each group (+/+ N = 2,
jcpk/jcpk N = 2). A one-way ANOVA was performed on the two groups. There was a significant
difference between genotypic groups (P = 0.012). PANEL B: Amplification profile plotting ∆RFU
(relative fluorescence units) versus cycle number. All sample groups were plotted on the same
graph. PANEL C: Standard curve generated from the iCycler software (BioRad, Hercules, CA).
Blue dots indicate standards and red squares indicate experimental samples.
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Microarray Analysis
Renal gene misexpression is a feature of polycystic kidney disease in
rodents and is reflective of changes in cell proliferation, apoptosis, differentiation
and morphogenesis. In order to better understand the mechanism(s) involved in
the pathogenesis of renal cystic disease in the jcpk mouse model for polycystic
kidney disease, gene expression profiling by microarray analysis was performed
using 8-day old littermates from a +/jcpk X +/jcpk genetic cross (Figure 4.29).

PANEL A

PANEL B

Figure 4.29 Microarray analysis of normal versus polycystic kidneys. The Atlas Mouse 1.2
Microarray used for this analysis contains over 1,176 different genes (CLONTECH, Mt. View,
CA). These genes were profiled for differences in expression between normal (+/+) and affected
(jcpk/jcpk) kidney. PANEL A: Normal kidney microarray panel. PANEL B: jcpk/jcpk kidney
microarray panel.
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Expression differences in the jcpk/jcpk kidney were only considered
significant if they represented a two-fold difference (plus or minus) when
compared to the normal control. Of the more than 1100 genes profiled on the
mouse microarray, 50 genes were found to have higher expression values (> 2fold difference) and 152 genes were found to have lower expression values (< 2fold difference) in jcpk/jcpk kidneys when compared to normal kidneys. In the
cystic kidney, alterations in the expression levels of mRNAs were found, for the
most part, in one of four general groups: proliferation/cell growth, apoptosis,
extracellular matrix, or cellular junction components.
Several genes were abnormally expressed that exert an effect on cellular
growth and proliferation. Two Pax genes, Pax2 and Pax8, were found to be
elevated in jcpk/jcpk kidneys. Pax2 was elevated almost 3-fold in mutant kidney
compared to wild type, whereas Pax8 was elevated 2-fold. Normally, both Pax2
and Pax8 are expressed in the mesenchymal/epithelial conversion during
nephron formation and decrease as the kidney completes nephrogenesis (279).
These genes are down-regulated as the kidney matures.

Transgenic

overexpression of Pax2 has been shown to cause epithelial hyperproliferation
and cyst formation (58-60, 201).

Overexpression of both Pax2 and Pax8 in

jcpk/jcpk kidney is indicative of a hyperproliferative state. The overexpression of
Pax2 was confirmed by real-time PCR analysis which indicated an over five-fold
increase of Pax2 in jcpk/jcpk kidney compared to wild type kidney (Figure 4.30).
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Figure 4.30 Pax2 gene expression analysis by real-time analysis. Equal volumes of cDNA
from 4-day old mice were subjected to PCR using primers homologous to a specific region of the
mouse Pax2 gene. The reporter used to detect product formation was SYBR Green (1:20,000
dilution). Four replicates of each cDNA sample were compared to amplification standards from
102 to 1010 molecules per reaction. PANEL A: Template quantity analysis. Means were grouped
as (+/+) or (jcpk/jcpk) mice. The values shown represent the mean + standard error for each
group (+/+ N = 5, jcpk/jcpk N = 5) with 4 replicates for each animal. A one-way ANOVA was
performed on the above groups. There was a significant difference between genotypic groups (P
= <0.001) PANEL B: Amplification profile plotting ∆RFU (relative fluorescence units) versus
cycle number. All sample groups were plotted on the same graph. PANEL C: Standard curve
generated from the iCycler software (BioRad, Hercules, CA). Blue dots indicate standards and
red squares indicate experimental samples.
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A study in the cpk mouse model for PKD demonstrated that nuclear
expression of Pax2, which is normally down-regulated in normal mature epithelial
cells, is persistent in many epithelial cells in the cpk mutant (186). However,
reducing the Pax2 gene dose in the cpk mouse model by breeding cpk/cpk mice
to Pax2 homozygotes and heterozygotes led to an increase in apoptosis and less
severe cystic disease (117). In addition, the high rate of apoptosis in polycystic
kidneys may exert counter-proliferative or counter-proto-oncogenic effects which
may explain the low incidence of renal cell carcinoma in ADPKD (152, 185).
Proliferation and apoptosis are tightly regulated during nephrogenesis. In
normal mature kidneys and in the majority of kidneys with noncystic diseases,
there is a very low rate of epithelial proliferation, and apoptotic DNA
fragmentation is undetectable. The exact role of apoptosis with respect to
cystogenesis is uncertain. However, microarray analysis identified several genes
that are known to function in apoptosis that had altered expression in the
jcpk/jcpk kidney. Expression of the apoptosis regulator Bax was elevated 2-fold
in the jcpk/jcpk kidney compared with the normal kidney. The expression of
interleukin-converting enzyme (Ice) was also increased 2-fold in the PKD
affected kidney. However, the expression of the anti-apoptotic gene Bcl-2 was
found to be down-regulated 2-fold in the affected kidney. It has been established
that the ratio of Bcl-2 to Bax determines the relative cellular sensitivity or
resistance to apoptotic stimuli (211). This data has not been confirmed by realtime PCR. A decrease in the ratio of Bcl-2/Bax favors apoptosis. As a side note,
in BALB/c-cpk mice, both the expression of Bax and Bcl-2 were elevated (4).
This is contradictory to what is seen in the jcpk mouse model. However, it has
been shown that transgenic knockouts of bcl-2 develop renal cysts and renal
failure (240).

Our microarray data suggest an expression pattern in which

survival and apoptotic factors are altered thus favoring apoptosis. This seems to
suggest that, at least in the jcpk mouse model, a decrease in anti-apoptotic
factors may exert a cystogenic effect (209). Further studies are needed to define
the role of apoptosis in cystic disease progression (209, 231).
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A number of cytoskeletal proteins were altered in their gene expression
when comparing wild type and affected kidneys. Fibronectin had over a 5-fold
increase in expression compared to wild type. Fibronectin has also been shown
to be overexpressed in other mouse models including C57BL/J6-cpk and
BALB/c-bpk (63, 64). Extracellular matrix genes that were also found to be upregulated greater than 2-fold were tubulin, keratin, entactin, syndecan, nidogen
and laminin. The products of all of these genes are required for the function and
maintenance of the cytoskeleton within the epithelial cell.
Microarray analysis also indicated that there was a decline in the
expression of genes encoding junctional proteins in the jcpk/jcpk kidney
compared to the normal control. These genes include alpha-1-catenin, occludin,
integrins and cadherin-6. All of these genes encode proteins that are important
in the function and maintenance of cell-cell and cell-matrix contacts including
tight junctions, desmosomes and focal adhesions (1, 111, 164, 223).
Other genes found to have putative protein interactions with jcpk were
also found to be altered in the microarray analysis. Yeast two-hybrid analysis
was performed and using Bicc1 as bait, several putative interactions were
identified (E. Bryda, unpublished data). Two of these proteins were the 40S
ribosomal subunit and ubiquitin conjugating enzyme E2. Genes for both of these
were found to be down-regulated in cystic kidneys.

Whether these are true

interactions and their decreased expression is a direct result of the Bicc1
mutation has yet to be determined.

Analysis of the EGFR Receptor and Ligands
A number of elegant studies during the last decade have provided
evidence for a major role for the epidermal growth factor (EGF)-transforming
growth factor-α (TGF-α)-EGF receptor (EGFR) axis in promoting epithelial
hyperplasia, cyst formation and enlargement, and for its potential as a target for
treatment in PKD. It has been previously demonstrated that the expression of
Egf mRNA and protein is markedly down-regulated in the kidneys of cpk and pcy
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mice and of Han:SPRD-Cy rats (44, 74, 136, 275). The expression of Tgf-α
mRNA and protein in human ADPKD kidneys was found to be increased (136).
Both Egf and Tgf-α utilize the same receptor, Egfr, and have been shown to
induce abnormal epithelial hyperplasia and solute transport in both murine
metanephric organ culture and in normal human kidney cell in culture, leading to
cyst formation (184). Further, this ligand-induced cyst formation is mediated by
Egfr tyrosine kinase activity (184). Egfr (ErbB1) is overexpressed and mislocated
to the apical surface of cystic epithelial cells in human ADPKD and ARPKD, as
well as in the cpk, bpk, and orpk mouse models of PKD (61, 244).
In order to determine the mRNA expression of Egfr, Egf, and Tgf-α, both
relative RT-PCR and real-time PCR were employed to identify differences in agematched +/+ and jcpk/jcpk kidneys.

Relative RT-PCR is a commonly used

method for the quantitative analysis of gene expression. The assumption behind
this method is simple: start with equal amounts of RNA from multiple samples,
use identical RT-PCR conditions on each, and amplify the same target from each
sample. Relative RT-PCR requires an optimized internal control, such as β-actin,
and can sometimes take more time than real-time PCR to obtain reproducible
results. This is because real-time PCR is a technique allowing the quantification
of starting amounts of nucleic acid during the PCR reaction without the need for
post-PCR analysis.

Amplification is measured directly, as discussed earlier,

using a fluorescent reporter to monitor the PCR reaction as it occurs in real time.
This eliminates the need for both post-run electrophoresis and densitometry
analysis. The starting amount for each unknown template can be determined
immediately following the PCR reaction.
Both relative and real-time PCR analyses show that Egfr mRNA is
expressed in higher levels in jcpk homozygous mice compared to unaffected
littermates (+/+) (Figure 4.31 and 4.32). Both analyses indicate a two to threefold difference in expression between wild type and jcpk homozygous samples.
Both analyses indicated no difference in Tgf-α mRNA expression in normal
versus affected mice (Figure 4.33 and Figure 4.34). This is different than what is
seen in human ADPKD and other mouse models where Tgf-α was found to be
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up-regulated (136).

Also, relative RT-PCR showed no difference in Egf

expression, but it was found to be down-regulated (1.5-fold decrease) using realtime analysis in jcpk/jcpk mice (Figure 4.35 and 4.36).

Real-time PCR is

considered to be a much more sensitive quantitative method than relative PCR.
This could account for the difference in expression found between the two
methods.
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Figure 4.31 RT- PCR analysis of Egfr (ErbB1) gene expression. Relative RT-PCR analysis
of Egfr mRNA expression in 4-day old mouse kidney. An unpaired two-tailed t-test revealed a
difference in the mean values of the two groups (wild type N=4, jcpk/jcpk N=4) that is greater than
would be expected by chance. Thus, there is a statistically significant difference between
affected and normal groups (P = 0.011). EGFR is expressed at higher levels in affected mice. Βactin was used as an internal control. The y-axis was determine by dividing the mean band
intensity of Egfr by the mean band intensity of β-actin.
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Figure 4.32 Real-time PCR analysis of Egfr mRNA expression. PANEL A: Template quantity
analysis of 4-day old normal (+/+ N=4) and affected littermates (jcpk/jcpk N=4). An unpaired twotailed t-test showed a significant difference between groups. (P = < 0.001). PANEL B:
Amplification profile of EGFR amplification up to 35 cycles. PANEL C: Standard curve generated
from standards ranging from 300 to 3 x 109 product molecules per reaction.
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Figure 4.33 RT-PCR analysis of Tgf-α gene expression. Relative RT-PCR analysis of Tgf-α
mRNA expression in four day-old mice (wild type N=4, jcpk/jcpk N=4). Analysis performed as in
Figure 4.31. An unpaired two-tailed t-test revealed no difference between affected and nonaffected groups (P = 0.863).
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Figure 4.34 Real-time PCR analysis of Tgf-α mRNA expression. PANEL A: Quantity analysis
of 4-day old normal (wild type N=4) and affected 4-day old littermates (jcpk/jcpk N=4). An
unpaired two-tailed t-test showed no significant difference between groups (P = 0.696). PANEL
B: Amplification profile of Tgf-α amplification up to 35 cycles. PANEL C: Standard curve
generated from standards ranging from 300 to 3 x 109 product molecules.
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Figure 4.36 Real-time PCR analysis of Egf mRNA expression. The reporter used to detect
product formation was SYBR Green. Three replicates of each 4-day old littermate were compared
to amplification standards ranging from 400 to 4 x 109 molecules per reaction. PANEL A: A
mean quantity for each littermate was determined and those means were grouped as either
normal or PKD affected mice. The values shown represent the mean + standard error for each
group (normal N = 4, PKD N = 2) An unpaired two-tailed t-test was performed on the above
groups. There was a significant difference between groups (P = 0.048). PANEL B: Amplification
profile plotting ∆RFU (relative fluorescence units) versus cycle number. All sample groups and
standard groups are plotted on the same graph. PANEL C: Standard curve generated from the
BioRad iCycler software. Blue dots indicate standards and red squares indicate unknown
samples.
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To begin to explore the possible relationship between the jcpk mutation
and Egfr, a genetic approach was taken. Mice heterozygous for the jcpk allele
were bred with mice carrying the waved-2 mutation, a point mutation that
decreases EGFR tyrosine kinase activity. Mice that carry two mutant waved-2
alleles are recognized phenotypically by the presence of a wavy coat and curly
whiskers (Figure 4.37).
PANEL A

♀ +/jcpk

x

♂ wa2/wa2

+/+ +/wa2

PANEL B

♀ +/jcpk +/wa2

+/jcpk +/wa2
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x
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PKD

??

+/+ +/wa2
+/+ wa2/wa2
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Figure 4.37 Breeding scheme between jcpk and waved-2 mice. A three-part breeding
scheme was used to produce double homozygous mice to determine if the wa2 mutation has an
effect on PKD progression in jcpk homozygotes. PANEL A: Cross 1: +/jcpk females and
wa2/wa2 males were mated to produce mice that were heterozygous for both the jcpk and
waved-2 mutations. PANEL B: Cross 2: double heterozygous females generated in Cross 1
were mated to wa2/wa2 males to produce offspring for use in Cross 3. PANEL C: Cross 3:
double heterozygous females were mated to males that were heterozygous for the jcpk mutation
and homozygous for the wa2 mutation. The genotypes and expected phenotypes of the offspring
are indicated.
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The rationale for undertaking this approach was based on a previous
study in the orpk mouse model for PKD where animals homozygous for both orpk
and waved-2 showed a marked decrease in the formation of collecting tubule
cysts and an improvement in renal function.

This study served as the basis for

clinical trials in which PKD patients were treated with EGFR tyrosine kinase
inhibitors (244).
If the higher levels of EGFR detected in jcpk/jcpk kidneys by RT-PCR and
real-time PCR analysis (Figures 4.31 and 4.32) contribute to cyst formation, it
seemed reasonable to hypothesize that decreasing levels of EGFR kinase
activity by introducing the waved-2 mutation might slow cyst progression in
jcpk/jcpk wa2/wa2 animals. Using the crosses described in Figure 4.37, mice
homozygous for both mutations were generated and were observed for changes
in the progression of the disease, changes in cyst size and time of death. Double
homozygotes were extremely rare in this study with fewer than ten double
homozygotes detected during a three year period. All double homozygotes that
were allowed to live until PKD caused death survived no longer than 10 days
after birth. This is similar to the death rate found in jcpk homozygous mice.
Histological analysis showed no difference in cyst size or disease progression in
the kidneys of double homozygous animals when compared to littermates that
were homozygous for jcpk and either wild type or heterozygous at the wa2 locus
(data not shown). Based on this preliminary data, a decrease in tyrosine kinase
activity of Egfr does not make a difference in disease progression in the jcpk
model.
While it has been shown in a number of studies that there is up-regulation
of ErbB1 (Egfr) in cystic kidneys, overexpression of ErbB2 has also been
detected in a small number of patients with ADPKD as well as patients with
ARPKD (101, 170).

ErbB2 (also referred to as Neu or HER2), is a

transmembrane glycoprotein with intrinsic tyrosine kinase activity and is
structurally related to epidermal growth factor receptor (EGFR). EGFR often
forms active heterodimers with ErbB2 as well as other members of the EGFR
family. ErbB2 is reported to mediate differentiation and proliferation in epithelial
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cells and is expressed in a tissue-specific and developmental stage-specific
manner (101). Further, the expression of ErbB2 as a mouse transgene causes
multifocal hyperplasia of renal tubular epithelium and cyst formation (242).
ErbB2 was shown to be up-regulated in jcpk kidneys in the microarray analysis.
Therefore, in order to determine the expression of ErbB2 in jcpk/jcpk versus
normal mouse kidney, real-time PCR analysis was performed using primers
specific to mouse ErbB2. Template quantity analysis showed a 3-fold increase in
the expression of ErbB2 in cystic kidneys (Figure 4.38). Altered expression of
ErbB2 has not been examined in other mouse models for PKD.
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Figure 4.38 Real-time PCR analysis of ErbB2. The reporter used to detect product formation
was SYBR Green. PANEL A: A mean quantity for each 4-day old littermate was determined and
those means were grouped as either normal (+/+) or affected (jcpk/jcpk) mice (N=5 (+/+), N=5
(jcpk/jcpk). It was determined that there was a statistical difference between groups (P = 0.029).
PANEL B: Amplification profile plotting ∆RFU (relative fluorescence units) versus cycle number.
All sample groups and standard groups are plotted on the same graph. PANEL C: Standard
curve generated from the BioRad iCycler software. Blue dots indicate standards and red squares
indicate unknown samples.
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Protein Analysis
Western Blot Analysis
Two distinct mRNA transcripts for mouse Bicc1 have been previously
described (41). These two transcripts differ by one exon at the 3’ end of the
transcript.

The two transcripts were designated transcript A which does not

contain the extra exon and is 21 exons in length, and transcript B which contains
22 exons. In silico translational analyses of the full-length mRNA transcripts of
mouse Bicc1 has predicted two putative isoforms of the Bicc1 protein. The first
isoform derived from mRNA transcript A is 977 amino acids in length with a
predicted mass of 105 kDa (Figure 4.13). The second putative isoform derived
from mRNA transcript B is 951 amino acids length with a mass of 102 kDa
(Figure 4.13). The proteins are predicted to have similar isoelectric points of 8.79
and 8.80, respectively. Western blot analysis using a polyclonal antibody raised
in rabbit against amino acids 1-81 of the mouse Bicc1 protein identifies a single
protein band in kidney between 75 and 100 kDa (Figure 4.39). This band may
represent both putative isoforms of Bicc1 since the resolving power of the
polyacrylamide gel was not great enough to separate two proteins so close in
size.

A smaller band of less than 75 kDa was found to be expressed only in

heart. The significance of this unique band as a potential third Bicc1 protein
isoform has yet to be determined.
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Figure 4.39 Western blot analysis of the Bicc1 protein. PANEL A: Western blot containing
total protein from +/+ mouse kidney (Lane 1) and +/+ mouse heart (Lane 2). The blot was probed
with a polyclonal antibody raised in rabbit against the first 81 amino acids of the mouse Bicc1
protein. Arrow indicates the Bicc1 protein between 75 and 100 kDa. PANEL B: Western blot
analysis demonstrating the specificity of the Bicc1 antibody. Asterisk indicates band representing
the fusion protein (AB101) which includes the N-terminal 81 amino acids of Bicc1. AB101 was the
antigen used to generate the Bicc1 antibody.

Functional Domains
The Bicc1 protein is predicted to contain several putative functional
domains (Figure 4.40). Three K homology (KH) domains are located in tandem
near the N-terminus.

One sterile alpha motif (SAM) is located near the C-

terminus of the protein. A descriptive nucleotide to amino acid comparison map
with highlighted functional domains can be found in Appendix E.

1

KH1

KH2

KH3

SAM

977

Figure 4.40 Mouse Bicc1 has two types of functional domains. Based on in silico motif
analysis, the Bicc1 protein contains three KH domains thought to bind RNA and one SAM domain
thought to be involved in protein-protein interactions. The specific intercellular functional partners
of Bicc1 are currently unknown.
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Bicaudal-C Species Conservation
Currently, the function of mammalian Bicaudal-C is unknown; however,
previous investigations of the Drosophila orthologue, Bic-C, have shown that it is
required for a number of processes in oogenesis, including the establishment of
anterior-posterior polarity of the oocyte (143, 156).

Specifically, Bic-C is a

maternally expressed protein that is thought to regulate the translation of oskar
mRNA during oogenesis (220).

Mutations in Bic-C in Drosophila result in

mislocalization of oskar mRNA and severe defects in anterior-posterior patterning
of the developing embryo (220).
Database mining utilizing pBLAST and multiple sequence alignment
carried out with the full-length protein sequence corresponding to mouse
Bicaudal-C, determined that the Bicaudal-C protein was present in at least 10
different species. Based on current nucleotide and protein sequence databases
containing information from a variety of organisms, the Bicc1 protein is found to
be present in Homo sapiens, Mus musculus, Rattus norvegicus, Xenopus, Fugu,
Caenorhabditis elegans, Caenorhabditis briggsae, Danio rerio, Anopheles
gambiae, and Drosophila malenogaster.
The presence of Bicc1 throughout such diverse phyla may indicate an
important and highly conserved function. Bicaudal-C protein sequences from all
ten species listed above were compared for amino acid conservation (Figure
4.41). Mouse and rat Bicaudal-C shared the most residues in common as did
both species of Caenorhabditis. However, both species of Caenorhabditis share
only about 23% of amino acid residues with mouse. When comparing protein
sequences of mouse and human, 77% of amino acid residues are conserved
between the two species.
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Figure 4.41 Sequence comparison of Bicaudal-C from 10 different species. All protein
sequences were retrieved from GenBank or Ensembl databases. Amino acids were compared
using GeneStream alignment software (www.expasy.org). Values represent the percentage of
identical amino acid residues.

SAM Domain
The sterile alpha motif (SAM) domain is a novel protein module of
approximately 70 amino acids originally found in a number of developmental
proteins (230). It is proposed that SAM domains may mediate protein-protein
contacts, yet the molecular mechanisms employed in vivo remain unclear (238).
The SAM domain of Bicc1 was examined independently of the whole
protein sequence in several species including mouse, rat, human, Xenopus,
Drosophila, Danio, and Anopheles. Over 95% of all amino acid residues were
conserved in 4 of the species examined (Figure 4.42 and Figure 4.43). Danio
rerio shares close to 60% of its amino acid residues with mouse, rat, human, and
Xenopus.

All organisms examined except for Danio contained a conserved

tyrosine at position 19 of the SAM domain.

This tyrosine is conserved in other

SAM domain containing proteins (230). When this tyrosine is phosphorylated
within the SAM domain, these proteins bind to SH2 domain-containing proteins in
order to mediate cell-cell initiated signal transduction (39).
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Figure 4.42 Multiple species sequence alignment of the SAM domain of Bicaudal-C. The
SAM domains of mouse, rat, human, Xenopus, Danio, Drosophila and Anopheles were compared
using Multialign and CLUSTAL W software (www.expasy.org) Amino acid residues conserved in
all species are highlighted in red. Residues present in four or more species are shown in blue.
The conserved tyrosine is positioned at residue 19. Fugu and C.elegans were not included
because their relative amino acid conservation compared to other species was less than 10%.
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Figure 4.43 Percent sequence homology of the Bicc1 SAM domain in 7 species. The SAM
domain is highly conserved among mouse, human, rat, and Xenopus. Sequences were aligned
and compared using Multialign and CLUSTAL W analysis software. The sequence homology
between species is given as a percentage.

KH Domains
The K homology (KH) domain was first identified in the human
heterogeneous nuclear ribonucleoprotein (hnRNP) K (236, 237).

It is an

evolutionarily conserved sequence of approximately 70 amino acids that is
present in a wide variety of quite diverse nucleic acid-binding proteins (81).
While a detailed picture of the KH domain-nucleic acid interaction is not yet
available, a number of proteins containing KH domains have been shown to bind
RNA (81). KH motifs are found in one or multiple copies, suggesting that they
may function cooperatively or, in the case of single KH motif proteins,
independently. Significant sequence similarity in the KH motifs of proteins from
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different species reflects descent from a common ancestor and a high degree of
functional conservation.
The KH domains of Bicaudal-C in 10 phyla were examined using the
computer program MotifScan (www.expasy.com) to determine their conservation
and amino acid identity. MotifScan compares the protein of interest to current
protein databases to determine if and what protein motifs are present and utilizes
a statistical algorithm to score whether these matches are true or false positives
based on amino acid identity. All three of the KH domains are present in all
species examined except for Danio rerio which only contains KH3 (Table 4.4).

Table 4.4 Conservation of KH domains across species

Species

KH Domains

Domains Conserved

Mouse

3

KH1, KH2, KH3

Human

3

KH1, KH2, KH3

Rat

3

KH1, KH2, KH3

Xenopus

3

KH1, KH2, KH3

Fugu

3

KH1,KH2, KH3

Danio rerio

1

KH3

Drosophila

3

KH1, KH2, KH3

Anopheles

3

KH1, KH2, KH3

C. elegans

3

KH1, KH2, KH3

C. briggsae

3

KH1, KH2, KH3

Multi-sequence alignment of all three KH domains in 9 species indicates a
high degree of amino acid conservation. Mouse and human share 88% of the
residues within their KH domains (Figure 4.44). Interestingly, Danio rerio only
contains KH3 but this domain is over 80% similar to mouse, human, rat, and
Xenopus. C. elegans is the most divergent sharing only 20-30% of its amino acid
residues with other species.
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Next, individual KH domains were compared among different species.
Over 98% of amino acids are conserved in KH2 and KH3 when comparing
mouse and human sequences (Appendix F). However, only 72% of residues are
conserved when comparing the residues within KH1.

Even the sequence

between the KH domains seems to be conserved. When comparing mouse and
human sequences, there is 100% conservation of the amino acids located
between the KH1 and KH2 domains and over 94% conservation of the amino
acids located between the KH2 and KH3 domains.

%
Mouse
Human
Rat
Xenopus
Fugu
C. elegans
Danio
Drosophila
Anopheles

Mouse
Human
88
98
92
75
28
80
49
50

Rat
95
81
67
22
83
41
44

Xenopus
91
65
26
80
47
49

Fugu
76
27
80
47
48

C.elegans
20
77
44
46

Danio
8
24
25

Drosophila
38
40

69

Figure 4.44 Percent sequence homology of all three KH domains. The KH domain is highly
conserved among mouse, human, rat, and Xenopus. Sequences were aligned and compared
using Multialign and CLUSTAL W analysis software.

GXXG Consensus Conservation
The most conserved sequence within the KH domain is the consensus
VIGXXGXXI where X is any amino acid. This conserved sequence most often
maps within the middle of the KH domain and is thought to mediate the function
of the motif (87). Further, the conformations of residues in and around the KH
consensus are very similar among different KH-containing proteins.

The

importance of this sequence is that it is where the protein chain is thought to fold
into two alpha helices at an angle of 100°-120° to each other. This folding is vital
to the function of the KH domain. A variable residue turn (GXXGXX) is the
“hinge” that connects these two helices.

The two largely invariant glycines

separated by two variable residues in the turn (GXX) serve as C- and N-caps of
the two alpha helices. KH2 and KH3 of mouse Bicc1 protein have the conserved
consensus motif (Figure 4.45). KH1 is observed by in silico analysis in almost all
of the species considered; however, this domain does not fit the amino acid
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pattern (GXXGXX) commonly seen in other KH domains (or KH2 and KH3 for
that matter). Based solely on conservation analysis, KH1 would not be expected
to function in a similar way as KH2 and KH3 domains despite its species
conservation. Perhaps this domain has a function in stabilizing the folding of the
Bicc1 protein for RNA or protein binding. More studies need to be performed to
evaluate this function. Both KH2 and KH3 have been preserved throughout a
number of phyla (Figure 4.45). The exceptions are Drosophila, Anopheles, and
C. elegans.

CONSENSUS
MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILIA
ANOPHELES
C.ELEGANS

KH2
VIGXXGXXI

KH3
VIGXXGXXI

VIGKGGNNI
VIGKGGNNI
VIGKGGNNI
VIGKGGNNI
VIGKGGNNI

MMGRNGSNV
MMGRNGSNI
MMGRNGSNV
MMGRNGCNI
MKGRNGSNI
MMGRNGSNI
VKGKNNVNL
VLGRSSSNL
GLLRTESNL

IIGRGGNNI
IIGRGGNNI
IIGKGGRGI

Figure 4.45 Consensus sequence comparison in multiple species. KH domains two and
three were compared to the VIGXXGXXI consensus sequence present in functional KH motifs.
Sequences were aligned using CLUSTAL W on www.expasy.org. Danio rerio only contains the
third KH domain. Blue highlight indicates amino acid is conserved in five or more species
examined. Red highlight indicates amino acid is conserved in all species examined.

Structural analysis of the mouse Bicc1 KH domains indicates that the
domains fall into the category of type-1 KH motifs. Type-1 KH motifs contain a
beta-alpha-alpha-beta-beta-alpha folding structure where the VIGXXGXXI
consensus motif is located between helices 1 and 2.

Other KH domain

containing proteins that fall within this category are FMR1, Vigilin (Vg1), and
Nova-1 (100, 237), (29).
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RNA Binding Study
In vitro RNA-binding properties of His-V5-Bicc1
Many KH proteins can bind either RNA or single-stranded DNA in vitro
(29).

Currently, the physiological targets of mouse Bicc1 are unknown.

An

accepted methodology to test whether a protein has affinity for RNA is its in vitro
ability to bind to synthetic homoribopolymers. In order to determine the RNA
binding ability of mouse Bicc1, a full-length Bicc1 construct and a number of
constructs containing only portions of the Bicc1 gene were designed and used in
binding assays with poly(U)-Sepharose beads.

The PCR-derived constructs

encoding the full-length recombinant histidine-V5-mouse Bicc1 or partial forms
were directionally inserted into pET101/D-TOPO (Figure 4.46 and Appendix G).
Recombinant proteins were expressed in BL21 (DE3) chemically
competent E. coli. Cell lysates for each recombinant construct were incubated
with either poly(U)-Sepharose or Sepharose 4B agarose beads.

Proteins

retained on the beads were separated by SDS-PAGE and analyzed by
immunoblotting using a horseradish peroxidase-conjugated monoclonal antibody
specific to the V5 epitope on each recombinant protein. The results of the RNA
binding assays are summarized in Figure 4.47.
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AMINO ACIDS
1

KH1

KH2

KH3

2

KH1

KH2

KH3

3

KH1

KH2

4
5

KH2

SAM

KH3

KH1

6

KH1

7

KH2

8

KH3

SIZE kDa

1-934

108.0

1-407

50.0

1-209

28.0

125-407

36.0

1-93

15.0

1-132

19.5

125-209

12.0

272-407

20.0

Figure 4.46 Schematic diagram summarizing recombinant RNA binding constructs. RTPCR products were directionally cloned into the pET101/D-TOPO vector and expressed in
BL21(DE3) cells. The relative sizes for each expressed recombinant protein and the amino acids
of Bicc1 encoded by each construct are listed to the right of the construct.

The full-length Bicc1 construct (#1, Figure 4.47) as well as the
recombinant construct containing only three KH domains (#2, Figure 4.47) bound
to poly(U) in the presence of 150 mM NaCl concentration. The construct
representing the putative protein produced due to the Bicc1jcpk mutation (#5,
Figure 4.47) did not bind poly(U). This indicates that the mutation eliminates the
RNA binding function of the protein. When the constructs were assayed with
Sepharose 4B agarose beads alone, no signal was detected.
To more precisely determine which domain(s) is required for mouse Bicc1
to bind RNA, recombinant constructs were designed that contained either two
domains or a single isolated KH domain. The construct containing KH domains
two and three (#4, Figure 4.47) was retained on the homoribopolymers; however,
the construct containing only KH domains one and two (#3, Figure 4.47) was not
retained.

Further, of the single KH domain constructs, only the construct

containing KH3 (#8, Figure 4.47) bound to RNA. This suggests that KH domain
three is responsible for RNA binding. Data is summarized in Figure 4.48.
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KH2

KH1

KH2

4
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KH2

KH2

KH3
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KH1
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Figure 4.47 RNA binding assay using immobilized poly(U) homoribopolymer. Recombinant
constructs are numbered on the left and the corresponding binding results are shown to the right
of each construct. Lane L is a protein molecular weight ladder, Lane C is the isolated cell lysate
(a positive control indicating the expression of each recombinant protein). Lane U contains the
lysate exposed to poly(U) Sepharose. Presence of the recombinant protein in this lane indicates
successful binding. Lane 4B is the lysate plus Sepharose 4B (negative control). Pictures are a
summary of at least two independent observations.

The data indicating that KH3 is important for binding correlates well with
previous experiments in Drosophila involving a strong mutant allele in Bic-C, BicCRU35, which carries a point mutation leading to a substitution of arginine for

glycine (amino acid 295). This mutation is just prior to KH3 and was found to
completely abolish Bic-C binding to oskar mRNA during oogenesis (143, 220).
This substitution is predicted to destabilize KH domain three by placing a
charged residue into a hydrophobic core.
important for Bicaudal-C protein function.
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This would suggest that KH3 is

RECOMBINANT CONSTRUCT
Full Length
KH1+KH2+KH3
KH1 + KH2
KH2 + KH3
KH1 only
jcpk mutation
KH2 only
KH3 only

BINDING
YES
YES
NO
YES
NO
NO
NO
YES

Figure 4.48 Summary of RNA binding analysis. All constructs containing KH3 were found to
bind poly(U) Sepharose.

Asymmetry Study
L/R Patterning Defects in jcpk/jcpk Mice
The establishment of the three body axes – anteroposterior (A/P),
dorsoventral (D/V) and left-right (L/R) – is central to the organization of the
vertebrate body plan. Nearly all visceral organs of the thorax and abdomen are
L/R asymmetrical with respect to the midline. The L/R axis is established last
and defects that arise from abnormal L/R patterning are less severe than
aberrant A/P or D/V patterning. Some anomalies in humans associated with L/R
patterning include situs inversus, organ isomerism, or single organ inversions.
These anomalies have been shown to occur in approximately 1 in 10,000
patients (95). The process in which L/R asymmetry is established involves the
biased transfer of signaling molecules via rapidly beating cilia (153).
Cilia and flagella are complex organelles with more than 200 peptides
involved in their formation, maintenance, and function (99). Mutations in the
genes that code for these proteins have been implicated in disorders such as
retinal degeneration, situs inversus, and polycystic kidney disease (PKD). There
is a growing body of evidence that links ciliary dysfunction, embryonic L/R
129

patterning defects and cystic disease of the visceral organs (e.g., kidney, liver
and pancreas) (99, 108, 172, 197).

In order to determine if L/R patterning

defects were present in the jcpk mouse model of PKD, an anatomical survey of
litters was performed.

Mating between +/jcpk heterozygous mice were

performed and litters from these matings that contained at least one polycystic
pup were sacrificed at 4 or 5 days after birth. Internal organs were evaluated for
patterning defects visible by gross examination.

Any defects present were

recorded and tail snips were taken for genotype analysis.

Individual

characteristics were recorded in a searchable database to determine the
statistical occurrence of any defects.
Genotype analysis indicated that of the 129 mice used in the study, 35
were +/+, 57 were +/jcpk mice and 37 were jcpk/jcpk. Twenty-five litters were
examined where six was the average litter size with a range of 2-11 pups/litter.
Of the 37 homozygous jcpk/jcpk mice dissected, one mouse was found to have
multiple patterning defects. These abnormalities include altered heart situs and
right pulmonary isomerism (Figure 4.49).

Normally, the apex of the heart is

pointed toward the left (levocardia). However, in dextrocardia, the apex of the
heart is abnormally pointing toward the right.

A normal set of mouse lungs

contains five individual lobes with four lobes on the right and a single lobe on the
left. This is often referred to as a 4 + 1 arrangement. When right pulmonary
isomerism occurs, the four right lung lobes are mirrored on the left, where the
lung lobes are present in a 4 + 4 arrangement. Similar asymmetry defects were
also observed in transgenic pkd-2 mutant embryos (197). Since only 37 jcpk/jcpk
mice were examined, more mice are needed to establish a solid link between the
jcpk mutation and L/R patterning abnormalities.
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3

1
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3
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PANEL A

jcpk/jcpk
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2
3
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3
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Figure 4.49 Comparison of the presence of L/R patterning defects in littermates. Three
animals from the same litter were examined for patterning defects. H = heart, lung lobes are
designated by numbers. PANEL A: In homozygous normal (+/+) mice, the lungs display normal
4+1 asymmetry and the heart is pointed to the left (levocardia). PANEL B: A jcpk/jcpk littermate
that is asymmetrically normal. PANEL C: Another jcpk/jcpk littermate. The heart is abnormally
positioned to the right (dextrocardia) and the lungs display 4+4 symmetry.
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CHAPTER V
DISCUSSION

Summary and Conclusions
Cystic diseases of the kidney are a clinically important and genetically
diverse group of disorders that share a common altered regulation of tubular
morphology. Despite their clinical and pathological heterogeneity, the fact that
the disease results in a similar outcome, cyst formation, has led to extensive
investigation into the mechanisms of cystogenesis and disease progression.
Renal pathologies found in essentially all forms of polycystic kidney disease
include increased fluid secretion, matrix remodeling, increased cellular
proliferation, increased apoptosis, and altered differentiation of the epithelial cells
lining the renal cysts (257).
Genetic and molecular analysis in a number of animal models has
facilitated the characterization of novel genes required for normal epithelial
function and maintenance. Ultimately, these discoveries have contributed to the
understanding of the cellular pathology of cystic disease.

Numerous mouse

models have been described with mutant phenotypes that closely resemble
human PKD with respect to cyst morphology and localization, as well as disease
progression.

Among these models, the juvenile congenital polycystic kidney

(jcpk) model for PKD is distinct from other mouse models for PKD based on its
early age of onset and histological appearance.
The objective of the preceding body of research was to characterize the
jcpk mouse model for polycystic kidney disease (PKD) through both genetic and

molecular analyses. The jcpk locus was previously localized to a 1 cM region
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located on mouse Chromosome 10 (28). Two other mouse models, bpk and
67Gso, were shown to be allelic to jcpk through complementation and FISH

analyses (90, 206).

The purpose of the research was to identify the PKD-

susceptibility gene shared by the jcpk, bpk and 67Gso mouse models as well as
to use current molecular analyses to evaluate the mRNA and protein expression
of jcpk. These investigations will lay the groundwork for establishing a role for
the jcpk gene in the context of current theories of PKD pathogenesis.
With the use of genetic and physical mapping strategies, it was
determined that the mouse gene, Bicaudal-C (Bicc1), is the disease-susceptibility
gene responsible for PKD in the jcpk mouse model. The jcpk mutation was
chemically induced by the mutagen, chlorambucil, and was originally predicted to
consist of a large sequence alteration such as a deletion or chromosomal
rearrangement (66). This hypothesis was based on previous observations of the
predominant mutations produced by this drug (67). However, it was determined
that the mutation in the jcpk mouse model is a single base-pair change (G to A)
in the consensus splice acceptor site prior to exon three (41).

Though

unexpected that a point mutation would be caused by chlorambucil mutagenesis,
it has recently been shown that at least one other chlorambucil-induced mutation
is due to a single base pair change in a donor splice site (54).

Thus,

chlorambucil may induce this type of mutation more frequently than originally
thought.
Interestingly, different mutations in the Bicc1 gene have also been found
to be responsible for PKD in the bpk and 67Gso mouse models.

All three

mutations (jcpk, bpk, and 67Gso) produce PKD phenotypes that differ in both the
age of onset and disease severity (40, 66, 90). Unlike jcpk, the bpk allele is an
insertional mutation at the 3’ end of Bicc1, whereas 67Gso is a translocation
mutation involving Chromosomes 10 and 2.

The phenotypic differences

observed in the three models may be due to the type of mutation carried in each
case. However, differences in the genetic background that each mutation is
carried on (jcpk-B6, bpk-BALB/c, and 67Gso-BLH) are also likely to influence
phenotypic outcome.
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In many mammalian systems, the phenotypic expression of mutations can
be greatly influenced by genetic background. For example, the age of onset and
the progression of PKD caused by mutations in the PKD1 locus can be markedly
variable (232). In ARPKD, the phenotypic variation is even more dramatic. In
this disorder, the presentation can range from a neonate with the classic
oligohydramnios sequence (Potter’s facies, pulmonary hypoplasia, and joint
contractures), to infants with oliguria or anuria, to older children who have
symptoms relating primarily to hepatic fibrosis, such as portal hypertension.
Although some of the variability in these disorders is likely due to different
mutations in the same gene, the observation that the apparent phenotype of
ARPKD can be quite variable within a kindred population, despite the fact that
the affected members have presumably all inherited the same mutation,
suggests that genetic background plays an important role in the expression of
PKD (113, 123). The identification of modifying loci that affect expression of
human diseases represents an area of considerable importance because their
characterization might provide insight into fundamental biological processes. In
addition, these genes may provide useful targets for therapeutic intervention that
could significantly ameliorate disease-related morbidity (113).
Mouse models have represented an attractive system for characterizing
modifying loci that are responsible for affecting the expression of mutant
phenotypes. The existence of inbred strains allows the generation of progeny in
which the parental origin of alleles is known (113). The development of maps of
highly polymorphic markers and the ease with which these markers can be
tested has made the localization of modifier loci possible. However, the influence
of these loci has been difficult to assess since modifying loci many times do not
have simple additive effects but display complex epistatic interactions. Even
when these loci can be localized by genetic mapping, they may be obscured
when isolated in a different genetic background by congenic analysis (113). This
again reiterates the importance of the use of animal models for studying complex
traits, as it is likely that the influence of modifier loci would be obscured in
humans with highly heterogeneous genetic backgrounds.
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A number of mouse PKD-susceptibility genes have been shown to have
modifying effects on other mouse cystic genes. The region containing Invs on
mouse Chromosome 4 has been suggested to contain a putative genetic modifier
that modulates PKD phenotype in multiple renal cystic mouse models, such as
the pcy, cpk, and jck mouse models (133, 278). In the pcy mouse, this locus
(MOP1) modifies 36.7% of the variance for the renal cystic pcy phenotype (278).
Another modifier, MOP2, has also been shown to influence 48.6% of the
variance for pcy (278). Both of these modifiers (MOP1 and MOP2) have been
shown to influence PKD progression in pcy/pcy homozygotes in a complex
additive manner (278).
The genetic region containing the Bicc1 gene overlaps with the genetic
interval thought to contain a putative PKD modifying locus, Pkdm2, which
influences the disease severity of another mouse PKD gene, Nek8 (jck) (115).
Now that the jcpk gene has been identified, it will be possible to design
experiments to determine whether Bicc1 is in fact a modifier for Nek8 and, if so,
characterize the nature of the relationship between Bicc1 and Nek8.
Understanding the interaction between PKD-susceptibility genes and their
putative genetic modifiers will help to define critical pathways fundamental to
cystogenesis and PKD pathogenesis.
Bicaudal-C is highly conserved throughout many species. Multi-species

analysis indicates that orthologues exist in human, frog, rat, zebrafish, fruitfly,
mosquito, nematode and pufferfish. Such high conservation suggests a critical
function in development or cellular regulation.

It has been shown that the

Drosophila orthologue of Bicaudal-C (Bic-C) plays an important role in anterior-

posterior patterning of the developing oocyte (220).

At least 12 dominant

patterning Bic-C alleles have been identified that produce different phenotypic
consequences (143, 220).

It has been determined that gene lesions that

truncate the protein or mutate the functional domains in Drosophila Bic-C lead to
defects in oogenesis and anterior-posterior patterning. Severe mutations in BicC result in anterior cells of the embryo or oocyte adopting posterior cell fates

producing profound developmental abnormalities (79). Thus, Bic-C is thought to
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be finely regulated in normal development, such that small changes in dosage
result in relatively large phenotypic consequences (143).
Northern blot and RT-PCR analysis has indicated that mouse Bicc1 is
expressed in a number of tissues including kidney, heart, lung, and liver. The
Bicc1 gene was also found to be expressed in both embryonic and liver cell lines

but not in any of the hematopoietic cell lines examined.

The Bicc1 mRNA

transcript in all tissues examined by Northern blot analysis was approximately 5.9
kb in length. Analysis of Bicc1 expression in embryos indicated that the Bicc1
gene is expressed as early as embryonic day 5 (E5). Increased expression is
observed from E7 to E15. This data correlates with previous studies using in situ
hybridization which indicated that Bicc1 is expressed in the mouse embryo at
E13 in the derivatives of the pleuroperitoneal membrane, the diaphragm and the
pericardium, as well as the mesenchyme of the developing lung, the
mesonephros and the metanephros (272).
Both real-time PCR and Northern blot analysis indicated that there was no
difference in the expression of Bicc1 in Bicc1jcpk homozygotes compared to agematched controls. There was also no difference in the expression of Bicc1 when
comparing Bicc1bpk homozygotes to age-matched controls.

This situation is

unusual, especially when considering that the Bicc1jcpk mutation produces a
premature termination codon (PTC) which should make the transcript susceptible
to nonsense-mediated mRNA decay (NMD)(31). The mRNA transcript produced
by the Bicc1bpk mutation would also be a target for NMD due to its extended
3’UTR (93).
NMD has been shown to be a mechanism developed by cells to maintain
homeostasis by destroying mRNA species which contain PTCs or extended
3’UTRs so that only proteins of the correct length are produced (31). This is
important since many times mutants mRNAs can be translated and have
deleterious dominant negative effects on the cell (226).

Given the type of

mutation and the observation that Bicc1jcpk and Bicc1bpk are expressed at a
normal level compared to controls, it is difficult to speculate why these abnormal
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mRNA transcripts are not degraded by NMD. Sequence analysis alone is not
enough to determine this mechanism, thus further investigation is required.
Expression analysis by RT-PCR demonstrates that Bicc1 encodes two
splice variants, transcript A and transcript B. Both transcripts are expressed in a
number of normal tissues as well as Bicc1jcpk/jcpk kidneys. It has also been shown
that both of these transcripts exist in human kidney (E. Bryda, unpublished data).
Transcripts A and B were shown to differ by only 80 nucleotides and sequence
analysis indicated that the only difference between the two transcripts was either
inclusion or exclusion of exon 21. Transcript A contains exons 1-20 and exon 22
and is predicted to encode a protein that is 977 amino acids in length. Transcript
B contains exons 1-22 and is expected to encode a protein that is 951 amino
acids in length. The predicted protein encoded by Transcript B is shorter due to
a termination codon in exon 21 of the coding region.
Western blot analysis using a polyclonal antibody raised in rabbit against
amino acids 1-81 of the mouse Bicc1 protein identified a single protein band in
kidney between 75 and 100 kDa. This band most likely represents both putative
isoforms of Bicc1 since the resolving power of the polyacrylamide gel was not
great enough to separate two proteins so close in size.

A smaller band of less

than 75 kDa was found to be expressed only in heart. The significance of this
unique band as a potential third Bicc1 protein isoform has yet to be determined.
Analysis by mass spectrometry would be a valuable tool for determining the
identity of this unique protein band.
Through in silico motif analysis, it was determined that the two putative
protein isoforms of Bicc1 contain several functional motifs.

Three K homology

(KH) domains are located in tandem near the N-terminus.

One sterile alpha

motif (SAM) is located near the C-terminus of the protein.

The particular

mechanics involved in the specific the function of the KH domain-nucleic acid
interaction are not yet available; however, a number of proteins containing KH
domains have been shown to bind RNA (80). The function of the SAM domain is
more elusive, but is thought to play a role in protein-protein interactions (230).
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SAM domains have been shown to be able to self-associate as well as
oligomerize and bind to other SAM domains (238).

By phosphorylation of a

conserved tyrosine within the SAM domain, the motif also has the ability to
interact with SH2 domain-containing proteins (230).

Src Homology 2 (SH2)

domains are protein modules of about 100 amino acids in size which are found in
a large number of proteins involved in signal transduction. The function of SH2
domains is to specifically recognize the phosphorylated state of tyrosine
residues, thereby allowing SH2 domain-containing proteins to localize to
tyrosine-phosphorylated sites (128, 219). SH2 domains function as regulatory
modules of intracellular signaling cascades by interacting with high affinity to
phosphotyrosine-containing target peptides in a sequence-specific manner (229).
Determining the specific signaling partners of Bicc1 will hopefully elucidate its
role in cell signaling.
More recent research has revealed a completely unanticipated function for
some SAM domains: binding RNA (9). The Nanos protein gradient in Drosophila,
required for proper abdominal segmentation, is generated in part via translational
repression of its mRNA by Smaug. Smaug functions in the proper establishment
of the anterior-posterior axis of the developing embryo. A combination of
structural and genetic analyses have indicated that the SAM domain of Smaug
interacts specifically with nanos mRNA.

It is the localization of nanos that

specifies the posterior pole of the embryo (268).

Disrupting Smaug function

leads to the translation of unlocalized nanos mRNA and ectopic Nanos protein
resulting in lethal body patterning defects (49).
The K homology (KH) domain is an evolutionarily conserved sequence of
around 70 amino acids that is present in a number of quite diverse nucleic acidbinding proteins (81). Significant sequence similarity in the KH motifs of proteins
from different species reflects descent from a common ancestor and a high
degree of functional conservation. All species examined contained all three KH
domains except for Danio rerio which contained only KH domain 3.

The

conservation of this domain among all species suggests that perhaps KH domain
3 is important to the RNA binding ability of the Bicc1 protein.
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In the jcpk mouse model, the mutant Bicc1 protein is altered immediately
after amino acid 48 and terminates shortly thereafter. Therefore, the putative
truncated protein that is produced does not contain any intact functional domains
and is predicted to be nonfunctional. In the bpk mutant, the insertion responsible
for the mutation occurs within the terminal exon.

The consequence of this

insertion is that the Bicc1 gene would encode intact KH and SAM domains, but
result in a protein that is elongated by 149 amino acids. Both the jcpk and bpk
alleles would be predicted to have a dramatic effect on any phenotype dependent
on the expression of Bicc1. The current hypothesis is that the jcpk mutation
affects both proteins encoded by transcripts A and B, whereas the bpk mutation
only affects the protein encoded by transcript A. This in part may explain why the
Bicc1jcpk allele produces a more severe phenotype with an earlier age of onset

compared to that conferred by the Bicc1bpk allele. However, future transcript or
isoform-specific analyses using transcript-specific RNA interference or transcriptspecific antibodies are needed to explore this phenotypic difference.
It has previously been determined that KH domain containing proteins can
bind either RNA or single-stranded DNA in vitro (29). Using recombinant protein
constructs encoding the full-length mouse Bicc1 protein or truncated forms, the in
vitro ability of Bicc1 to bind RNA using synthetic homoribopolymers was

explored. It was determined that the full-length Bicc1 protein binds RNA and that
KH domain three is responsible for that binding. This is not entirely surprising
considering that KH domain 3 is the only domain conserved in all 10 species
examined in this study. It was also determined that the Bicc1jcpk mutation causes
the complete loss of RNA binding. This data confirms previous observations in
Drosophila melanogaster where a strong mutant allele, Bic-CRU35, lacks RNA

binding activity. The mutation present in this allele is a point mutation resulting in
a single amino acid change just prior to the third KH domain (143).
Microarray analysis was used to examine multiple gene expression
alterations in Bicc1jcpk homozygotes. Changes in expression seen in jcpk/jcpk
kidneys when compared to normal control kidneys included: altered expression
of extracellular matrix (ECM) constituents, increased expression of epithelial
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proliferative factors such as Pax2 and Pax8, an increase in factors favoring
apoptosis, and alterations in the expression of cell junction components.

Even

though microarray analysis was performed on samples collected late in the
pathological progression in the jcpk mouse model (postnatal day 8), valuable
phenotypic information was gathered. The microarray data for jcpk/jcpk kidney
from animals with advanced PKD showed a gene expression profile that is
consistent with that seen in both human ARPKD and ADPKD and many other
mouse models for PKD.
Several studies on human and animal models for PKD have demonstrated
a number of ECM abnormalities, suggesting that an abnormal cellular matrix
plays a key role in the development of tubular cysts. The ECM consists of a
meshwork of collagens, proteoglycans, and other high molecular weight
glycoproteins such as laminin, entactin, nidogen, syndecans and fibronectin (36).
Cell adhesion is central to the interaction of cells with the ECM and is mediated
by specific cell membrane adhesion receptors, the integrins. Integrins are linked
to the ECM via both talin and vinculin. Interactions of ECM proteins with cell
surface receptors induces organization of the cytoskeletal network which
modulates differentiation and development of cell membrane domains (36). The
formation of cell-cell contacts and expression of specialized adhesion molecules
integrates the epithelial cells into a polarized monolayer and maintains the
separation of the cell membrane domains (106, 107). Precise coordination of
ECM and cell adhesion factors in the kidney tubule results in a continuous layer
of polarized epithelial cells that interact with their environment to control both the
concentration and flow of renal filtrate (106). Alterations in either or both of these
factors (as seen in jcpk homozygotes) would result in a disease state favoring
cyst formation.
A characteristic observed among many animal models and some human
forms of PKD are alterations in the EGFR/EGF/TGF-α axis. Studies in a number
of laboratories have determined that 1) EGF and TGF-α are cystogenic in vitro;
2) cystic renal tissue has decreased preproEGF and EGF concentrations but
increased expression of TGF-α and EGFR; and 3) renal cyst fluid contains
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bioactive and immunoreactive EGF peptides in mitogenic concentrations (184).
Using real-time PCR analysis, the levels of gene expression for each
component of this receptor pathway were examined. It was determined that Egf
mRNA expression in Bicc1jcpk/jcpk kidneys was reduced while the expression of
Egfr was elevated compared to normal (+/+) littermates.

This pattern of

expression has also been observed in other rodent PKD models and human
ADPKD (43, 75, 78, 105). EGF has been shown to be produced by the kidney
and appears to be a regulator of renal function by enhancing cellular proliferation,
migration, and differentiation in the normal kidney (78). However, the relative
decrease in renal EGF expression may serve to up-regulate the expression of
EGFR in the cystic kidney.

This data is consistent with data gathered from

microarray analysis that suggests an increase in markers of epithelial cell
proliferation. This altered expression of proliferation and growth factor-related
mRNAs also confirms data from other models suggesting that cell proliferation is
a component in the pathogenesis of cystic disease (77, 169, 213).
Unlike other human and other mouse models for PKD, Tgf-α expression
did not change when comparing wild type and affected kidneys. In number of
animal and cell systems for PKD, Tgf-α has been shown to be overexpressed
when compared to wild type controls (126, 136).

A transgenic mouse model

over-expressing Tgf-α develop renal cysts (276). Normally, Tgf-α is thought to
play several important roles in the kidney, such as modulation of glomerular
hemodynamics, renal metabolism, tubular transport functions, and eicosanoid
synthesis (97, 250). It is expressed at similar levels as the EGFR and was
originally thought to be the fetal ligand for the EGFR (84, 85). It is currently not
understood why Tgf-α expression is not altered in the jcpk mouse model.
Perhaps this ligand does not play a major role in cyst formation in this model for
PKD.
A common feature of the development of ARPKD in human and mice is
mislocalization of the EGFR from the basolateral surface of normal collecting
tubule epithelium to the apical surface on the cells lining cystic structures (11).
This mislocalization is accompanied by an increase in the mRNA, protein, and
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tyrosine kinase activity of the EGFR in the cystic kidneys (184). It is possible that
the increased EGFR tyrosine kinase activity in the collecting tubules is part of an
autocrine/paracrine cycle that drives the cellular proliferation which is required for
cyst formation and enlargement (183). In order to determine whether the activity
of the EGFR axis was directly part of cystogenesis in the jcpk mouse model, a
genetic approach was used in which a mutant Egfr gene (waved-2) was
introduced into the jcpk model. In the waved-2 mutation, a T to G point mutation
results in reduced tyrosine kinase activity of the EGFR (71).

Double

homozygotes for Bicc1jcpk and waved-2 were observed for changes in disease
progression. Interestingly, double homozygotes do not show any obvious signs
of altered disease progression. This contrasts with the results observed in orpk
and waved-2 (wa2) double homozygous mice (212).

There, a substantial

decrease in cyst formation was observed accompanied with an improvement of
overall kidney function in orpk;wa2 double mutants.

In the case of the jcpk

mouse model, the few double homozygotes recovered in our studies never lived
past ten days of age.

Histological analysis did not reveal any significant

differences in cyst pathogenesis between jcpk homozygotes and jcpk;wa2 double
homozygotes.

Therefore, it seems that altering the activity of the EGFR in

Bicc1jcpk/jcpk mice does not notably alter the progression of PKD. It is likely that
jcpk and orpk are genes that belong to two different signal transduction

pathways. The orpk gene is more likely to be involved in a pathway in which
EGFR mediates cyst formation, whereas Bicc1 likely belongs to a yet
undiscovered regulatory pathway.
Controlled apoptosis is also a key player in cellular differentiation and
epithelial cell maturation (152). The mature mammalian kidney is a quiescent
organ with little or no mitotic activity, and little or no apoptosis. Large-scale
apoptosis occurs during metanephric development, which may serve to match
the number of collecting ducts developed from the metanephric mesenchyme
(152, 185). As a result, after all the differentiated nephrons are formed, the
mature kidney can no longer generate new nephrons. In polycystic kidneys,
uncompensated apoptosis and the inability to regenerate new nephrons results in
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the progressive loss of renal tissue (277). EGF expression has been shown to
inhibit developmentally-regulated apoptosis in the kidney (42). Therefore, in the
normal kidney, the early expression of growth factors, such as EGF, may inhibit
apoptosis as well as inhibit epithelial cell progression into a mature differentiated
state. However, the increased expression of pro-apoptotic factors and a decline
in normal EGF expression early in nephrogenesis in PKD-affected animals would
therefore contribute to the progression of PKD pathogenesis. Further, apoptosis
must be important in cyst formation since Bcl-2 knockout mice develop PKD
(121, 240). However, the specific role of apoptosis in the pathogenesis of PKD is
still unclear (256).
Another interesting observation uncovered in both real-time PCR and
microarray analysis is the increased expression of ErbB2 in Bicc1jcpk/jcpk kidneys.
Human epidermal growth factor receptor-2 (HER2/neu; ErbB2) belongs to a
family of four transmembrane receptor tyrosine kinases involved in signal
transduction pathways that regulate cell growth and proliferation. Amplification or
overexpression of HER2/neu occurs in about 30% of human breast and ovarian
cancers and is associated with a poor clinical outcome, including short survival
time and short time to relapse (291). In humans, ErbB2 has been shown to be
overexpressed in a small number of patients with either ADPKD or ARPKD (101,
170).

Until now, the gene expression of ErbB2 has not been evaluated in any

other mouse models for PKD. Further, the expression of ErbB2 as a mouse
transgene has been shown to cause multifocal hyperplasia of renal tubular
epithelium and cyst formation (242). It is difficult to speculate why ErbB2 is
increased in PKD considering the low frequency of renal carcinoma associated
with human and animal models of PKD (6). This finding may define a new role
for ErbB2 in cystic disease.
The present study has identified a number of misexpressed genes in the
cystic kidneys of Bicc1jcpk homozygotes.

One gene that was found to have

increased mRNA expression in Bicc1jcpk/jcpk kidneys compared to normal was
Pax2.

Pax genes encode a family of transcriptional regulators specifically

expressed during the development of a wide range of structures and organs (88,
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255). As indicated by both human and mouse mutations, at least eight Pax
genes have critical morphogenetic functions during the develop of complex
tissues (38, 243).
During embryonic development, the Pax2 gene is essential for the
differentiation and proliferation of the renal epithelium in both mouse and human
(124, 217). Genetic evidence in mice and humans indicates that Pax2 plays a
critical role in normal renal development and may sit atop a molecular cascade
which unfolds during the transition from undifferentiated mesenchyme to the
early stages of nephrogenesis (253). During the normal course of kidney
development, Pax2 is expressed in the nephric duct, the ureteric bud, and the
induced mesenchyme which ultimately generates much of the glomerular,
proximal tubular, and distal tubular epithelium (59).
It has also been shown that Pax2 is required for the specification and
differentiation of the renal epithelium (186).

Pax2 is down-regulated as the

kidney matures and transgenic overexpression of Pax2 has been shown to cause
increased cellular proliferation, and cyst formation (60, 186).

Persistent

expression of Pax2 in cpk mice is correlated with cyst formation and progression
(186). Thus, the results found in Bicc1jcpk/jcpk kidney are consistent with data from
both human and other mouse models that suggest that renal cysts consist of
dedifferentiated epithelial cells that require embryonic factors, such as Pax2, for
continued growth and expansion.
Another developmental gene found to be increased in Bicc1jcpk/jcpk kidneys
was Pax8.

Less is known about the role of Pax8 in kidney development;

however, it has been suggested that Pax8 is a critical regulator in the initial
phases of kidney development (24). Pax8 is expressed in the S-shaped body
and early proximal tubule and preliminary data suggest that renal morphogenesis
is unaffected by its absence (201).

This may be due to the overlapping

embryonic expression patterns between Pax8 and that of Pax2 (253).

Most

likely, Pax8, like Pax2, is a mediator of epithelia maturation and increased
expression helps to maintain the dedifferentiated state seen in cystic epithelium.
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These numerous abnormalities in the expression of genes involved in
kidney development and cell proliferation suggest that the kidney epithelial cells
in Bicc1 mutants are unable to complete the terminal phases of tubuloepithelial
differentiation and therefore maintain a dedifferentiated state. This, along with
the abnormal expression of growth factors and their receptors increases
epithelial cell proliferation, producing a disease state favoring cyst formation.
Treatments aimed to regulate common pathways in kidney development and
epithelial maturation may lead to the development of clinically relevant
treatments to slow or halt the progression of PKD.

However, caution needs to

be taken in that some treatments, as in the case of EGFR tyrosine kinase
inhibitors, may not work for all forms of cystic disease.
Because signaling from cell-cell and cell-matrix adhesion complexes
regulate cell proliferation and polarity, it is not surprising to observe alterations in
the expression of these genes in Bicc1jcpk/jcpk mutant mice. It has previously been
shown that polycystin-1 is part of a cellular complex containing both E-cadherin
and the catenins (109).

The catenins have effects on such diverse cellular

functions as the polarization of the cytoskeleton (174), regulation of gene
transcription (30), and the formation of desmosomes (146), all of which are
altered in PKD. Inversin is another PKD-susceptibility genes that encodes a
protein that is complexed with the catenins and cadherins (178). In Bicc1jcpk/jcpk
mutants, both K-cadherin and α-catenin are each down-regulated more than fivefold compared to wild type. Like polycystin-1 and inversin, perhaps Bicc1 is part
of a protein complex that is critical for the stabilization of adherens junctions and
the maintenance of a fully differentiated polarized renal epithelium. Mutations in
the Bicc1 gene would therefore result in the phenotype observed in the jcpk
mouse model.
There is a growing body of evidence that links ciliary dysfunction and
cystic disease of the visceral organs, e.g. kidney, liver, and pancreas. Primary
cilia are most commonly thought to be only associated with the embryonic node;
however, primary cilia are a common feature of polarized epithelial cells in
eukaryotes and are thought to serve either a chemosensory or mechanosensory
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function (181). The proteins encoded by Kif3a, cpk, orpk, Invs, Pkd1, and Pkd2
have been shown to be either structural components of cilia or cilia formation
(181). A few mouse mutants for PKD have shortened or absent cilium but this is
not a common denominator among all mouse model for PKD that have defects in
cilia proteins (161, 179, 191, 213).
A number of groups have reported the possible involvement of genes
associated with PKD in either the assembly or function of cilia in mice and
Caenorhabditis elegans. The first evidence observed for the ciliocentric theory of

PKD pathogenesis was provided in the orpk mouse model, where a null mutation
was found to cause embryonic lethality and an absence (or severe stunting) of
cilia on embryonic node epithelium, disrupting early morphological left-right axis
determination (161).

The product of this gene, polaris, is localized in the

axoneme and basal body of primary cilia and is required for ciliary assembly
(287).
Similarly, the inv mouse model for PKD has a connection to primary cilia.
Several isoforms of the inversin protein have been described and have been
localized to primary apical cilia, cell-cell adhesion sites and the nucleus (157,
178). The human gene, INVS, when mutated, has been shown to cause NPHP2,
an infantile form of nephronophthisis with clinical manifestations that include
renal cysts (187).
The cpk mouse model for PKD has also been linked with cilia. The gene,
Cys1, encodes cystin-1, which has been localized within the axonemal region of

primary cilia, partially overlapping with polaris (108). Interestingly, cpk mutants
have PKD despite structurally normal cilia (89, 213).
In preliminary confocal microscopy studies, it has been observed in cell
culture that the Bicc1 protein is present in the apical cilium of renal epithelial cells
as well as having diffuse expression in the cytoplasm (L. Guay-Woodford,
unpublished data). It has not been determined whether or not mouse Bicc1 is
associated with specific cytoplasmic organelles; however, previous work has
shown that in mouse primary oocytes, Bicc1 mRNA is associated with the Golgi
complex (272).
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Previous work has demonstrated that the Bicc1 orthologues in Drosophila
and Xenopus play critical roles in regulating embryonic patterning (220, 271). In
the mouse, Bicc1 is expressed in the embryonic node at E7.5 (271). At the late
headfold stage, Bicc1 expression specifically demarcates the layer of the node
from which definitive endoderm and midline mesoderm arises. In contrast to
many other genes expressed in the node at this stage, Bicc1 is never detected in
the primitive streak suggesting that it marks the undifferentiated cells of this
organizing center (272). Perhaps the single epithelial cilium is important in the
functional differentiation of polarized lumen-forming epithelia and it is ciliary
dysfunction that underlies the PKD phenotype in Bicc1jcpk.
Based on the putative functional domains of mouse Bicc1, it is unlikely
that the protein plays a structural role in maintenance or formation of the cilia.
However, it may serve to localize specific mRNAs that are involved in
ciliogenesis or perhaps play a role in the translational repression of cilia proteins.
Abnormalities in both of these mechanisms would cause defects in cilia formation
or lead to cyst formation. It may also be possible that Bicc1 is part of a yet
undefined molecular pathway that may also be responsible for epithelial cell
homeostasis.
The potential connection between cilia and PKD is intriguing in light of the
knowledge of the role of primary cilium found on epithelial cells lining the nephron
and collecting duct. Whether renal cilia perform a similar function as embryonic
node cilia with regard to fluid movement, or the act as organelles responsible for
sensing local environments, remains to be explored. Elucidating the function of
primary cilia and their association with PKD will require a detailed
characterization of proteins involved in ciliogenesis and cilia function, plus the
development of reagents and assays to test their role in renal physiology.
Bicc1 may also be among the several PKD-causing proteins that appear
to be expressed in apical cilia and are also associated with L/R axis
determination. Based on the finding of a single Bicc1jcpk homozygote with lung
isomerism and abnormal heart situs, it is tempting to speculate that Bicc1 plays a
role in L/R patterning defects. However, more mice are needed to provide a solid

147

link between mutations in Bicc1 and L/R patterning defects. Patterning defects
have not been observed in Bicc1bpk homozygous mice (91). The majority of
Bicc1jcpk homozygotes that are born do not seem to have L/R patterning defects.

It is essential to investigate patterning abnormalities in Bicc1jcpk embryos to
determine the extent of those defects, considering that the majority of similar
types of defects in other mouse models are lethal and only seen at the embryonic
stage. Determining whether or not mutations in Bicc1 affect both renal and node
cilia would provide important clues to the role that the Bicc1 protein has, if any, in
the function of primary cilia.
L/R patterning defects have not been associated with all genes encoding
cystoproteins. For example, ultrastructural studies have demonstrated that cilia
in cpk mutants are morphologically normal yet functionally defective (108).
Cystin has also been shown to only be present in chordates and not in primitive
ciliated eukaryotes such as C. elegans (108). Researchers have predicted that
cystin has a later phylogenetic origin than proteins associated with intraflagellar
transport, such as polaris, inversin, polycystin-2 and Kif3a (137, 172, 187).
Cystin more likely has a specialized function in ciliated epithelium of higher
vertebrates rather than a key role in ciliogenesis (108).
Extrapolating from the observations in other mouse models, Bicc1 may be
directly involved in the process of ciliogenesis, a process that is both critical in
embryonic patterning and organogenesis. The high level of species conservation
of Bicc1 indicates that it is likely a key player in both embryonic and organ
development in a wide range of organisms. However, further research needs to
be performed in order to elucidate the exact role of the Bicc1 gene in both normal
development as well as cystogenesis.
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Future Directions
Positional cloning and preliminary molecular characterization are only the
first steps in elucidating the pathogenesis of PKD in the jcpk mouse model. More
information is needed to understand the role of the Bicc1 protein in normal
mammalian development and organogenesis. Bicc1 is a protein that contains
two distinct types of relatively uncharacterized functional motifs, KH and SAM
domains. A number of approaches exist to evaluate their function.
Determining the particular mRNAs that bind to the KH domains is of
considerable importance. A technique known as SELEX (Selective Evolution of
Ligands for EXponential enrichment) provides one potential approach for the
identification of RNA binding motifs that are recognized by the Bicc1 protein.
This technique involves serial enrichment of a synthetic nucleic acid population in
order to select a specific consensus sequence that has affinity for the protein
being examined (120, 202, 265). Discovery of these consensus elements will
provide important information for evaluating the in vivo RNA targets of Bicc1. At
that point, specific RNA-Bicc1 interactions can be identified and a putative
functional model for Bicc1 can emerge.
A second area of research that needs to be explored is the importance
and function of the SAM domain at the C-terminus of the Bicc1 protein. Previous
studies involving other proteins that contain SAM domains have shown that SAM
domains often facilitate homo- or heterodimerization. Additionally, these SAM
domain-containing proteins sometimes interact with proteins that contain SH2
and SH3 domains (128, 238). More recent studies have shown that the SAM
domain in the Drosophila protein Smaug plays a role in RNA-binding (9). The
SAM domain in the Bicc1 protein was not examined for its independent ability to
bind RNA. However, based on the RNA binding analysis of the recombinant fulllength protein and the recombinant containing only the three KH domains, the
SAM domain is not essential for RNA binding.

This domain should now be

included in future RNA binding analyses to determine if the SAM domain in Bicc1
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does interact with RNA and if the SAM domain alters the affinity of RNA binding
in the Bicc1 protein.
Additional studies are needed to determine the functional relevance of the
alternative transcripts identified for Bicc1.

As previously noted, the Bicc1jcpk

mutation alters both Bicc1 transcripts A and B resulting in the truncation of both
encoded proteins, whereas Bicc1bpk affects only the protein product of transcript
A. Specific antibody analyses and allele-specific expression studies are needed
to determine the novel importance of each transcript and its corresponding
protein. Employing specific antibodies to block the function of a specific Bicc1
isoform will provide insight into which particular isoform is important in cyst
formation. It is interesting to consider whether these different transcripts encode
proteins with distinct functions that may or may not act in the same signaling
pathway. For example, one protein isoform could be localized in or near the cilia,
whereas the other protein isoform could be available in the cytoplasm for cell
signaling. At the present date, a model for Bicc1 function is purely speculative.
Left-right patterning defects have been observed in one Bicc1jcpk
homozygous animal. Examination of additional animals is necessary to confirm
this preliminary observation and determine the relative frequency of these
defects in homozygous affected animals.

In addition, studies using timed

matings to recover embryos at defined stages of development will test the
hypothesis that L/R patterning defects occur at a greater frequency but due to
prenatal lethality, these animals have not been detected in our post-natal studies.
Also, detailed heart-specific histological studies need to be performed to
determine if structural defects exist in the heart. These types of abnormalities
would include septation defects, pericardial effusion, and valve defects. These
defects were first observed in the Pkd2 mouse model for PKD (197, 282).
Further study of the heart is also warranted in light of the possible presence of
the unique heart-specific Bicc1 protein isoform as suggested by Western blot
analysis.

Bicc1 may have a novel function in the heart that has yet to be

determined.
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A challenge for the ciliocentric model of PKD pathogenesis is to establish
a definitive causal connection between cilia and cyst formation.

A possible

approach to study this would be to selectively inhibit the cilial function of
cystoproteins and then assess the effect on cyst formation. Unfortunately, it is
still not known how proteins are targeted and transported to the basal bodies and
cilium.

Considering that Bicc1 is an RNA-binding protein, it is possible that it

may play a role in this cilia-specific targeting.
Another challenge is trying to explain how cilial dysfunction results in such
disparate renal phenotypes among a large number of PKD mouse models and
human cystic diseases. In the case of ADPKD, macroscopic cystic disease is the
principal finding, even in the end-stage kidney, whereas in NPHP, kidneys are
small and fibrous. The localization of most cystoproteins is not limited to the cilia.
Proteins such as polycystin-1, nephrocystin, and inversin, have been detected
not only in cilia but also within other structures involved in cell-cell and cell-matrix
interactions such as adherens junctions and desmosomes (23, 57, 154, 178).
Dysfunction of any of these structures could independently result in altered
tubular morphology leading to a cyst-inducing environment. This observation
suggests that many cystoproteins are multifunctional and it is uncertain which of
their activities are directly related to cyst formation. Also, like Bicc1, many of
these cystoproteins have multiple isoforms and little research has been
performed to determine the significance of these independent protein forms.
A theory including both possibilities is that cilial dysfunction initiates cyst
formation but the loss of functional cystoproteins at extraciliary sites determines
the final phenotypic outcome. The identification of a variety cystoproteins has
laid the ground work for arriving at a model that encompasses all forms of cystic
disease. The characterization of the many complex pathways that lead to cyst
formation will not only provide new insights into PKD pathogenesis, but will serve
to identify new genetic markers for prognosis and ultimately establish a platform
from which to develop targeted therapeutic interventions to halt disease
progression.
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APPENDIX A

The following “overgo” primers were designed for multiplex oligonucleotide
hybridization as discussed in Physical and Genetic Mapping in Chapter III of
Materials and Methods:
282P18T7
F: 5’ATCAGGTTCAGAGTGGGCATGTTG3’
R: 5’CATCCTCATATTGGCCCAACATGC3’;
282P18SP6
F: 5’GCTTTTGACGTGAACATAGAAGGG3’
R: 5’TTCCCTCTCGTTATGCCCCTTCTA3’;
393H9T7
F: 5’TGGAAGAGTCCATGGATTTGAAAG3’
R: 5’TATCCTACCATGCTTTCTTTCAAA3’;
393H9SP6
F: 5’ATGGCAGTTTTCCAGCGATGAGGA3’
R: 5’AAAGCTCATCCCTGCTTCCTCATC3’;
323G11T7
F: 5’ATGACACTATGCCACCCACCTTGA3’
R: 5’TAGCTCTAAGGCCAACTCAAGGTG3’;
323G11SP6
F: 5’TGTGCCTTCCTGTTTGGTTCCGTA3’
R: 5’GATTTTCACATGGCGGTACGGAAC3’;
440N1SP6
F: 5’ACGCTCATTGACAGCAATCAGGAG3’
R: 5’TGCGCAGTAAAGAGAACTCCT3’;
440N1T7
F: 5’AAAGGGTTGAGGGTTGGAACAGTG3’
R: 5’GACATGTGCAGTGAACCACTGTTC3’;
480A14SP6
F: 5’GCAAATATTCTATGCCAGGAAAGC3’
R: 5’TCTTCTGTGGGAAGAGGCTTTCCT3’;
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480A14T7
F: 5’CAGCACATTTCTCAGGACAGTCTG3’
R: 5’CAGCATCCAGAAGCCCCAGACTGT3’;
348F2T7
F: 5’TTCGGTGCAACGCAGAACTCAAAC3’
R: 5’GCCACGGTTCTGAATAGTTTGAGT3’;
348F2SP6
F: 5’AGCCACCACGAACATTTAAGCCAC3’
R: 5’AGTCGATGACAACCGTGTGGCTTA3’;
337L15T7
F: 5’AGAGCTGGGAACGAATAAAGGGAG3’
R: 5’CCTGCCCTATTTGTTCCTCCCTTT3’;
337L15SP6
F: 5’GTGATCAGGTGTCACTTTGGTGTG3’
R: 5’AAACCATGGCACCTAGCACACCAA3’;
395K6SP6
F: 5’AATTCCTACGAGGAGGGTGGCACA3’
R: 5’GTTTCTGAGGCTTACCTGTGCCAC3’;
395K5T7
F: 5’TTAAGAGCAGCAGCTCCTGTGGAT3’
R: 5’GTTCTCTGATAGCGTCATCCACAG3’;
326F24T7
F: 5’GCACACTTGACCTGTATTCTGTCC3’
R: 5’TTCCATGACAACCGCAGGACAGAA3’;
326F24SP6
F: 5’TGAGGTGGGCTTTCAAGAACATTG3’
R: 5’CACACTTGGCACAATGCAATGTTC3’;
3’307I23
F: 5’CTTATCAGAGCAGAGGTTCAGCTC3’
R: 5’GGAAATGCACACCATCGAGCTGAA3’;
5’340N8
F: 5’GGTGCATCAGGAATGATGAATCTG3’
R: 5’ACCAGGGATTTATGTCCAGATTCA3’;
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D10Ertd214E
F: 5’GCACCACATGTTTCAGTAGCAAGG3’
R: 5’ATATCCATGGCATCGGCCTTGCTA3’;
226L21T7
F: 5’GAGAAGCCACTGCATTTCCAGAGA3’
R: 5’GGGAGCAAGTTATTCCTCTCTGGA3’;
225C18SP6
F: 5’CAGCTGGTATAGAAGGGCAATGAC3’
R: 5’GGAATGAGGGGTTTCAGTCATTGC3’;
M-02039
F: 5’TCTCAGAAGCCCTTCTGTCCCCAC3’
R: 5’AATGGAGTGGCACGTGGTGGGGAC3’;
312N7T7
F: 5’GTTCCCTCTGAGCTTTAACACCAG3’
R: 5’TCCCACTTCTTCAGTCCTGGTGTT3’;
114H21SP6
F: 5’GACAGCTTGACATGCTGTCCTATG3’
R: 5’TGTGAACCCCACATGTCATAGGAC3’
337G9SP6
F: 5’GTAACACAGTTCCTGCTGCTGGTA3’
R: 5’TCACACCAGGGCCCTGTACCAGCA3’;
536B11T7
F: 5’GATTGCTTGGTCTACGTAGGAAGC3’
R: 5’ATGTGGTATCCCTCTCGCTTCCTA3’;
536B11SP6
F: 5’CATGAGCCATAGAACCGTGTCATG3’
R: 5’TGTGCATTTGTGTGCGCATGACAC3’.
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APPENDIX B

The following primers were used for PCR amplification as described in Physical
and Genetic Mapping in Chapter III.
33E18T7
F: 5’CTTTGGCAGAAGGGGTGAGC3’
R: 5’GCCAGGCTACAGTTACAGCTCC3’;
536B11
F: 5’GCAGGAAAGAGAAAGCGCAA3’
R: 5’AACATTGGCTGCTGGGCTAA3’;
400E17T7
F: 5’TCAAAAAGATTGGGGCAAAG3’
R: 5’GCTCTCCGTAGTCCACTCCA3’;
5’400E17
F: 5’GTAATGGAACTCACCACCTGCTCTG3’
R: 5’CGTCCTTCATACACTCCTGTGAACC3’;
3’400E17
F: 5’AATACTCAAGCTTTGATCTGCGGT3’
R: 5’ATTAAGTTGGTTACCCCCAGGGTT3’;
114H21T7
F: 5’TCTCCTGATGGATGGCTTCT3’
R: 5’GTTGTACCCATTTTCCTGCC3’;
114H21SP6
F: 5’AAGAAATGGCAGGCAGAGAA3’
R: 5’CAATGCCCACCTTTACGTCT3’;
17205SP6
F: 5’TCCTTACCTACCTGGCATGG3’
R: 5’AGAGCGGCACTCCGTAGATA3’;
226L21T7
F: 5’CCAGCTACCTCATCTCTGCC3’
R: 5’GATCGGAAGCAAATGCTGAT3’;
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226L21SP6
F: 5’GGATCTGCCAGAGTGGACAT3’
R: 5’CAGGCCTGAGAGGTAACTGC3’;
536B11T7
F: 5’TACGTAGGAAGCGAGAGGGA3’
R: 5’GCATCTCAGCCACAACAGAA3’;
536B11SP6
F: 5’TTTGGCACAGAGAAGCACAC3’
R: 5’GAGCCCTGAGACATAGCTGG3’;
172O5T7
F: 5’GCCATCTCTGCATCTCTGAA3’
R: 5’AGAGACCCTGGAAGGAAGGT3’;
400E17SP6
F: 5’GGGTGACCAGCATCACACTG3’;
R: 5’TGTGATATCTTGGGGGTGGC3’;
114H21T7
F: 5’TTAAAGGACTGGCCACCAAG3’
R: 5’AGTCCAATTCACATTCCCCA3’;
400E17T7
F: 5’TGGCTTGCACACTCAGGTTG3’
R: 5’ATTCCCTGGACAGATGGCCT3’;
50A5T7
F: 5’GAAGGCTCGGCTATGCAA3’
R: 5’GTTGTAGCGCAAGATTTCGG3’;
50A5SP6
F: 5’CATGGCAGTGGAGAAAGTGA3’
R: 5’AAATTCCCGGGATAATGGG3’;
115L9T7
F: 5’CTTGGTATTCCACTGGCGAT3’
R: 5’CAAAAAGACGGTGCTGACAA3’;
115L9SP6
F: 5’AGCAATACCCTACCCCTCGT3’
R: 5’TAAGCTCTCAGTCCCTCCCA3’;
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Tfam
F: 5’TGCTGAGTTCTGCCTTTTGC3’
R: 5’AGCCTGGCAGCTTCTTTGAA3’;
225C18T7
F: 5’GAGCCCTGAGACATAGCTGG3’
R: 5’TTTGGCACAGAGAAGCACAC3’;
295N22T7
F: 5’TGCAGCAAGATTTCTGATGG3’
R: 5’AGGCAAGTGGAGAACTGGAA3;
225C18SP6
F: 5’AAGACAGACAACCGCTGCTT3’
R: 5’GCTGGGGCTTACGTAATTGA3’;
M-02039
F: 5’TGCCACTCCATTCCCTGTCA3’
R: 5’AGTGTCCACGGGGCTTCTTG3’;
59E15T7
F: 5’CCTTGGGCAGAAATGGAAGG3’
R: 5’GCAAAATGGGTCGCCAAGGT3’;
337G9T7
F: 5’GGCCACCTGCAACTCTGCTT3’
R: 5’GAGGGAAAAGGCTTGGCTCC3’;
337G9SP6
F: 5’GGCATTATGGGCACACCGAT3’
R: 5’TGGGGCTGAAGAGATGGCTC3’;
59E15SP6
F: 5’TCACAAAGCCCTCACACAACG3’
R: 5’TCCATGCTGTGCCATGTGTTT3’;
312N7T7
F: 5’TCAAAGGCTCTTGGCCTTGC3’
R: 5’GCAAGGTGTGGGAAATTGGG3’;
312N7SP6
F: 5’AGTTCAGCCCTGGCATCAGC3’
R: 5’AGAGATGGCAAGGGCAGTGG3’;
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226L21SP6
F: 5’ACGTGGACAAACCCAAAAAG3’
R: 5’GTTCCTTTGCGTGTGGATTT3’;
337G9T7
F: 5’TGCCGTGAACTACATACCCA3’
R: 5’GGATGATTCGGCTCAGGTAA3’;
310N21T7
F: 5’AAACAGCCGTCCCTAGGATT3’
R: 5’TGGTTAGCTCTGGGCTCATT3’;
310N21SP6
F: 5’ATTTCAGGCTACTCCGCT3’
R: 5’AGATGGAGACTCTGCCAGGA3’;
282P18T7
F: 5’TCTTGGTAGCTGGCAGGAGT3’
R: 5’TTTCATCCTTTCAGGGCATC3’;
282P18SP6
F: 5’TTTCATCCTTTCAGGGCATC3’
R: 5’AGTATAGCAGGCCCTCCTCC3’;
244D3T7
F: 5’GAAGAGGGAGGGTGATGGAT3’
R: 5’GCTGTGGTTGCATATTCCCT3’
244D3SP6
F: 5’AGTGAGCACAGTGCAAGCTC3’
R: 5’AACAGTTGTTTTTCTTATTGCAGC3’;
395K5SP6
F: 5’AAACCATCAGAACCACAGCC3’
R: 5’AAACCATCAGAACCACAGCC3’;
395K5T7
F: 5’CCAAGTAACCCAAACATCCG3’
R: 5’GTGGGCTGGTGTTTCTGAAT3’;
328F8SP6
F: 5’GGGTCATGTTTTGCAATGAA3’
R: 5’GCACCTGCAAACTGACACAT3’;
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259N19T7
F: 5’TCGGTGGGTACCTGAGGTTACTG3’
R: 5’TGGCTAAGAGCATGAGAAGAAAGGA3’;
259N19SP6
F: 5’CTTTGGCACAGAGAAGCACACAC3’
R: 5’CAGCCAAGCTGAGCAGGATCTAA3’;
326F24T7
F: 5’AGTCCCCGCAATTGGCTGTA3’
R: 5’ACCCCTCACCTGGGGAATGA3’;
326F24SP6
F: 5’GGATGCTGGAGACCCAGAGC3’
R: 5’CAGCCTCCTGAATGCTGGGT3’.
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APPENDIX C

The following primers were used for RH Mapping as described in Physical and
Genetic Mapping in Chapter III.
HTL5/10
F: 5’CGGGCTGGACAAGAGCCTGG3’
R: 5’CCTCCAGAAGCAGAAGCACCACTC3’;
5’400E17
F: 5’GTAATGGAACTCACCACCTGCTCTG3’
R: 5’CGTCCTTCATACACTCCTGTGAACC3’
400E17SP6
F: 5’GGGTGACCAGCATCACACTG3’
R: 5’TGTGATATCTTGGGGGTGGC3’;
225C18SP6
F: 5’AAGACAGACAACCGCTGCTT3’
R: 5’GCTGGGGCTTACGTAATTGA3’;
114H21T7
F: 5’TCTCCTGATGGATGGCTTCT3’
R: 5’AGTCCAATTCACATTCCCCA3’;
Tfam
F: 5’GAAGTGATCTCATCCGTCGAAGGT3’
R: 5’TAAGCAAAAGGCAGAACTCAGCATC3’;
5’307I23
F: 5’GGAAATGCACACCATCGAGCTGAA3’
R: 5’GGAAATGCACACCATCGAGCTGAA3’;
5'115A16
F: 5’GGGTGCAGACTGTGATCTTCTCAAT3’
R: 5’ATTCGTTCTTAGCACTCTCCAGCCT3’;
PSO2
F: 5’GCAAGGGTAGATCAGGTTAAG3’
R: 5’GCCAGTCTGTAAGAAGTGCT3’;
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SPL3
F: 5’ACCCTTGTGAAGTTCCTTGG3’
R: 5’ATTGTGCTCTACGGAGCCAG3’;
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APPENDIX D

The following primers were used for DNA and/or cDNA sequencing analysis of
the Bicc1 gene as described in Chapter III, DNA Sequencing:
RT-PCR Primers
BG062853
F: 5’AATCCGGCAAGGGTGGTAAC3’
R: 5’CAATGGTGCCCTGGAGGTAG3’;
BF785275
F: 5’CATGCAGACAGAAGGCGAAA3’
R: 5’AGGAGCCCTCATAGCCGTGT3’;
KHDOMAIN
F: 5’CAGGAAGAAACTCGAGGCCA3’
R: 5’AATGTGGCCTGGGCAGTAGA3’;
JCPK20-22
F: 5’GTGCCCGAAGGAAAATGCTG3’
R: 5’GCAGGCGAGTGCAGTGAAGA3’;
BIC-C
F: 5’ACCATGGCCTCGCAGAGC3’
R: 5’TGGCCATGAAGTACAGGTACGA3’;
SP3
F: 5’AAAACAGCTCAAGGGCAGGG3’
R: 5’GCCCTGACTGCCTCTCCTTT3’;
493392E3-4
F: 5’GAGAGCACTATCTAAGCAGCAGCA3’
R: 5’GAGAGCACTATCTAAGCAGCAGCA3’;
AI26426RT
F: 5’CCAAACATGTTCACTGGGCA3’
R: 5’ATGTGCAGTGGGTTCACACC3’;
RIKEN48334
F: 5’AGGGAAGCTTACGCACCTCG3’
R: 5’CAGCCTGACATTTTAACAGCCAC3’;
162

Genomic Primers

EXON1
F: 5’GCAAGCTGACAAAGTTGGGG3’
R: 5’AAGCAAGCTTGTACGCCTGG3’;
EXON2
F: 5’CCTGGGTGTGAGAAACCAGC3’
R: 5’AGGGCAGCTTCCATCTAGCA3’;
EXON3
F: 5’CACACCCCCTCTTCTCCCTC3’
F: 5’TTGACAAGCACTTGAGGCCA3’;
EXON4
F: 5’GCAGACTCCCATGCACCTTT3’
R: 5’TCGCAGTGGTGTGATTTGCT3’;
EXON5
F: 5’GGTGGTGGTAACACATCGGG3’
R: 5’TCCAGTGATATCTGGCCATTGA3’;
EXON6 (Genomic2)
F: 5’CAAAAGGGAGAAATGCTGTGG3’
R: 5’TGACGTCTGCAGAGAGGCAC3’;
EXON7 (Genomic3)
F: 5’GCCTGAAGGCAGTTCAAGTCTC3’
R: 5’CAACTGTTCCCACACAGGCA3’;
EXON8 (Genomic4)
F: 5’CCATGACCACACCCAGAACA3’
R: 5’GCCTACAGCGACACAATAACCC3’;
EXON9
F: 5’CCCCAGATAGTCTCCTGCCC3’
R: 5’ATAACGGAGGGGGCACTGTT3’;
EXON10
F: 5’TGGTATCCAGCCTCCTGTGG3’
R: 5’TCATGCGTGCATCCTACCAG3’;
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EXON11
F: 5’GCTTGAGCTGAGGTTCGTCC3’
R: 5’GGGAGAGCATAGAGACCGGG3’;
EXON12
F: 5’GGAACCCAGCTTCTTGGAGG3’
R: 5’AGCCACAAGCCAGTCTGAGG3’;
EXON14
F: 5’CTCTCTCCCCCAACGTCCTC3’
R: 5’TTCAAGAGGCAGCAGGAAGC3’;
EXON15
F: 5’GGCAGGTGATAGCTGAAGCA3’
R: 5’AATTCATTAGCAGGCGGGTG3’;
EXON16
F: 5’TTTGTGGTCCCATGATGCAG3’
R: 5’TCCCCTCTGGTGGCTTGATA3’;
EXON18
F: 5’TTCCTGAGAATGGGTGTGCC3’
R: 5’GCCAATGGTCACTGGGGAAA3’;
EXON19
F: 5’GGCTCATCCGAACAACGAAA3’
R: 5’CCTGATGAGGAAGAAGGGCA3’;
EXON20
F: 5’TGTCCCCTGGACAGATCCAT3’
R: 5’GGCAGGAGGAACTACTCCCC3’;
EXON22
F: 5’CAAACACCATTTGCCCTGGT3’
R: 5’CCCTTTGGTGCTTTTATGGC3’.
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APPENDIX E
Mouse Bicaudal-C Transcripts
TRANSCRIPT A
1
1

M A S Q S E P G Y L A A A Q S D P G S N
ATGGCCTCGCAGAGCGAGCCGGGCTACCTGGCGGCGGCGCAGTCGGACCCCGGCTCCAAC

21
61

S E R S T D S P V A G S E D D L V A A A
AGCGAGCGCAGCACCGACTCGCCGGTGGCCGGCTCCGAGGACGATCTGGTGGCCGCGGCG

41
121

P L L H S P E W S E E R F R V D R K K L
CCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCGCGTGGACAGGAAGAAACTC

61
181

KH1
1 2
E A M L Q
A A A E G K G R S G E D F F Q
GAGGCCATGCTCCAAGCTGCAGCTGAAGGAAAAGGCCGAAGTGGGGAAGACTTTTTTCAG

81
241

K
I M E E T N T Q I A W P S K L K I G A
AAGATCATGGAGGAGACAAACACGCAGATTGCATGGCCGTCCAAACTGAAGATCGGGGCT

101
301

K S K K
D P H I K V S G K K E D V K E A
AAATCCAAGAAAGATCCCCACATCAAGGTTTCTGGGAAGAAAGAGGATGTGAAGGAAGCC

121
361

4 5
KH2
K E M I M S V L D T K S N R V T L K M D
AAAGAAATGATCATGTCTGTCTTAGACACAAAAAGCAACCGCGTCACATTGAAGATGGAT

141
421

V S H T E H S H V I G K G G N N I K K V
GTCTCGCACACGGAGCACTCCCACGTCATCGGCAAGGGTGGTAACAACATTAAAAAGGTC

161
481

M E D T G C H I H F P D S N R N N Q A E
ATGGAAGACACGGGCTGCCACATCCACTTCCCAGACTCCAACAGGAACAACCAGGCAGAG

181
541

K S N Q V S I A G Q P A G V E S A R A R
AAGAGTAACCAGGTGTCTATAGCAGGACAGCCAGCAGGAGTAGAATCGGCCCGAGCAAGG

2

3

3 4

5

6

6

7

201
601

I R E L L P L V L M F E L P I A G I L Q
ATTCGGGAGCTGCTTCCTTTGGTGCTGATGTTTGAGTTACCGATTGCCGGGATTCTCCAG

221
661

P V P D P N T P S I Q H I S Q T Y S V S
CCAGTCCCCGATCCCAACACCCCGTCCATTCAGCACATCTCACAAACCTACAGCGTTTCT

241
721

V S F K Q R S R M Y G A T V T V R G S Q
GTGTCCTTTAAGCAGAGGTCTCGAATGTATGGTGCTACAGTCACAGTACGAGGCTCTCAG

165

7

261
781

8

281
841

N N T N A V K E G T A M L L E H L A G S
AATAACACTAATGCTGTGAAGGAAGGAACAGCCATGCTGTTGGAACACCTTGCGGGAAGC
KH3
L A S A I P V S T Q L D I A A Q H H L F
TTGGCCTCCGCCATCCCCGTGAGCACACAACTGGACATAGCAGCCCAGCATCACCTCTTC

301
901

M M G R N G S N V K H I M Q R T G A Q I
ATGATGGGCCGGAACGGGAGCAACGTCAAACACATCATGCAGAGGACAGGGGCGCAGATT

321
961

H F P D P S N P Q K K S T V Y L Q G T I
CACTTTCCCGACCCCAGCAATCCACAGAAGAAATCCACCGTCTACCTCCAGGGCACCATT
8

9

341
1021

E S V C L A R Q Y L M G C L P L V L M F
GAGTCTGTCTGCCTAGCAAGGCAGTATCTCATGGGGTGTCTTCCTCTGGTGTTGATGTTT

361
1081

D M K E D I E V D P Q V I A Q L M E Q L
GATATGAAGGAAGACATTGAAGTGGACCCACAGGTCATCGCACAGCTGATGGAACAGCTG
9 10

381
1141

D V F I S I K P K P K Q P S K S V I V K
GACGTCTTTATCAGTATTAAACCAAAGCCCAAACAGCCGAGCAAGTCTGTGATTGTGAAA

401
1201

S V E R N A L N M Y E A R K C L L G L E
AGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAGTGTCTCCTCGGACTTGAA

421
1261

S S G V S I A T S L S P A S C P A G L A
AGCAGTGGGGTTTCCATAGCAACCAGTCTATCCCCAGCATCGTGCCCTGCCGGCCTGGCC

441
1321

C P S L D I L A S A G L G L T G L G L L
TGTCCCAGCCTGGATATCTTAGCTTCGGCAGGCCTCGGACTCACTGGACTAGGTTTATTG

461
1381

G P T T L S L N T S A T P N S L L N A L
GGGCCCACCACATTGTCGCTAAATACGTCAGCCACCCCAAACTCACTCCTGAATGCTCTC

481
1441

N T S V S P L Q S S S S G T P S P T L W
AACACTTCGGTCAGTCCTTTGCAAAGTTCAAGTTCTGGTACTCCCAGTCCTACACTGTGG

501
1501

A P P I A N T A S A T G F S T I P H L M
GCACCCCCAATCGCTAACACTGCAAGCGCCACAGGTTTCTCTACGATACCACACCTTATG

521
1561

L P S T A Q A T L T N I L L S G V P T Y
CTTCCCTCTACTGCCCAGGCCACATTAACCAATATTTTGCTGTCTGGAGTGCCCACATAC

10

11

11 12

166

541
1621

G H T A P S P P P G L T P V D V H I N S
GGGCACACGGCTCCATCTCCCCCACCTGGCTTGACTCCTGTTGATGTTCACATCAACAGC
12 13

561
1681

M Q T E G K N I S A S I N G H V Q P A N
ATGCAGACAGAAGGCAAAAACATCTCTGCGTCTATAAATGGACATGTGCAGCCTGCAAAC

581
1741

M K Y G P L S T S S L G E K V L S S N H
ATGAAATACGGTCCGCTGTCCACTTCATCGCTTGGGGAAAAAGTGCTGAGTTCGAATCAT

601
1801

G D P S M Q T A G P E Q A S P K S N S V
GGTGACCCATCCATGCAGACAGCTGGGCCCGAACAGGCTTCTCCTAAATCAAACTCGGTG
13 14

621
1861

E G C N D A F V E V G M P R S P S H S G
GAAGGCTGCAATGATGCCTTTGTTGAAGTGGGCATGCCTCGAAGTCCCTCCCATTCTGGA

641
1921

N A G D L K Q M L G A S K V S C A K R Q
AACGCTGGCGACTTGAAGCAGATGCTGGGTGCCTCCAAGGTCTCCTGTGCCAAGCGGCAG
14

15

661
1981

T V E L L Q G T K N S H L H G T D R L L
ACGGTTGAGCTACTGCAGGGCACGAAGAACTCGCACCTCCACGGCACTGACAGACTACTC

681
2041

S D P E L S A T E S P L A D K K A P G S
TCAGACCCTGAACTGAGCGCCACAGAAAGTCCGCTTGCTGACAAGAAGGCCCCGGGGAGC

701
2101

E R A A E R A A A A Q Q K S E R A R L A
GAACGTGCAGCTGAGAGGGCAGCAGCTGCCCAGCAGAAATCGGAGAGGGCCCGCCTGGCC

721
2161

S Q P T Y V H M Q A F D Y E Q K K L L A
TCGCAGCCAACATATGTCCACATGCAGGCATTTGATTATGAGCAGAAGAAACTATTAGCC

741
2221

T K A M L K K P V V T E V R T P T N T W
ACCAAAGCGATGTTAAAGAAGCCAGTGGTGACTGAGGTCAGAACACCTACGAATACGTGG

761
2281

S G L G F S K S M P A E T I K E L R R A
AGTGGCCTGGGATTCTCAAAGTCCATGCCGGCAGAAACCATTAAGGAACTGAGGAGAGCC

781
2341

N H V S Y K P T M T T A Y E G S S L S L
AACCACGTATCCTATAAGCCCACGATGACCACCGCCTATGAGGGCTCCTCATTGTCCCTC

801
2401

S R S S S R E H L A S G S E S D N W R D
TCAAGGTCCAGCAGTCGTGAGCACCTGGCAAGTGGAAGCGAGTCAGACAACTGGAGAGAC

15

16

17 18

167

821
2461

R N G I G P M G H S E F S A P I G S P K
CGGAATGGAATAGGCCCCATGGGTCACAGTGAATTCTCAGCACCAATCGGCAGCCCCAAG

841
2521

R K Q N K S R E H Y L S S S N Y M D C I
CGCAAGCAGAACAAATCAAGAGAGCACTATCTAAGCAGCAGCAACTACATGGACTGCATT

861
2581

SAM DOMAIN
S S L T G S N G C N L N S C F K G S D L
TCCTCGCTGACGGGAAGCAATGGCTGTAACCTGAACAGCTGCTTCAAAGGCTCCGACCTC

881
2641

19 20
conserved tyrosine
P E L F S K L G L G K Y T D V F Q Q Q E
CCCGAGCTTTTCAGCAAGCTGGGCCTAGGCAAATACACGGATGTCTTCCAGCAGCAAGAG

901
2701

I D L Q T F L T L T D Q D L K E L G I T
ATCGATCTTCAGACATTCCTCACCCTCACAGATCAGGATCTGAAGGAGCTGGGAATCACA

18

19

20 22

921
2761

T F G A R R K M L L A I S E L S K N R R
ACCTTTGGTGCCCGAAGGAAAATGCTGCTGGCAATCTCAGAGCTAAGTAAAAACCGAAGA

941 K L F E P P N A S C T S F L E G
G A S G
2821 AAACTTTTTGAACCACCAAACGCATCATGCACCTCCTTCCTGGAAGGC▼GGAGCCAGTGGG
GC (bpk)insertion
2881

R L P R Q Y H S D I A S V S G R W AGGCTGCCTCGCCAGTATCATTCAGACATTGCGAGCGTCAGTGGCCGCTGGTAGCGGTAC

2941

GCTTCTGGACACGCACCTGCTATCTTGCAAAGGTGGACACGATCCGTGGACAGTCTTCAC

3001

TCACTCGCCTGCCCTTGGCACTCGGAGTGTCTGGTATCAGGACCAAAGTGTTGATTTCGT

3061

ACCTGTACTTCATGGCCAAAAAAAAAAAAAAAA
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TRANSCRIPT B
1
1

M A S Q S E P G Y L A A A Q S D P G S N
ATGGCCTCGCAGAGCGAGCCGGGCTACCTGGCGGCGGCGCAGTCGGACCCCGGCTCCAAC

21
61

S E R S T D S P V A G S E D D L V A A A
AGCGAGCGCAGCACCGACTCGCCGGTGGCCGGCTCCGAGGACGATCTGGTGGCCGCGGCG

41
121

P L L H S P E W S E E R F R V D R K K L
CCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCGCGTGGACAGGAAGAAACTC
1

2

61
181

KH1
E A M L Q
A A A E G K G R S G E D F F Q
GAGGCCATGCTCCAAGCTGCAGCTGAAGGAAAAGGCCGAAGTGGGGAAGACTTTTTTCAG

81
241

K
I M E E T N T Q I A W P S K L K I G A
AAGATCATGGAGGAGACAAACACGCAGATTGCATGGCCGTCCAAACTGAAGATCGGGGCT

101
301

K S K K
D P H I K V S G K K E D V K E A
AAATCCAAGAAAGATCCCCACATCAAGGTTTCTGGGAAGAAAGAGGATGTGAAGGAAGCC

121
361

KH2
4 5
K E M I M S V L D T K S N R V T L K M D
AAAGAAATGATCATGTCTGTCTTAGACACAAAAAGCAACCGCGTCACATTGAAGATGGAT

141
421

V S H T E H S H V I G K G G N N I K K V
GTCTCGCACACGGAGCACTCCCACGTCATCGGCAAGGGTGGTAACAACATTAAAAAGGTC

161
481

M E D T G C H I H F P D S N R N N Q A E
ATGGAAGACACGGGCTGCCACATCCACTTCCCAGACTCCAACAGGAACAACCAGGCAGAG

181
541

K S N Q V S I A G Q P A G V E S A R A R
AAGAGTAACCAGGTGTCTATAGCAGGACAGCCAGCAGGAGTAGAATCGGCCCGAGCAAGG

201
601

I R E L L P L V L M F E L P I A G I L Q
ATTCGGGAGCTGCTTCCTTTGGTGCTGATGTTTGAGTTACCGATTGCCGGGATTCTCCAG

221
661

P V P D P N T P S I Q H I S Q T Y S V S
CCAGTCCCCGATCCCAACACCCCGTCCATTCAGCACATCTCACAAACCTACAGCGTTTCT

241
721

V S F K Q R S R M Y G A T V T V R G S Q
GTGTCCTTTAAGCAGAGGTCTCGAATGTATGGTGCTACAGTCACAGTACGAGGCTCTCAG

2

3

3 4

56

6 7

169

7

8

261
781

N N T N A V K E G T A M L L E H L A G S
AATAACACTAATGCTGTGAAGGAAGGAACAGCCATGCTGTTGGAACACCTTGCGGGAAGC

281
841

KH3
L A S A I P V S T Q L D I A A Q H H L F
TTGGCCTCCGCCATCCCCGTGAGCACACAACTGGACATAGCAGCCCAGCATCACCTCTTC

301
901

M M G R N G S N V K H I M Q R T G A Q I
ATGATGGGCCGGAACGGGAGCAACGTCAAACACATCATGCAGAGGACAGGGGCGCAGATT

321
961

H F P D P S N P Q K K S T V Y L Q G T I
CACTTTCCCGACCCCAGCAATCCACAGAAGAAATCCACCGTCTACCTCCAGGGCACCATT

341
1021

E S V C L A R Q Y L M 8 9G C L P L V L M F
GAGTCTGTCTGCCTAGCAAGGCAGTATCTCATGGGGTGTCTTCCTCTGGTGTTGATGTTT

361
1081

D M K E D I E V D P Q V I A Q L M E Q L
GATATGAAGGAAGACATTGAAGTGGACCCACAGGTCATCGCACAGCTGATGGAACAGCTG
9 10

381
1141

D V F I S I K P K P K Q P S K S V I V K
GACGTCTTTATCAGTATTAAACCAAAGCCCAAACAGCCGAGCAAGTCTGTGATTGTGAAA

401
1201

S V E R N A L N M Y E A R K C L L G L E
AGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAGTGTCTCCTCGGACTTGAA

421
1261

S S G V S I A T S L S P A S C P A G L A
AGCAGTGGGGTTTCCATAGCAACCAGTCTATCCCCAGCATCGTGCCCTGCCGGCCTGGCC
10

11

441
1321

C P S L D I L A S A G L G L T G L G L L
TGTCCCAGCCTGGATATCTTAGCTTCGGCAGGCCTCGGACTCACTGGACTAGGTTTATTG

461
1381

G P T T L S L N T S A T P N S L L N A L
GGGCCCACCACATTGTCGCTAAATACGTCAGCCACCCCAAACTCACTCCTGAATGCTCTC

481
1441

N T S V S P L Q S S S S G T P S P T L W
AACACTTCGGTCAGTCCTTTGCAAAGTTCAAGTTCTGGTACTCCCAGTCCTACACTGTGG
11 12

501
1501

A P P I A N T A S A T G F S T I P H L M
GCACCCCCAATCGCTAACACTGCAAGCGCCACAGGTTTCTCTACGATACCACACCTTATG

521
1561

L P S T A Q A T L T N I L L S G V P T Y
CTTCCCTCTACTGCCCAGGCCACATTAACCAATATTTTGCTGTCTGGAGTGCCCACATAC

170

541
1621

G H T A P S P P P G L T P V D V H I N S
GGGCACACGGCTCCATCTCCCCCACCTGGCTTGACTCCTGTTGATGTTCACATCAACAGC

561
1681

M Q T E G K N I S A S I N G H V Q P A N
ATGCAGACAGAAGGCAAAAACATCTCTGCGTCTATAAATGGACATGTGCAGCCTGCAAAC

581
1741

M K Y G P L S T S S L G E K V L S S N H
ATGAAATACGGTCCGCTGTCCACTTCATCGCTTGGGGAAAAAGTGCTGAGTTCGAATCAT

601
1801

G D P S M Q T A G P E Q A S P K S N S V
GGTGACCCATCCATGCAGACAGCTGGGCCCGAACAGGCTTCTCCTAAATCAAACTCGGTG

12 13

13 14

621
1861

E G C N D A F V E V G M P R S P S H S G
GAAGGCTGCAATGATGCCTTTGTTGAAGTGGGCATGCCTCGAAGTCCCTCCCATTCTGGA

641
1921

N A G D L K Q M L G A S K V S C A K R Q
AACGCTGGCGACTTGAAGCAGATGCTGGGTGCCTCCAAGGTCTCCTGTGCCAAGCGGCAG
14

15

661
1981

T V E L L Q G T K N S H L H G T D R L L
ACGGTTGAGCTACTGCAGGGCACGAAGAACTCGCACCTCCACGGCACTGACAGACTACTC

681
2041

S D P E L S A T E S P L A D K K A P G S
TCAGACCCTGAACTGAGCGCCACAGAAAGTCCGCTTGCTGACAAGAAGGCCCCGGGGAGC

701
2101

E R A A E R A A A A Q Q K S E R A R L A
GAACGTGCAGCTGAGAGGGCAGCAGCTGCCCAGCAGAAATCGGAGAGGGCCCGCCTGGCC
15

16

721
2161

S Q P T Y V H M Q A F D Y E Q K K L L A
TCGCAGCCAACATATGTCCACATGCAGGCATTTGATTATGAGCAGAAGAAACTATTAGCC

741
2221

T K A M L K K P V V T E V R T P T N T W
ACCAAAGCGATGTTAAAGAAGCCAGTGGTGACTGAGGTCAGAACACCTACGAATACGTGG

761
2281

S G L G F S K S M P A E T I K E L R R A
AGTGGCCTGGGATTCTCAAAGTCCATGCCGGCAGAAACCATTAAGGAACTGAGGAGAGCC
17 18

781
2341

N H V S Y K P T M T T A Y E G S S L S L
AACCACGTATCCTATAAGCCCACGATGACCACCGCCTATGAGGGCTCCTCATTGTCCCTC

801
2401

S R S S S R E H L A S G S E S D N W R D
TCAAGGTCCAGCAGTCGTGAGCACCTGGCAAGTGGAAGCGAGTCAGACAACTGGAGAGAC

171

821
2461

R N G I G P M G H S E F S A P I G S P K
CGGAATGGAATAGGCCCCATGGGTCACAGTGAATTCTCAGCACCAATCGGCAGCCCCAAG

841
2521

R K Q N K S R E H Y L S S S N Y M D C I
CGCAAGCAGAACAAATCAAGAGAGCACTATCTAAGCAGCAGCAACTACATGGACTGCATT

861
2581

SAM DOMAIN
S S L T G S N G C N L N S C F K G S D L
TCCTCGCTGACGGGAAGCAATGGCTGTAACCTGAACAGCTGCTTCAAAGGCTCCGACCTC

18

19

19

881
2641

P E L F S K L G L G K Y T D V F Q Q Q E
CCCGAGCTTTTCAGCAAGCTGGGCCTAGGCAAATACACGGATGTCTTCCAGCAGCAAGAG

901
2701

I D L Q T F L T L T D Q D L K E L G I T
ATCGATCTTCAGACATTCCTCACCCTCACAGATCAGGATCTGAAGGAGCTGGGAATCACA

921
2761

T F G A R R K M L L A I S V C D S V Q I
ACCTTTGGTGCCCGAAGGAAAATGCTGCTGGCAATCTCAGTTTGTGACTCTGTTCAGATC

941
2821

R N K I L R A A R I L CGCAACAAGATCCTGAGAGCTGCCAGGATTCTGTGAACCTTGGAATGTCAAAGAAAAAAG

20 21

21

2882

22

AGCTAAGTAAAAACCGAAGAAAACTTTTTGAACCACCAAACGCATCATGCACCTCCTTCC

2941 TGGAAGG▼CGGAGCCAGTGGGAGGCTGCCTCGCCAGTATCATTCAGACATTGCGAGCGTCA
GC (bpk)insertion
3001

GTGGCCGCTGGTAGCGGTACCTTCTGGACACGCACCTGCTATCTTGCAAAGGTGGACACG

3061

ATCCGTGGACAGTCTTCACTGCACTCGCCTGCCCTTGGCACTCGGAGTGTCTGGTATCAG

3121

GACCAAAGTGTTGATTTCGTACCTGTACTTCATGGCCAAAAAAAAAAAAAAAA

172

20

APPENDIX F
KH Domain Multialignment

KH1
MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

--------------KIMEETNTQIAWPSKLKIGAKSKK---------------DPHIKVS
-------------HRVVGQPDQPYKYITGFKQFHRNTKEAQYILQCQSQSTCVDPHIKVS
-----------------------------------------------------DPHIKVS
AAEGKGKSGEDFFQKIMEETNTQIAWPSKLKIGAKSKK---------------DPHIKVS
--------------QIMDETQTQIAWPSKLKIGAKSKK-------------------GDC
------------------------------------------------------------------------HDIMNTTDTYVSWPCRLKIGAKSKK---------------DPHVRIV
-------------TNIMKETTTYVSWPCRLKIGAKTKK---------------DPHIRIV

31
47
7
45
27

MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

GKKEDVKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEDTGCHIHFP
GKKEDVKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEETGCHIHFP
GKKEAVKEAKEMIMAVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEDTGCHIHFP
GKKENVKEAKERIMSVLDTKSNRVTLKMDVLHTEHSHVIGKGGNNIKKVMEETGCHIHFP
ILKGQMSTSITFSASFHPLVSNRVTLKMDVSHTEHSHVIGKGGNNIKRVMEETGCHIHFP
-----------------------------------------------------------GKVDQVQRAKERILSSLDSRGTRVIMKMDVSYTDHSYIIGRGGNNIKRIMDDTHTHIHFP
GKMADVLRAKDKVMARLDSRGSRVIMKMDVSYTDHSFIIGRGGNNIKKIMEETATHIHFP

91
107
67
105
87

MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

DSNRNNQAEKSNQVSIAGQPAGVESARARIRELLPLVLMFELPIAGILQPVPDPNTPSIQ
DSNRNNQAEKSNQVSIAGQPAGVESARVRIRELLPLVLMFELPIAGILQPVPDPNSPSIQ
DSNRNNQVEKSNQVSIAGQPAGVESARARIRELLPLVLMFELPIAGILQPVPDPNTPSIQ
DSNRNNQAEKSNQVSIAGQPAGVESARVRIRELLPLVLMFELPIAGILQPIPDPNSPTIQ
DSNRNNQAEKSN------------------QELLPLVLSFELP--AIMQ--SDPSSPTVQ
------------------------------QELLPLVLMFELPVIGQLN--PDPSSPAIQ
DSNRSNPTEKSNQVSLCGSLEGVERARALVRLSTPLLISFEMPVMGPNKPQPDHETPYIK
DSNRSNPTEKSNQVSMCGSIEGVERARSLVRNSTPLLISFELPILAPGKTPPDNDTPYVK

151
167
127
165
125
28
152
152

MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

HISQTYSVSVSFKQRSRMYGATVTVRGSQNNTNAVKEGTAMLLEHLAGSLASAIPVSTQL
HISQTYNISVSFKQRSRMYGATVIVRGSQNNTSAVKEGTAMLLEHLAGSLASAIPVSTQL
HISQTYSVSVSFKQRSRMYGATVIVRGSQNNTNAVKEGTAMLLEHLAGSLASAIPVSTQL
QISQTYNLTVSFKQRSRVYGATVIVRGSQNNTSAVKEGTAMLLEHLAGSLATAIPVSTQL
HISQTYNLTVSFKPPTRLYRASGVVRGSQNNTNAVKRGTALLLEHLVGSLASTISVSTHL
HISQTYNISVAFKQRSRLYGATGVVRGSQNNAAAVKRGTAVLLEHLAGNLASAITISTQL
MIETKFNVQVIFSTRPKLHTSLVLVKGSEKESAQVRDATQLLINFACESIASQILVNVQM
EIEAEYGVQVIFSTRPKLHSSLVLVKGSEKEERMVKEATRRLMDLMCENMASQIPVHMQL

211
227
187
225
185
88
212
212

MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

DIAAQHHLFMMGRNGSNVKHIMQRTGAQIHFPDPS----NPQKKSTVYLQGTIESVCLAR
DIAAQHHLFMMGRNGSNIKHIMQRTGAQIHFPDPS----NPQKKSTVYLQGTIESVCLAR
DIAAQHHLFMMGRNGSNVKHIMQRTGAQIHFPDPS----NPQKKSTVYLQGTIESVCLAR
DIAAQHHLFMMGRNGCNIKHIMQRTGAQIHFPDPN----NPLKKSTVYLQGTIDSVCLAR
DIAPQHHLFMKGRNGSNIKHITQRTGAQIHFPDPN----SPQKKSTVYIQGTIESVCLAR
DIALQHHLFMMGRNGSNIKHIMQRTGAQVHFPDPN----CPQKKSTVYVQGTIDSVCLAR
EISPQHHEIVKGKNNVNLLSIMERTQTKIIFPDLSDMNVKPLKKSQVTISGPIDDVYLAR
EISTQHHPIVLGRSSSNLREIMNRTGTQIMFPDANDVNIKPIKRSQVTITGSINGVYLAR

267
283
243
281
241
144
272
272

MOUSE
HUMAN
RAT
XENOPUS
FUGU
DANIO
DROSOPHILA
ANOPHELES

QYL
QYL
QYL
QYL
QYL
QYL
QQL
QQL
* *

32
32

KH2

92
92

KH3

270
286
246
284
244
147
275
275

Red = conserved in all species
Blue = conserved in four or more species
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APPENDIX G
PRIMER MAP FOR RECOMBINANT PROTEINS

Primers used are indicated in purple.
1
1

Bicc1/pET.f
M A S Q S E P G Y L A A A Q S D P G S N
ATGGCCTCGCAGAGCGAGCCGGGCTACCTGGCGGCGGCGCAGTCGGACCCCGGCTCCAAC

21
61

S E R S T D S P V A G S E D D L V A A A
AGCGAGCGCAGCACCGACTCGCCGGTGGCCGGCTCCGAGGACGATCTGGTGGCCGCGGCG

41
121

P L L H S P E W S E E R F R V D R K K L
CCCCTCTTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCGCGTGGACAGGAAGAAACTC

61
181

1 2
pET101/AB.r
KH1
E A M L Q
A A A E G K G R S G E D F F Q
GAGGCCATGCTCCAAGCTGCAGCTGAAGGAAAAGGCCGAAGTGGGGAAGACTTTTTTCAG

2

3

81
241

K
I M E E T N T Q I A W P S K L K I G A
AAGATCATGGAGGAGACAAACACGCAGATTGCATGGCCGTCCAAACTGAAGATCGGGGCT

101
301

K S K K
D P H I K V S G K K E D V K E A
AAATCCAAGAAAGATCCCCACATCAAGGTTTCTGGGAAGAAAGAGGATGTGAAGGAAGCC

121
361

KH2.f
KH2
4 5
K E M I M S V L D T K S N R V T L K M D
AAAGAAATGATCATGTCTGTCTTAGACACAAAAAGCAACCGCGTCACATTGAAGATGGAT
KH1.r

141
421

V S H T E H S H V I G K G G N N I K K V
GTCTCGCACACGGAGCACTCCCACGTCATCGGCAAGGGTGGTAACAACATTAAAAAGGTC

161
481

M E D T G C H I H F P D S N R N N Q A E
ATGGAAGACACGGGCTGCCACATCCACTTCCCAGACTCCAACAGGAACAACCAGGCAGAG

3 4

174

5

6

181
541

K S N Q V S I A G Q P A G V E S A R A R
AAGAGTAACCAGGTGTCTATAGCAGGACAGCCAGCAGGAGTAGAATCGGCCCGAGCAAGG

201
601

6 7
KH1+KH2.r
I R E L L P L V L M F E L P I A G I L Q
ATTCGGGAGCTGCTTCCTTTGGTGCTGATGTTTGAGTTACCGATTGCCGGGATTCTCCAG

221
661

P V P D P N T P S I Q H I S Q T Y S V S
CCAGTCCCCGATCCCAACACCCCGTCCATTCAGCACATCTCACAAACCTACAGCGTTTCT

241
721

V S F K Q R S R M Y G A T V T V R G S Q
GTGTCCTTTAAGCAGAGGTCTCGAATGTATGGTGCTACAGTCACAGTACGAGGCTCTCAG

261
781

7 8
KH3.f
N N T N A V K E G T A M L L E H L A G S
AATAACACTAATGCTGTGAAGGAAGGAACAGCCATGCTGTTGGAACACCTTGCGGGAAGC

281
841

KH3
L A S A I P V S T Q L D I A A Q H H L F
TTGGCCTCCGCCATCCCCGTGAGCACACAACTGGACATAGCAGCCCAGCATCACCTCTTC

301
901

M M G R N G S N V K H I M Q R T G A Q I
ATGATGGGCCGGAACGGGAGCAACGTCAAACACATCATGCAGAGGACAGGGGCGCAGATT

321
961

H F P D P S N P Q K K S T V Y L Q G T I
CACTTTCCCGACCCCAGCAATCCACAGAAGAAATCCACCGTCTACCTCCAGGGCACCATT
8

9

341
1021

E S V C L A R Q Y L M G C L P L V L M F
GAGTCTGTCTGCCTAGCAAGGCAGTATCTCATGGGGTGTCTTCCTCTGGTGTTGATGTTT

361
1081

D M K E D I E V D P Q V I A Q L M E Q L
GATATGAAGGAAGACATTGAAGTGGACCCACAGGTCATCGCACAGCTGATGGAACAGCTG
9 10

381
1141

D V F I S I K P K P K Q P S K S V I V K
GACGTCTTTATCAGTATTAAACCAAAGCCCAAACAGCCGAGCAAGTCTGTGATTGTGAAA

175

401
1201

KH1+KH2+KH3.r
S V E R N A L N M Y E A R K C L L G L E
AGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAGTGTCTCCTCGGACTTGAA

421
1261

S S G V S I A T S L S P A S C P A G L A
AGCAGTGGGGTTTCCATAGCAACCAGTCTATCCCCAGCATCGTGCCCTGCCGGCCTGGCC

441
1321

C P S L D I L A S A G L G L T G L G L L
TGTCCCAGCCTGGATATCTTAGCTTCGGCAGGCCTCGGACTCACTGGACTAGGTTTATTG

461
1381

G P T T L S L N T S A T P N S L L N A L
GGGCCCACCACATTGTCGCTAAATACGTCAGCCACCCCAAACTCACTCCTGAATGCTCTC

481
1441

N T S V S P L Q S S S S G T P S P T L W
AACACTTCGGTCAGTCCTTTGCAAAGTTCAAGTTCTGGTACTCCCAGTCCTACACTGTGG

501
1501

A P P I A N T A S A T G F S T I P H L M
GCACCCCCAATCGCTAACACTGCAAGCGCCACAGGTTTCTCTACGATACCACACCTTATG

521
1561

L P S T A Q A T L T N I L L S G V P T Y
CTTCCCTCTACTGCCCAGGCCACATTAACCAATATTTTGCTGTCTGGAGTGCCCACATAC

541
1621

G H T A P S P P P G L T P V D V H I N S
GGGCACACGGCTCCATCTCCCCCACCTGGCTTGACTCCTGTTGATGTTCACATCAACAGC

10

11

11 12

12 13

561
1681

M Q T E G K N I S A S I N G H V Q P A N
ATGCAGACAGAAGGCAAAAACATCTCTGCGTCTATAAATGGACATGTGCAGCCTGCAAAC

581
1741

M K Y G P L S T S S L G E K V L S S N H
ATGAAATACGGTCCGCTGTCCACTTCATCGCTTGGGGAAAAAGTGCTGAGTTCGAATCAT

601
1801

G D P S M Q T A G P E Q A S P K S N S V
GGTGACCCATCCATGCAGACAGCTGGGCCCGAACAGGCTTCTCCTAAATCAAACTCGGTG

176

13 14

621
1861

E G C N D A F V E V G M P R S P S H S G
GAAGGCTGCAATGATGCCTTTGTTGAAGTGGGCATGCCTCGAAGTCCCTCCCATTCTGGA

641
1921

N A G D L K Q M L G A S K V S C A K R Q
AACGCTGGCGACTTGAAGCAGATGCTGGGTGCCTCCAAGGTCTCCTGTGCCAAGCGGCAG
14

15

661
1981

T V E L L Q G T K N S H L H G T D R L L
ACGGTTGAGCTACTGCAGGGCACGAAGAACTCGCACCTCCACGGCACTGACAGACTACTC

681
2041

S D P E L S A T E S P L A D K K A P G S
TCAGACCCTGAACTGAGCGCCACAGAAAGTCCGCTTGCTGACAAGAAGGCCCCGGGGAGC

701
2101

E R A A E R A A A A Q Q K S E R A R L A
GAACGTGCAGCTGAGAGGGCAGCAGCTGCCCAGCAGAAATCGGAGAGGGCCCGCCTGGCC

721
2161

S Q P T Y V H M Q A F D Y E Q K K L L A
TCGCAGCCAACATATGTCCACATGCAGGCATTTGATTATGAGCAGAAGAAACTATTAGCC

741
2221

T K A M L K K P V V T E V R T P T N T W
ACCAAAGCGATGTTAAAGAAGCCAGTGGTGACTGAGGTCAGAACACCTACGAATACGTGG

761
2281

S G L G F S K S M P A E T I K E L R R A
AGTGGCCTGGGATTCTCAAAGTCCATGCCGGCAGAAACCATTAAGGAACTGAGGAGAGCC

15

16

17 18

781
2341

N H V S Y K P T M T T A Y E G S S L S L
AACCACGTATCCTATAAGCCCACGATGACCACCGCCTATGAGGGCTCCTCATTGTCCCTC

801
2401

S R S S S R E H L A S G S E S D N W R D
TCAAGGTCCAGCAGTCGTGAGCACCTGGCAAGTGGAAGCGAGTCAGACAACTGGAGAGAC

821
2461

R N G I G P M G H S E F S A P I G S P K
CGGAATGGAATAGGCCCCATGGGTCACAGTGAATTCTCAGCACCAATCGGCAGCCCCAAG

177

18

19

841
2521

R K Q N K S R E H Y L S S S N Y M D C I
CGCAAGCAGAACAAATCAAGAGAGCACTATCTAAGCAGCAGCAACTACATGGACTGCATT

861
2581

SAM DOMAIN
S S L T G S N G C N L N S C F K G S D L
TCCTCGCTGACGGGAAGCAATGGCTGTAACCTGAACAGCTGCTTCAAAGGCTCCGACCTC
19

881
2641

P E L F S K L G L G K Y T D V F Q Q Q E
CCCGAGCTTTTCAGCAAGCTGGGCCTAGGCAAATACACGGATGTCTTCCAGCAGCAAGAG

901
2701

I D L Q T F L T L T D Q D L K E L G I T
ATCGATCTTCAGACATTCCTCACCCTCACAGATCAGGATCTGAAGGAGCTGGGAATCACA

921
2761

20 21
pET101/FL.7r
T F G A R R K M L L A I S V C D S V Q I
ACCTTTGGTGCCCGAAGGAAAATGCTGCTGGCAATCTCAGTTTGTGACTCTGTTCAGATC

941
2821

R N K I L R A A R I L CGCAACAAGATCCTGAGAGCTGCCAGGATTCTGTGAACCTTGGAATGTCAAAGAAAAAAG
21

2883

22

AGCTAAGTAAAAACCGAAGAAAACTTTTTGAACCACCAAACGCATCATGCACCTCCTTCC

2941 TGGAAGG▼CGGAGCCAGTGGGAGGCTGCCTCGCCAGTATCATTCAGACATTGCGAGCGTCA
GC (bpk)insertion
3001

GTGGCCGCTGGTAGCGGTACCTTCTGGACACGCACCTGCTATCTTGCAAAGGTGGACACG

3062

ATCCGTGGACAGTCTTCACTGCACTCGCCTGCCCTTGGCACTCGGAGTGTCTGGTATCAG

3122

GACCAAAGTGTTGATTTCGTACCTGTACTTCATGGCCAAAAAAAAAAAAAAAA

178

20
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